CN1942466B - Caspase inhibitors and uses thereof - Google Patents

Caspase inhibitors and uses thereof Download PDF

Info

Publication number
CN1942466B
CN1942466B CN2005800112311A CN200580011231A CN1942466B CN 1942466 B CN1942466 B CN 1942466B CN 2005800112311 A CN2005800112311 A CN 2005800112311A CN 200580011231 A CN200580011231 A CN 200580011231A CN 1942466 B CN1942466 B CN 1942466B
Authority
CN
China
Prior art keywords
compound
group
acid
independently
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800112311A
Other languages
Chinese (zh)
Other versions
CN1942466A (en
Inventor
J-D·沙里耶
S·迪朗
M·莫尔蒂默尔
M·奥唐纳
A·拉瑟福德
S·拉马亚
J·R·斯塔德利
M·蒂多
A·卢克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Priority claimed from PCT/US2005/006540 external-priority patent/WO2005085236A2/en
Publication of CN1942466A publication Critical patent/CN1942466A/en
Application granted granted Critical
Publication of CN1942466B publication Critical patent/CN1942466B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention provides a compound of formula (I): wherein the variables are as defined herein. The present invention also provides processes for preparing the compounds of formula (I), and intermediates thereof, pharmaceutical compositions comprising those compounds, and methods of using the compounds and compositions.

Description

Aspartic acid specific cysteine proteinase inhibitors and uses thereof
Technical field
The present invention relates to can be used as the compound and the composition thereof of aspartic acid specificity cysteine protease (caspase) inhibitor.
The present invention also relates to prepare the method for these compounds.
The invention further relates to the pharmaceutical composition that comprises described compound and these compounds and combination treatment thereof and relate to the purposes of the illness of aspartic acid specificity cysteine protease-mediation.
Background technology
Aspartic acid specificity cysteine protease is a L-Cysteine HCL Anhydrous family, and they are the crucial media in the inflammation.(pre)-IL-1 β before aspartic acid specificity cysteine protease-1 (ICE) processing, the activity form [WO99/47545] of generation IL-1 β.ICE also with former (pro)-IGIF to the conversion of IGIF and/or the generation relevant (the same) of IFN-γ.IL-1 β is influential (for example referring to WO 99/47545 to the pathology relevant with inflammatory, infectivity and autoimmune disorders with IFN-γ; J.I nvest.Dermatology, 120 (1), pp.164-167 (2003); Br. J.Dermatology, 141, pp.739-746 (1999); Science, 282, pp.490-493 (1998); Schweiz.Med.Wochens chr., 130, pp. 1656-1661 (2000)).
Aspartic acid specificity cysteine protease also is the crucial medium [N.A.Thornberry, Chem.Biol., 5, pp.R97-R103 (1998)] in the signal transmission approach that decomposes of apoptosis and cell.It is different because of cell type and stimulator that these signals send approach, but as if the dead approach of all cells program all concentrates on the joint effect device approach that causes the decomposition of key protein matter.Aspartic acid specificity cysteine protease participates in effector phase and its upstream initiating stage that signal sends approach.The upstream aspartic acid specificity cysteine protease that participates in firing event becomes activatory, activates the aspartic acid specificity cysteine protease that other participate in the apoptosis later stage then.
Use peptide class aspartic acid specific cysteine proteinase inhibitors verified the practicality of the various mammalian diseases states relevant of aspartic acid specific cysteine proteinase inhibitors treatment with the apoptosis increase.For example, in rodent model, aspartic acid specific cysteine proteinase inhibitors reduces infarct size and the apoptosis that suppresses the myocardial cell after being presented at myocardial infarction, minimizing by in wind-induced lesion volume and neurological damaged, apoptosis and neurological are damaged after the wound in the minimizing traumatic brain injury, effectively treatment fulminant liver is destroyed, the survival rate [H.Yaoitaetal. behind the raising endotoxin shock Circulation, 97, pp.276-281 (1998); M.Endresetal., J.Cerebral Blood Flow and Metabolism, 18, pp.238-247, (1998); Y.Cheng etal., J. Clin. Invest., 101, pp.1992-1999 (1998); A.G.Yakovlevetal., J.Neurosci., 17, pp.7415-7424 (1997); I.Rodriquez etal., J.Exp.Med., 184, pp.2067-2072 (1996); Grobmyer etal., Mol.Med., 5, p.585 (1999)].
But, because their peptide attribute, this class inhibitor is a feature with worthless pharmacological properties normally, and for example cell permeability and cytoactive are poor, oral absorption is poor, poor stability and metabolism rapid [J.J.Plattner and D.W.Norbeck, in Drug Discovery Technologies, C.R.Clark and W.H.Moos, Eds. (Ellis Horwood, Chichester, England, 1990), pp.92-126].This has hindered them to be developed as effective medicine.These and other utilize the research of peptide class aspartic acid specific cysteine proteinase inhibitors verified, asparagicacid residue participates in crucial and interaction [K.P.Wilsonetal. aspartic acid specificity cysteine protease, Nature, 370, pp.270-275 (1994); Lazebnik et al., Nature, 371, p.346 (1994)].
Therefore, peptidyl and non-peptidyl aspartic acid compound can be used as aspartic acid specific cysteine proteinase inhibitors.
Need have compound, particularly some aspartic acid specificity cysteine protease be had the activity of selection as the ability of aspartic acid specific cysteine proteinase inhibitors.
Summary of the invention
The invention provides formula I compound:
I
Wherein each variable is as herein defined.
The present invention also provides this compounds of method, composition, pharmaceutical composition and use of these compounds of preparation and the method that composition suppresses aspartic acid specificity cysteine protease.The special useful as selective aspartic acid specificity cysteine protease-1/ of these compounds aspartic acid specificity cysteine protease-8 inhibitor.
Detailed Description Of The Invention
The invention provides formula I compound:
Figure S05811231120061019D000032
Wherein:
Y is
Figure S05811231120061019D000033
Or
Figure S05811231120061019D000034
R is R 3C (O)-, HC (O), R 3SO 2-, R 3OC (O), (R 3) 2NC (O), (R 3) (H) NC (O), R 3C (O) C (O)-, R 3, (R 3) 2NC (O) C (O), (R 3) (H) NC (O) C (O) or R 3OC (O) C (O) one;
R 1Be H, aliphatic group, cycloaliphatic groups, aryl, heterocyclic radical, heteroaryl, cycloalkyl-aliphatic group-, cycloalkenyl group-aliphatic group-, aryl-aliphatic group-, heterocyclic radical-aliphatic group or heteroaryl-aliphatic group-, wherein arbitrarily hydrogen atom alternatively with independently by R 8Replace, the group with two hydrogen atoms of same atomic linkage is replaced by carbonyl alternatively and independently arbitrarily;
Ring A is:
Or
Figure S05811231120061019D000042
Wherein in each ring, arbitrarily hydrogen atom is alternatively with independently by R 4Replace, the group with two hydrogen atoms of same atomic linkage is replaced by carbonyl alternatively and independently arbitrarily;
R 3Be aliphatic group, cycloaliphatic groups, aryl, heterocyclic radical, heteroaryl, cycloaliphatic groups-aliphatic group-, aryl-aliphatic group-, heterocyclic radical-aliphatic group or heteroaryl-aliphatic group-; Perhaps two R with same atomic linkage 3Group constitutes 3-10 unit's aromatics or non-aromatic ring with this atom; Wherein ring condenses with aryl, heteroaryl, cycloalkyl or heterocyclic radical alternatively arbitrarily; Wherein 3 aliphatic carbon atoms can be selected from O, N, NR at the most 9, S, SO and SO 2Group replace R wherein 3By at the most 6 independently be selected from R 8Substituting group replace;
R 4Be halogen ,-OR 9,-NO 2,-CN ,-CF 3,-OCF 3,-R 9, 1,2-methylene-dioxy, ethylenedioxy ,-N (R 9) 2,-SR 9,-SOR 9,-SO 2R 9,-SO 2N (R 9) 2,-SO 3R 9,-C (O) R 9,-C (O) C (O) R 9,-C (O) C (O) OR 9,-C (O) C (O) N (R 9) 2,-C (O) CH 2C (O) R 9,-C (S) R 9,-C (S) OR 9,-C (O) OR 9,-OC (O) R 9,-C (O) N (R 9) 2,-OC (O) N (R 9) 2,-C (S) N (R 9) 2,-(CH 2) 0-2NHC (O) R 9,-N (R 9) N (R 9) COR 9,-N (R 9) N (R 9) C (O) OR 9,-N (R 9) N (R 9) CON (R 9) 2,-N (R 9) SO 2R 9,-N (R 9) SO 2N (R 9) 2,-N (R 9) C (O) OR 9,-N (R 9) C (O) R 9,-N (R 9) C (S) R 9,-N (R 9) C (O) N (R 9) 2,-N (R 9) C (S) N (R 9) 2,-N (COR 9) COR 9,-N (OR 9) R 9,-C (=NH) N (R 9) 2,-C (O) N (OR 9) R 9,-C (=NOR 9) R 9,-OP (O) (OR 9) 2,-P (O) (R 9) 2,-P (O) (OR 9) 2Or-(H) (OR of P (O) 9);
R 2Be-C (R 5) (R 6) (R 7), aryl, heteroaryl or C 3-7Cycloalkyl;
R 5Be H or C 1-6The straight or branched alkyl;
R 6Be H or C 1-6The straight or branched alkyl;
R 7Be-CF 3,-C 3-7Cycloalkyl, aryl, heteroaryl, heterocycle or C 1-6The straight or branched alkyl, wherein each carbon atom of this alkyl is alternatively with independently by R 10Replace;
Perhaps R 5And R 7Constitute 3-10 unit cycloaliphatic groups with the carbon atom that they connected;
R 8And R 8' be independently of one another halogen ,-OR 9,-NO 2,-CN ,-CF 3,-OCF 3,-R 9, 1,2-methylene-dioxy, ethylenedioxy ,-N (R 9) 2,-SR 9,-SOR 9,-SO 2R 9,-SO 2N (R 9) 2,-SO 3R 9,-C (O) R 9,-C (O) C (O) R 9,-C (O) C (O) OR 9,-C (O) C (O) N (R 9) 2,-C (O) CH 2C (O) R 9,-C (S) R 9,-C (S) OR 9,-C (O) OR 9,-OC (O) R 9,-C (O) N (R 9) 2,-OC (O) N (R 9) 2,-C (S) N (R 9) 2,-(CH 2) 0-2NHC (O) R 9,-N (R 9) N (R 9) COR 9,-N (R 9) N (R 9) C (O) OR 9,-N (R 9) N (R 9) CON (R 9) 2,-N (R 9) SO 2R 9,-N (R 9) SO 2N (R 9) 2,-N (R 9) C (O) OR 9,-N (R 9) C (O) R 9,-N (R 9) C (S) R 9,-N (R 9) C (O) N (R 9) 2,-N (R 9) C (S) N (R 9) 2,-N (COR 9) COR 9,-N (OR 9) R 9,-C (=NH) N (R 9) 2,-C (O) N (OR 9) R 9,-C (=NOR 9) R 9,-OP (O) (OR 9) 2,-P (O) (R 9) 2,-P (O) (OR 9) 2With (H) (OR of-P (O) 9);
R 9Be hydrogen, aliphatic group, cycloaliphatic groups, aryl, heterocyclic radical, heteroaryl, cycloaliphatic groups-aliphatic group-, aryl-aliphatic group-, heterocyclic radical-aliphatic group or heteroaryl-aliphatic group-, wherein arbitrarily hydrogen atom alternatively with independently by R 8Replace, the group with two hydrogen atoms of same atomic linkage is replaced by carbonyl alternatively and independently arbitrarily;
R 10Be halogen ,-OR 11,-NO 2,-CN ,-CF 3,-OCF 3,-R 11Or-SR 11R wherein 11Be C 1-4-aliphatic group-.
The present invention also provides formula II compound:
Figure S05811231120061019D000051
Wherein:
Y is
Or
R 1Be H, aliphatic group, cycloalkyl (for example cyclopentyl), cycloalkenyl group, aryl, heterocyclic radical, heteroaryl, cycloalkyl-aliphatic group-, cycloalkenyl group-aliphatic group-, aryl-aliphatic group-, heterocyclic radical-aliphatic group or heteroaryl-aliphatic group-, wherein arbitrarily hydrogen atom alternatively with independently by R 8Replace, the group with two hydrogen atoms of same atomic linkage is replaced by carbonyl alternatively and independently arbitrarily;
Ring A is:
Figure S05811231120061019D000061
Or
Figure S05811231120061019D000062
Wherein in each ring, arbitrarily hydrogen atom is alternatively with independently by R 4Replace, the group with two hydrogen atoms of same atomic linkage is replaced by carbonyl (the perhaps carbonyl in alternate embodiments or (C 3-C6) volution) alternatively and independently arbitrarily;
R 4Be halogen ,-OR 9,-NO 2,-CN ,-CF 3,-OCF 3,-R 9, 1,2-methylene-dioxy, ethylenedioxy ,-N (R 9) 2,-SR 9,-SOR 9,-SO 2R 9,-SO 2N (R 9) 2,-SO 3R 9,-C (O) R 9,-C (O) C (O) R 9,-C (O) C (O) OR 9,-C (O) C (O) N (R 9) 2,-C (O) CH 2C (O) R 9,-C (S) R 9,-C (S) OR 9,-C (O) OR 9,-OC (O) R 9,-C (O) N (R 9) 2,-OC (O) N (R 9) 2,-C (S) N (R 9) 2,-(CH 2) 0-2NHC (O) R 9,-N (R 9) N (R 9) COR 9,-N (R 9) N (R 9) C (O) OR 9,-N (R 9) N (R 9) CON (R 9) 2,-N (R 9) SO 2R 9,-N (R 9) SO 2N (R 9) 2,-N (R 9) C (O) OR 9,-N (R 9) C (O) R 9,-N (R 9) C (S) R 9,-N (R 9) C (O) N (R 9) 2,-N (R 9) C (S) N (R 9) 2,-N (COR 9) COR 9,-N (OR 9) R 9,-C (=NH) N (R 9) 2,-C (O) N (OR 9) R 9,-C (=NOR 9) R 9,-OP (O) (OR 9) 2,-P (O) (R 9) 2,-P (O) (OR 9) 2Or-(H) (OR of P (O) 9);
R 2Be-C (R 5) (R 6) (R 7), aryl, heteroaryl or C 3-7Cycloalkyl;
R 5Be H or C 1-6The straight or branched alkyl;
R 6Be H or C 1-6The straight or branched alkyl;
R 7Be-CF 3,-C 3-7Cycloalkyl, aryl, heteroaryl, heterocycle or C 1-6The straight or branched alkyl, wherein each carbon atom of this alkyl is alternatively with independently by R 10Replace;
(perhaps in the alternate embodiment, R 5And R 7Constitute 3-10 unit cycloaliphatic groups with the carbon atom that they connected);
R 3Be phenyl, thiophene or pyridine, wherein each the ring alternatively by at the most 5 independently be selected from R 8' group replace, and wherein on this phenyl, thiophene or the pyridine at least one and key x position adjacent by R 12Replace, wherein R 12Has the straight chain atom that is no more than 5;
R 8And R 8' be independently of one another halogen ,-OR 9,-NO 2,-CN ,-CF 3,-OCF 3,-R 9, 1,2-methylene-dioxy, ethylenedioxy ,-N (R 9) 2,-SR 9,-SOR 9,-SO 2R 9,-SO 2N (R 9) 2,-SO 3R 9,-C (O) R 9,-C (O) C (O) R 9,-C (O) C (O) OR 9,-C (O) C (O) N (R 9) 2,-C (O) CH 2C (O) R 9,-C (S) R 9,-C (S) OR 9,-C (O) OR 9,-OC (O) R 9,-C (O) N (R 9) 2,-OC (O) N (R 9) 2,-C (S) N (R 9) 2,-(CH 2) 0-2NHC (O) R 9,-N (R 9) N (R 9) COR 9,-N (R 9) N (R 9) C (O) OR 9,-N (R 9) N (R 9) CON (R 9) 2,-N (R 9) SO 2R 9,-N (R 9) SO 2N (R 9) 2,-N (R 9) C (O) OR 9,-N (R 9) C (O) R 9,-N (R 9) C (S) R 9,-N (R 9) C (O) N (R 9) 2,-N (R 9) C (S) N (R 9) 2,-N (COR 9) COR 9,-N (OR 9) R 9,-C (=NH) N (R 9) 2,-C (O) N (OR 9) R 9,-C (=NOR 9) R 9,-OP (O) (OR 9) 2,-P (O) (R 9) 2,-P (O) (OR 9) 2With (H) (OR of-P (O) 9);
R 9Be hydrogen, aliphatic group, cycloalkyl, cycloalkenyl group, aryl, heterocyclic radical, heteroaryl, cycloaliphatic groups-aliphatic group-, aryl-aliphatic group-, heterocyclic radical-aliphatic group or heteroaryl-aliphatic group-(R in some embodiments, 9Any hydrogen atom alternatively with independently by R 8Replace, the group with two hydrogen atoms of same atomic linkage is replaced by carbonyl alternatively and independently arbitrarily; Its condition is if R 9By R 8Replace, wherein R 8Comprise R 9Substituting group, this R so 9Substituting group is not by R 8Replace);
R 10Be halogen ,-OR 11,-NO 2,-CN ,-CF 3,-OCF 3,-R 11Or-SR 11
R 11Be C 1-4-aliphatic group; And
R 12Be halogen ,-OR 11,-NO 2,-CN ,-CF 3,-OCF 3,-R 11,-SR 9
As at R 12Definition in employed, whether the atom of the linear bonding of " straight chain atom " expression also has with the atom of bifurcation approach bonding irrelevant with these atoms.According to this definition, ethyl and trifluoromethoxy have three straight chain atoms separately, and methyl has two straight chain atoms.In the above-described embodiment, R 12Have and be no more than 5 straight chain atoms.In two kinds of other embodiments, R 12Have and be no more than 4 straight chain atoms and be no more than 3 straight chain atoms.In other embodiment, R 12Have 2 straight chain atoms or 1 atom.
Just as used herein, represent to be only second to the position of x bonding position with key x position adjacent.In aryl rings, this position often is called as " ortho position ", and perhaps under the situation of benzyl ring, it can be called as " 2-position ".Following array structure is an example, R 12At " with key x position adjacent " and phenyl, thiophene and pyridine ring bonding.
Figure S05811231120061019D000081
In one embodiment of the invention, R is R 3C (O)-.
In some embodiment, R 3Be optional substituted C 6-10Aryl or heteroaryl.In other embodiments, R 3It is optional substituted phenyl.In other embodiment, R 3It is 8-10 unit optional substituted heteroaryl (just quinoline, isoquinoline 99.9 or quinazoline).In other embodiment, R 3It is the first heteroaryl (just pyridyl, pyrimidyl, pyrazinyl, thienyl, furyl, thiazolyl) of optional substituted 5-6.
In some embodiment, R 3Alternatively with independently by 0-5 R 8' the group replacement.
In one embodiment, The compounds of this invention is by formula II representative:
Wherein:
Figure S05811231120061019D000082
A) R 3Be phenyl, thiophene or pyridine;
B) each the ring alternatively by at the most 5 independently be selected from R 8' group replace;
C) on this phenyl, thiophene or the pyridine at least one and key x position adjacent by R 12Replace, wherein R 12Have and be no more than 5 straight chain atoms.
Another embodiment of the invention provides such compound, and wherein Y is:
Figure S05811231120061019D000083
In one embodiment of the invention, R 1By at the most 3 independently be selected from carbonyl and R 8Group replace.
In another embodiment, R 1Be C 1-12Aliphatic group or C 3-10Cycloalkyl, wherein each R 1Independently be selected from R by 1-3 alternatively 8Group replace.In another embodiment, R 1Be straight or branched C 1-4Alkyl, it independently is selected from R by 1-3 alternatively 8Group replace.
In one embodiment, R 1Be unsubstituted straight or branched C 1-4Alkyl (for example ethyl, sec.-propyl, n-propyl or normal-butyl).In another embodiment, R 1It is ethyl.
In any these embodiments, R 8Be halogen ,-OR 9,-CN ,-CF 3,-OCF 3Or-R 9In another embodiment, R 8Be-R 9, R wherein 9It is benzyl.
In another embodiment, Y is
In another embodiment, ring A independently is selected from carbonyl and R by 3 at the most (preferred 1) 4Group replace.
In one embodiment, ring A is:
Figure S05811231120061019D000092
Or
Figure S05811231120061019D000093
Alternatively by R 4Replace.
In another embodiment, ring A is:
Figure S05811231120061019D000094
Alternatively by R 4Replace.
In the another kind of mode of this embodiment, ring A is that unsubstituted proline(Pro) (that is to say R 4Be hydrogen).
In another embodiment, ring A is:
Or
Alternatively by R 4Replace.
In one embodiment, ring A is:
Figure S05811231120061019D000103
Alternatively by R 4Replace.
In any these embodiments, R 4Be halogen ,-OR 9,-CF 3,-OCF 3,-R 9Or-SR 9In some embodiments, R 4Be H.
In one embodiment, R 2Be C 3-4Branched-chain alkyl.
In another embodiment, R 5Be H or-CH 3, R 6Be-CH 3, and R 7Be-CH 3
In another embodiment, R 12Be-OCF 3,-OCH 3,-CF 3,-CH 3,-CH 2CH 3,-Cl or-F.
In another embodiment, R 12Be-CF 3,-CH 3,-Cl or-F.
In another embodiment, R 12Be-CH 3,-Cl or-F.
In another embodiment, each R 8' if present, be independently halogen ,-OR 9,-NO 2,-CN ,-CF 3,-OCF 3,-R 9, 1,2-methylene-dioxy, ethylenedioxy ,-N (R 9) 2,-SR 9,-SOR 9,-SO 2R 9,-SO 2N (R 9) 2,-C (O) R 9,-C (O) C (O) N (R 9) 2,-C (O) N (R 9) 2,-OC (O) N (R 9) 2,-(CH 2) 0-2NHC (O) R 9,-N (R 9) SO 2R 9,-N (R 9) SO 2N (R 9) 2,-N (R 9) C (O) OR 9,-N (R 9) C (O) R 9Or-N (R 9) C (O) N (R 9) 2
In another embodiment, R 8' be-NH 2,-N (R 9) 2,-N (R 9) C (O) R 9,-OCF 3,-OR 9,-CF 3,-R 9,-SR 9Or halogeno-group.In this embodiment, halogeno-group is Cl or F preferably, and R 9Straight or branched C preferably 1-4Alkyl.
According to a kind of embodiment, the invention provides the formula III compound:
Figure S05811231120061019D000111
Wherein each variable is defined as any embodiment of this paper.
In a kind of mode of this embodiment, under having, this compound shows stereochemistry:
Figure S05811231120061019D000112
Wherein each variable is defined as any embodiment of this paper.
In other modes of this embodiment, under having, this compound shows stereochemistry:
Or
Figure S05811231120061019D000114
Wherein each variable is defined as any embodiment of this paper.
In other embodiments, the invention provides formula I V compound:
Figure S05811231120061019D000115
Wherein each variable is defined as any embodiment of this paper.
In a kind of mode of this embodiment, under having, this compound shows stereochemistry:
Wherein each variable is defined as any embodiment of this paper.
The embodiment of this paper can make up to be provided according to compound of the present invention.
According to a kind of embodiment, the invention provides the compound that is selected from following table 1:
Table 1
Figure S05811231120061019D000121
Figure S05811231120061019D000131
Figure S05811231120061019D000141
Figure S05811231120061019D000161
Figure S05811231120061019D000171
In other embodiments, the invention provides the formula I I compound that is selected from following table 2:
Table 2
Figure S05811231120061019D000181
Figure S05811231120061019D000191
Figure S05811231120061019D000201
Figure S05811231120061019D000211
In some embodiments of the present invention, variable-definition is selected from those that table 1 and/or table 2 compound described.
The atom of specified quantity used herein comprises arbitrary integer therebetween.For example, the group with 1-4 atom may have 1,2,3 or 4 atom.
Aliphatic group used herein comprises straight chain and the branched group with specified quantity atom.If atomicity is unspecified, aliphatic group has 1 to 12 carbon atom.Just as will be understood, thiazolinyl and/or alkynyl aliphatic group have minimum 2 carbon atoms.Preferred aliphatic group is alkyl (preferably having 1 to 6 atom).
Cycloalkyl and cycloalkenyl group have 3 to 10 carbon atoms, and are monocycle or bicyclic, comprise linear condensed, bridging or volution.
" aromatic group " used herein or " aryl " expression contains 6-to the 10-unit ring system of at least one aromatic ring.The example of aromatic ring comprises phenyl and naphthyl.
" heteroaryl " used herein expression has 5-10 member and 1,2 or 3 and independently is selected from N, N (R 9), O, S, SO and SO 2Heteroatomic ring system, wherein at least one ring is heteroaromatic (for example pyridyl, thiophene or a thiazole).
" heterocycle " used herein expression has 3-10 member and 1,2 or 3 and independently is selected from N, N (R9), O, S, SO and SO 2Heteroatomic ring system, wherein not ring is not (for example piperidines and the morpholine) of aromatics.
The further example of heteroaryl comprises the 2-furyl, the 3-furyl, the TMSIM N imidazole base, the 2-imidazolyl, the 4-imidazolyl, the 5-imidazolyl, benzimidazolyl-, the 3-isoxazolyl, the 4-isoxazolyl, the 5-isoxazolyl, the 2-oxazolyl, the 4-oxazolyl, the 5-oxazolyl, the N-pyrryl, the 2-pyrryl, the 3-pyrryl, the 2-pyridyl, the 3-pyridyl, the 4-pyridyl, the 2-pyrimidyl, the 4-pyrimidyl, the 5-pyrimidyl, pyridazinyl (for example 3-pyridazinyl), the 2-thiazolyl, the 4-thiazolyl, the 5-thiazolyl, tetrazyl (for example 5-tetrazyl), triazolyl (for example 2-triazolyl and 5-triazolyl), the 2-thienyl, the 3-thienyl, benzofuryl, benzothienyl, indyl (for example 2-indyl), pyrazolyl (for example 2-pyrazolyl), isothiazolyl, 1,2,3-oxadiazole base, 1,2,5-oxadiazole base, 1,2,4-oxadiazole base, 1,2, the 3-triazolyl, 1,2, the 3-thiadiazolyl group, 1,3, the 4-thiadiazolyl group, 1,2, the 5-thiadiazolyl group, purine radicals, pyrazinyl, 1,3, the 5-triazinyl, quinolyl (2-quinolyl for example, the 3-quinolyl, the 4-quinolyl) and isoquinolyl (1-isoquinolyl for example, 3-isoquinolyl or 4-isoquinolyl).
The further example of heterocyclic comprises 3-1H-benzimidazolyl-2 radicals-ketone, 3-(1-alkyl)-benzimidazolyl-2 radicals-ketone, the 2-tetrahydrofuran base, the 3-tetrahydrofuran base, the 2-tetrahydro-thienyl, the 3-tetrahydro-thienyl, 2-morpholino base, 3-morpholino base, 4-morpholino base, the 2-parathiazan is for base, the 3-parathiazan is for base, the 4-parathiazan is for base, the 1-pyrrolidyl, the 2-pyrrolidyl, the 3-pyrrolidyl, 1-tetrahydrochysene piperazinyl, 2-tetrahydrochysene piperazinyl, 3-tetrahydrochysene piperazinyl, piperidino, the 2-piperidyl, the 3-piperidyl, the 1-pyrazolinyl, the 3-pyrazolinyl, the 4-pyrazolinyl, the 5-pyrazolinyl, piperidino, the 2-piperidyl, the 3-piperidyl, the 4-piperidyl, the 2-thiazolidyl, the 3-thiazolidyl, the 4-thiazolidyl, the 1-imidazolidyl, the 2-imidazolidyl, the 4-imidazolidyl, the 5-imidazolidyl, indolinyl, tetrahydric quinoline group, tetrahydro isoquinolyl, the benzo thiacyclopentane, benzo dithiane and 1,3-glyoxalidine-2-ketone.
Each above-mentioned aliphatic group, aryl, cycloaliphatic groups, heteroaryl and heterocyclic radical can contain suitable substituting group (preferably at the most 5), are independently selected from for example carbonyl and R 8Preferred substituted be halogen ,-OR 9,-NO 2,-CF 3,-OCF 3,-R 9, the oxo base ,-OR 9,-O-benzyl ,-O-phenyl, 1,2-methylene-dioxy, ethylenedioxy ,-N (R 9) 2,-C (O) R 9,-COOR 9Or-CON (R 9) 2, R wherein 9Be (preferably H, (C1-C6)-alkyl or (C2-C6)-thiazolinyl and-alkynyl, (C1-C6)-alkyl is most preferred) as herein defined.Should be understood that this definition will comprise fluoridized alkyl.
To be it is evident that some compound of the present invention may exist tautomeric form or hydrated form by those skilled in the art, all these compounds forms all belong to scope of the present invention.Unless otherwise prescribed, the structure that this paper described also means all stereochemical forms that comprise this structure, just R with regard to each asymmetric center and S configuration.Therefore, the enantiomorph of single three-dimensional chemical isomer and these compounds and non-enantiomer mixture all belong to scope of the present invention.
Unless otherwise prescribed, the structure that this paper described also means and comprises only distinguishing compound in the existence of one or more isotopic enrichment atoms.For example, but having these structure hydrogen is replaced or the carbon quilt by deuterium or tritium 13C-or 14The displaced compound of C-enrichment carbon all belongs to scope of the present invention.
The compounds of this invention can make by any means, comprises that those skilled in the art are about the known general synthetic method of similar compound (for example referring to WO 99/47545).The synthesis flow of following The compounds of this invention is provided for illustration purposes.
Use following abbreviation:
EDC is 1-(3-dimethylamino-propyl)-3-ethyl carbodiimide;
HOBt is an I-hydroxybenzotriazole;
THF is a tetrahydrofuran (THF);
TFA is a trifluoroacetic acid;
DCM is a methylene dichloride;
DMAP is the 4-Dimethylamino pyridine;
DIPEA is a diisopropylethylamine;
DMF is a dimethyl formamide;
TFA is a trifluoroacetic acid;
Z is a carbobenzoxy-(Cbz);
1H NMR is a nucleus magnetic resonance;
TLC is a thin-layer chromatography.
The general preparation flow of flow process I:E and F
Figure S05811231120061019D000241
Flow process I describes to prepare the general way of compd E disclosed in this invention and F.Easily from aspartic acid (by PG 1Protection is for ester) substance A that makes of the reductive action of α-carboxyl and substance B be (by PG 2Institute's N-protected) carboxylic moiety coupling obtains substance C.PG 1And PG 2It is the orthogonally protect group (blocking group that in the presence of another kind of blocking group, can be removed by selectivity just.Ideally, should remove PG 1And do not remove PG 2, vice versa).Here, according to the aspartic acid part of oxidation/ketalization/go to protect/cyclisation subsequent treatment molecule, obtain material D then.The ring A part of D is then by the further functionalized material E that obtains, and it is a disclosed part of the present invention.The provide protection of going of ketal obtains material F, and it represents other parts of disclosed invention.
In various embodiments of the present invention, PG 2Be the amine protecting group group that is fit to, include but not limited to T.W.Greene﹠amp; P.G.M Wutz, p " rotect ive Groups in OrganicSynthesis ", 3rdEdition, John Wiley﹠amp; Sons, Inc. (1999 and other versions) (" Greene") described amine protecting group group." Z " blocking group (carbobenzoxy-(Cbz)) is to be particularly useful in N-protected group of the present invention.PG therein 2In the protection proline(Pro) nitrogen compound, PG 2Z preferably.Should be understood that the Z group (" Z-type blocking group ") through modifying that The compounds of this invention and process are adopted also will fall into scope of the present invention.For example, Z can be at CH 2On group or the phenyl by R 8(preferred halogeno-group or C 1-6The straight or branched alkyl) replaces, obtain Z-type blocking group.
In various embodiments of the present invention, PG 1Be the carboxylic acid protective group who is fit to, include but not limited to GreeneDescribed acid protecting group.In some embodiments, PG 1Be C 1-6The straight or branched alkyl.The tertiary butyl is to be particularly useful in acid protecting group of the present invention.
In flow process I, compd A is the asparagicacid residue through modifying.Except compd A, reported other asparagicacid residues through modifying, comprise as follows:
PG wherein 3And PG 4It is suitable blocking group.These can be by method preparation known to the skilled through the aspartic acid of modifying.For example referring to US patent application publication US2002/0042376 (especially the 9th page of [0121] section and [0250] section of 21-22 page or leaf and [0123] section document of quoting) and United States Patent (USP) 6,235,899.Other sees C.Grosetal. " Stereochemical control in the preparation of a-aminoN-methylthiazolidine Masked Aldehydes used for PeptideAldehyde Synthesis " Tetrahedron, 58, pp.2673-2680 (2002); K.T.Chapman, " Synthesis of a Potent Reversible Inhibitor ofInterleukin-β Converting Enzyme " Bioorg.Med.Chem.Letts., 2, pp.613-618 (1982); M.D.Mullican etal. " The Synthesis andEvaluation of Pept idyl Aspartyl Aldehydes asInhibitors ofICE ' " 4, pp.2359-2364 (1994); M.H.Chen, etal. " An EfficientStereoselective Synthesisof[3S (1S; 9S)]-3-[[[9-(Benzoylamino) octahydro-6; 10-Dioxo-6H-pyridazino-(1; 2-a) (1; 2)-Diazepin-1-yl]-carbonyl] amino]-4-oxo butanoic acid, an interleukinconverting enzyme (ICE) Inhibitor " 9, pp.1587-1592 (1999).Therefore, flow process I (and following flow process III) can adopt these other asparagicacid residues.
The preparation of flow process II: formula I and II compound
Figure S05811231120061019D000261
Reagent and condition: (a) R 3COOH, HOBt, DMAP, EDC, THF; (b) R 3CONHCH (R 2) COOH, HOBt, DMAP, EDC, THF; (c) 2M HCl, MeCN.
Flow process II describes the generation of formula I and II compound, and wherein encircling A is unsubstituted proline(Pro).Here, the cyclic acetal form of The compounds of this invention is depicted as formula I, and the aldehyde form is depicted as formula II.Compound with the ring A except that unsubstituted proline(Pro) can be substituted in the method that flow process I is described.
Flow process II describes to be used for the approach of preparation formula I and II compound.Compound I can be from compound 1 preparation, amino in the condensation 1 and suitable functionalized carboxylic acid (or derivative).In this step, described to generate the standard coupling reagent of amido linkage; Also can adopt other conditions of generation amido linkage known in the art.
As known to the skilled, can be with carboxylic acid (C (O) OH) and amine coupling under the condition that is suitable for coupling amine and carboxylic acid.Select as an alternative, in this class coupling, can adopt carboxylic acid derivative (C (O) X) to replace carboxylic acid.Should be understood that under the background of coupling amine and carboxylic acid derivative, this derivative will activate acid, to promote and the amine coupling.Suitable X group is leavings group in itself, is known to the skilled.″March′s?Advanced?OrganicChemistry″，5 thEd.，Ed.：Smith，M.B.and?March，J.，J?ohn?Wiley&Sons，New?York：2001。
Coupling amine comprises solvent, carboxylic acid, alkali and the peptide-coupling reagent that merging is fit to the representative condition of acid.Described the example of the condition that is fit in US2002/0042376 and WO 01/81330, its full content is quoted at this as a reference.In some embodiments, in the flow process of this paper and embodiment, these conditions have been described.
The example of suitable derivatives includes but not limited to formula RX compound, wherein X be Cl, F, OC (=O) R " (R " be aliphatic group or aryl), SH, SR, SAr or SeAr.In some embodiment, R be C (=O).It is known in the art being suitable for using the condition of these suitable derivatives.
Flow process III: the preparation of compound 1
Figure S05811231120061019D000281
Reagent and condition: (a) Cbz-Pro-OH, EDC, HOBt, DMAP, DIPEA, THF;
(b)Sworn；(c)R 1OH，3
Figure S05811231120061019D000282
Sieve, DCM, TsOH; (d) TFA, DCM; (e) H 2, Pd (OH) 2, EtOAc, DMF, Et 3N; (f) EDC, HOBt, Et 3N, EtOAc, DMF; (g) H 2, Pd/C, citric acid.
Flow process III describes the possible approach of described compound 7 of a kind of preparation flow I and compound 1.The easily proline(Pro) of the compound 2 that makes from the reductive action of aspartic acid α-carboxyl and N-protected (perhaps other rings, wherein encircling A is not unsubstituted proline(Pro)) coupling generates 3.Here, proline(Pro) is with Z group (carbobenzoxy-(Cbz)) N-protected.Compound 3 is oxidized to aldehyde 4 then, and acetalation on the spot obtains acetal 5 again.At R 1Under the existence of-OH (or the acetal that is fit to generates reagent), protonic acid (for example TsOH) or Lewis acid and the solvent that is fit to, can generate acetal.Be suitable for generating wherein R 1The acetal that becomes the compound of ethyl generates reagent and can be regarded as the ethanol Equivalent, includes but not limited to triethyl orthoformate or diethyl acetal, for example (CH 3) 2C (OCH 2CH 3) 2Preferably, solvent is CH 2Cl 2, toluene or chlorobenzene.Suitable protonic acid includes but not limited to TFA, p-TsOH.Suitable Lewis acid includes but not limited to TiCl 4, MgBr 2And ZnCl 2
In flow process III, compound 3 is depicted under the Swern condition to the oxygenizement of compound 4 and carries out.Also can adopt other oxidizing conditions to prepare The compounds of this invention.Preferred oxidizing condition be gentle and relative fast, the epimerization of the sour side chain of the asparagicacid residue of being modified is minimized.In one embodiment, oxidation step is TEMPO oxidation (example I that vide infra-1 method C).Other oxidizing conditions comprise the Doss-Martin oxidation and cross ruthenic acid tetrapropyl ammonium (TPAP) oxidation.
Can separating aldehyde 4, but preferably need not to separate direct generation 5.(in 5) tertiary butyl ester go provide protection with spontaneous cyclic action, obtain the mixture of diastereomer, separate by column chromatography, obtain the cis ketal 6 and the trans ketal (this flow process is expression not) of enantiomer-pure.Go provide protection can be under protonic acid or Lewis acid condition, in appropriate solvent, carry out.Appropriate solvent includes but not limited to toluene, chlorobenzene and DCM.Suitable protonic acid includes but not limited to TFA, p-TsOH.Suitable Lewis acid includes but not limited to TiCl4, MgBr 2And ZnCl 2For making flow process cheer and bright, generate in the back in the step of compound 7 and 1 and only represented the cis ketal, but same order can be used to generate trans ketal.Utilize the condition of preparation amido linkage known in the art, make compound 6 be subjected to hydrogenolytic cleavage, gained compound 7 reacts with the amino acid of Z-protection, obtains compound 9.Compound 7 can generate and use on the spot.If isolating words are preferably used compound 7 soon after generation.Make compound 9 be subjected to hydrogenolytic cleavage at last, obtain compound 1, can be directly used in the preparation Compound I, described as flow process II.
Select as an alternative, compound 7 can be used to prepare Compound I, is described as flow process II.In this preparation, preparation amino-acid residue and required N-end group (referring to flow process II reaction (b)) in a step.
As described, can adopt the aspartame except that compound 2 to make The compounds of this invention about flow process I.
Flow process IV: the preparation of formula III and IV compound
Reagent and condition: (a) ROH/HOBt/DMAP/EDC/THF or RCl/Et 3N/DCM; (b) RNHCH (R 2) COOH, HOBt, DMAP, EDC, THF; (c) 2M HCl, MeCN.
Flow process IV describes the generation of formula III and IV compound, and wherein encircling A is 2-aza-bicyclo [2.2.1] heptane-3-carboxylic acid.Here, the cyclic acetal form of The compounds of this invention is depicted as formula III, and the aldehyde form is depicted as formula IV.Flow process IV describes to be used to prepare the approach of formula III and IV compound.Compound III can be from compound 11 preparations, amino under the condition that required R group is provided in the condensation 11, for example suitable functionalized carboxylic acid (or derivative), sulfonic acid (or derivative), chloro-formic ester or chloroformamide (or isocyanic ester) is for example under appropriate reaction conditions.In this step, described to generate the standard coupling reagent of CO-NH key; Also can utilize generation CO-NH (or alkyl-N or SO known in the art 2-N) other conditions of key provide the required compound that comprises R-N.Select as an alternative, Compound I can be from compound 17 preparations, amino in the condensation 17 and suitable functionalized carboxylic acid (or derivative), sulfonic acid (or derivative), chloro-formic ester or chloroformamide (or isocyanic ester).In this step, described to generate the standard coupling reagent of CO-NH key; Also can utilize other conditions of generation CO-NH key known in the art.
Flow process V: the preparation of compound 11
Reagent and condition: (a) EDC, HOBt, DMAP, DIPEA, THF; (b) Swern; (c) R 1OH,
Sieve, DCM, TsOH; (d) TFA, DCM; (e) H 2, Pd (OH) 2, EtOAc, DMF, Et 3N; (f) EDC, HOBt, Et 3N, EtOAc, DMF; (g) H 2, Pd/C, citric acid.
Flow process V describes the possible approach of described compound 17 of preparation flow III and compound 11.Easily 2-aza-bicyclo [2.2.1] heptane-3-carboxylic acid 10 of the compound 2 that makes from the reductive action of aspartic acid α-carboxyl and N-protected (as Tetrahedron:Asymmetry, 13,2002, the 25-28 preparation) coupling, generate 13.Compound 13 is oxidized to aldehyde 14 then, and acetalation on the spot obtains acetal 15 again.Tertiary butyl ester go provide protection with spontaneous cyclic action, obtain the mixture of diastereomer, separate by column chromatography, obtain the cis ketal 16 and the trans ketal (this flow process is expression not) of enantiomer-pure.Alternative ring A group be commercially available, bibliographical information is crossed or can prepare according to the document currently known methods.
For making flow process cheer and bright, generate in the back in the step of compound 17 and 11 and only represented the cis ketal, but same order can be used to generate trans ketal.Utilize the condition of preparation amido linkage known in the art, make compound 16 be subjected to hydrogenolytic cleavage, gained compound 17 reacts with the amino acid of Z-protection, obtains compound 19.
Select as an alternative, compound 17 can be used to prepare compound III, is described as flow process IV.Make compound 19 be subjected to hydrogenolytic cleavage at last, obtain compound 11, can be directly used in the preparation compound III, described as flow process IV.
Be used in the R among the flow process II 30COOH be commercially available, bibliographical information is crossed or according to the preparation of document currently known methods.With regard to Compound I I-30,2-chloro-3-methoxybenzoic acid be as J.Org.Chem, 59,1994, the 2939-2944 preparation.
With regard to Compound I I-32,2-chloro-3-trifluoro-methoxy-benzoic acid be from 2-amino-3-trifluoro-methoxy-benzoic acid (as J.Org.Chem, 68,2003,4693-4699 preparation) preparation, according to basically with J.Org.Chem, 59,1994, the report similar methods of 2939-2944 is utilized amino by the Sandmeyer metathesis of chlorine.
Therefore, the present invention also provides the method for preparing The compounds of this invention.
The method of preparation I compound is provided in one embodiment:
Wherein Y is:
Figure S05811231120061019D000311
Figure S05811231120061019D000321
Its dependent variable is defined as any embodiment of this paper, comprises making formula 1 compound:
Figure S05811231120061019D000322
Wherein each variable is defined as any embodiment of this paper, react with formula RX compound, wherein X is OH or suitable derivatives (being leavings group), is reflected at coupling amine and acid (when X is OH) or amine and suitable acid derivative ((leavings group when X is not OH; Carry out under the existence of condition Cl for example)), obtain formula I compound.
Another kind of embodiment provides the method for preparation I compound:
Figure S05811231120061019D000323
Wherein Y is:
Figure S05811231120061019D000324
Its dependent variable is defined as any embodiment of this paper, comprises making formula 7 compounds:
Figure S05811231120061019D000325
Wherein each variable is defined as any embodiment of this paper,
With formula RNHCH (R 2) C (O) X compound reaction, wherein X is OH or suitable derivatives, is reflected at coupling amine and acid (when X is OH) or suitable acid derivative (when X is not OH; For example X is Cl) the existence of condition under carry out, obtain formula I compound.
Another embodiment of the invention provides preparation formula IV the method for compound:
Wherein each variable is defined as any embodiment of this paper, comprises making formula I compound:
Figure S05811231120061019D000332
Wherein Y is:
Wherein R and R 1Be defined independently of one another, under hydrolysising condition, react, obtain formula II compound as any embodiment of this paper.In some embodiments, R is R 3C (=O).In other embodiments, when A was proline(Pro), R was R 3C (=O).The hydrolysising condition that transforms I and be II be the technician known (for example referring to Greene).This class condition comprises appropriate solvent (for example acetonitrile) and aqueous acids (for example 2M HCl).
Another kind of embodiment provides preparation formula 6-A the method for compound:
Figure S05811231120061019D000341
PG wherein 2Be the nitrogen-protecting group group that is fit to, R 1Be defined as any embodiment of this paper,
Comprise and make formula 5-A compound:
Figure S05811231120061019D000342
Under the cyclisation conditions that is fit to, react, obtain formula 6-A compound.The cyclisation conditions that is fit to comprises acid and the solvent that is fit to; The DCM solution of TFA for example.
Another kind of embodiment provides preparation formula 5-A the method for compound:
Figure S05811231120061019D000343
Comprise and make formula 4-A compound:
Figure S05811231120061019D000344
At R 1The existence of-OH (or the acetal that is fit to generates reagent), protonic acid or Lewis acid (for example TsOH) and the solvent that is fit to is reacted down, obtains formula 5-A compound.
Another kind of embodiment provides preparation formula 4-A the method for compound:
Comprise and make formula 3-A compound:
(for example Swern oxidation: Mancuso, A.J. under the oxidizing condition that is fit to; Swern, D.Synthesis, 1981,165-185) reaction obtains formula 4-A compound.Preferred oxidizing condition comprises TEMPO oxidation (example I that vide infra-1 method C).
Another kind of embodiment provides preparation formula 3-A the method for compound:
Figure S05811231120061019D000352
Comprise and make formula 2 compounds:
Figure S05811231120061019D000353
With formula 20-A compound:
Under the condition of coupling amine and carboxylic acid (when X is OH) or amine and suitable carboxylic acid (when X is not OH), react, obtain formula 3-A compound.
Another kind of embodiment provides the method for preparation formula 6 compounds:
Figure S05811231120061019D000355
PG wherein 2Be the nitrogen-protecting group group that is fit to, R 1Be defined as any embodiment of this paper,
Comprise and make formula 5 compounds:
Figure S05811231120061019D000361
Under the cyclisation conditions that is fit to, react, obtain formula 6 compounds.
Another kind of embodiment provides the method for preparation formula 5 compounds:
Figure S05811231120061019D000362
Comprise and make formula 4 compounds:
Figure S05811231120061019D000363
At R 1The existence of-OH (or the acetal that is fit to generates reagent), protonic acid or Lewis acid (for example TsOH) and the solvent that is fit to is reacted down, obtains formula 5 compounds.Preferably, solvent is CH 2Cl 2, toluene or chlorobenzene.
Another kind of embodiment provides the method for preparation formula 4 compounds:
Figure S05811231120061019D000364
Comprise and make formula 3 compounds:
Figure S05811231120061019D000371
(for example Swern oxidation) reaction obtains formula 4 compounds under the oxidizing condition that is fit to.Preferred oxidizing condition comprises TEMPO oxidation (example I that vide infra-1 method C).
Another kind of embodiment provides the method for preparation formula 3 compounds:
Comprise and make formula 2 compounds:
Figure S05811231120061019D000373
With formula 20 compounds:
Figure S05811231120061019D000374
Under the condition of coupling amine and carboxylic acid (when X is OH) or amine and suitable carboxylic acid (when X is not OH), react, obtain formula 3 compounds.
Another kind of embodiment provides the method for preparation formula 16 compounds:
Figure S05811231120061019D000375
PG wherein 2Be the nitrogen-protecting group group that is fit to, R 1Be defined as any embodiment of this paper,
Comprise and make formula 15 compounds:
Figure S05811231120061019D000381
Under the cyclisation conditions that is fit to, react, obtain formula 16 compounds.
Another kind of embodiment provides the method for preparation formula 15 compounds:
Figure S05811231120061019D000382
Comprise and make formula 14 compounds:
At R 1The existence of-OH (or the acetal that is fit to generates reagent), protonic acid or Lewis acid (for example TsOH) and the solvent that is fit to is reacted down, obtains formula 15 compounds.
Another kind of embodiment provides the method for preparation formula 14 compounds:
Comprise and make formula 13 compounds:
Figure S05811231120061019D000385
(for example Swern oxidation) reaction obtains formula 14 compounds under the oxidizing condition that is fit to.
Another kind of embodiment provides the method for preparation formula 13 compounds:
Figure S05811231120061019D000391
Comprise and make formula 2 compounds and formula 21 compounds:
Figure S05811231120061019D000392
Under the condition of coupling amine and carboxylic acid (when X is OH) or amine and suitable carboxylic acid (when X is not OH), react, obtain formula 13 compounds.
Another kind of embodiment provides the method for preparation formula 22 compounds:
Figure S05811231120061019D000393
Comprise and make formula 23 compounds:
Figure S05811231120061019D000394
At R 1The existence of-OH (or the acetal that is fit to generates reagent), protonic acid or Lewis acid (for example TsOH) and the solvent that is fit to is reacted down, obtains formula 22 compounds.Acetal generates Equivalent and includes but not limited to triethyl orthoformate, diethyl acetal, for example (CH 3) 2C (OCH 2CH 3) 2Preferably, solvent is CH 2Cl 2, toluene or chlorobenzene.
Another kind of embodiment provides the method for preparation formula 23 compounds, comprises making formula 2 compounds:
(for example Swern) reaction obtains formula 23 compounds under the oxidizing condition that is fit to.
Another kind of embodiment provides preparation formula 5-A the method for compound:
Figure S05811231120061019D000402
PG wherein 1Be the carboxylic acid protective group who is fit to, PG 2Be the nitrogen-protecting group group that is fit to, R 1Be as claim 1 or 5-9 any one defined,
Comprise and make formula 20-A compound:
Figure S05811231120061019D000403
With formula 22 compounds:
Figure S05811231120061019D000404
Under the condition of coupling amine and carboxylic acid (when X is OH) or amine and suitable carboxylic acid (when X is not OH), react, obtain formula 5-A compound.
Another kind of embodiment provides the method for preparation formula 5 compounds:
Figure S05811231120061019D000405
Comprise and make formula 20 compounds:
With formula 22 compounds:
Figure S05811231120061019D000412
Under the condition of coupling amine and carboxylic acid (when X is OH) or amine and suitable carboxylic acid (when X is not OH), react, obtain formula 5 compounds.
Another kind of embodiment provides preparation formula 5-A the method for compound:
Figure S05811231120061019D000413
Comprise and make formula 21 compounds:
With formula 22 compounds:
Figure S05811231120061019D000415
Under the condition of coupling amine and carboxylic acid (when X is OH) or amine and suitable carboxylic acid (when X is not OH), react, obtain formula 5-A compound.
According to the present invention, can be used alone or in combination these methods The compounds of this invention is provided.
Some embodiment of the present invention provides according to method disclosed herein from compound 3 preparation 4 (therein the embodiments of separating compound 4), from 3 preparations 5 (separating compound 4 not, but in the embodiment that directly reacts after generating on the spot) therein, from 4 preparations 5 with from the process of 5 preparations 6.In preferred embodiment, compound 6 is from compound 5 preparations; Compound 5 is from compound 4 preparations (no matter whether separating); Compound 4 is from compound 3 preparations.Preferably, compound 6 is used to prepare the aspartic acid specific cysteine proteinase inhibitors that contains proline(Pro).The aspartic acid specific cysteine proteinase inhibitors that this class contains proline(Pro) includes but not limited to be disclosed in those (they are all quoted at this as a reference) among WO 95/35308, WO 99/47545, WO 01/81330 and the WO 01/90063.For example, the Compound I A (and steric isomer) of WO 01/90063 (quoting at this as a reference especially) can prepare (for example referring to the 13rd page) as disclosed herein.For fear of query, should be understood that the compound that this class contains proline(Pro) can be depicted as formula I, except ring A is tetramethyleneimine
Figure S05811231120061019D000421
(that is to say it is) from the proline(Pro) deutero-.
Transform compound 6 for the method for the aspartic acid specific cysteine proteinase inhibitors that contains proline(Pro) preferably as disclosed herein.The method for preparing compound 3 also preferably as disclosed herein.But, additive method known to the skilled also can be used to transform compound 6 for to contain the aspartic acid specific cysteine proteinase inhibitors of proline(Pro) and/or to be used to prepare compound 3.
Other embodiments of the present invention provide formula 3 to 6,3-A to 6-A, and 13 to 16 compounds.
One embodiment of the present invention provide formula 4A compound:
Figure S05811231120061019D000422
Another embodiment of the invention provides formula 4 compounds:
Figure S05811231120061019D000431
Another embodiment of the invention provides formula 14 compounds:
Figure S05811231120061019D000432
One embodiment of the present invention provide formula 5-A compound:
Figure S05811231120061019D000433
Another embodiment of the invention provides formula 5 compounds:
Another embodiment of the invention provides formula 15 compounds:
Figure S05811231120061019D000435
One embodiment of the present invention provide formula 3-A compound:
Figure S05811231120061019D000436
Another embodiment of the invention provides formula 3 compounds:
Another embodiment of the invention provides formula 13 compounds:
Figure S05811231120061019D000442
In all above-mentioned embodiments, each variable is defined as any embodiment of this paper.In 3 optimal way, PG 2Be Z, and PG 1Be C 1-6Straight or branched alkyl (preferred tertiary butyl), independent or combination.
As will be for what the technician recognized, some method steps can be in the step of separating or finish on the spot.For example, go to protect and the reaction of subsequently amine can be (passing through separation of amine) of progressively finishing or (need not separation of amine) of finishing in a process.
In some embodiments, said process is as described herein carrying out (for example flow process, embodiment and follow explanation).
Resembling compound 3 such compounds can be used in the process for preparing the compound (for example aspartic acid specific cysteine proteinase inhibitors) that contains proline(Pro).The aspartic acid specific cysteine proteinase inhibitors that contains proline(Pro) includes but not limited to be disclosed in those (they are all quoted at this as a reference) among WO95/35308, WO 99/47545, WO 01/81330 and the WO 01/90063.For example, the Compound I A (and steric isomer) of WO 01/90063 (quoting at this as a reference especially) can prepare (for example referring to the 13rd page) as disclosed herein.
The compound that is used in the present composition and the method also can be modified by additional suitable functional group, to strengthen selectivity organism character.This class modification is known in the art, comprises that increase enters the bio-osmosis of given biosystem (for example blood, lymphsystem, central nervous system), increases oral administration biaavailability, increases solubleness so that drug administration by injection, change metabolism and change discharge rate.
For example, the hydroxy-acid group in the The compounds of this invention can be derived and is for example ester.Preferred ester will be from the following groups deutero-those:
C 1-6Straight or branched alkyl, alkenyl or alkynyl, wherein this alkyl, alkenyl or alkynyl are alternatively by C 6-10Aryl, CF 3, Cl, F, OMe, OEt, OCF 3, CN or NMe 2Replace;
C 1-6Cycloalkyl, wherein 1-2 carbon atom in this cycloalkyl alternatively by-O-or-NR 9-replace.
The compounds of this invention with carbonyl can similarly be derived is for example acetal, ketal, oxime (=NOR 9), hydrazine (=NN (R 9) 2), sulfo-acetal or sulfo-ketal.
Suitable sulfonamide derivatives is known in the art, is also included within the scope of the present invention.
Some said derivative will comprise blocking group known to the skilled (for example referring to Greene).As will in process of the present invention, also adopting these blocking groups for what the technician recognized.
Can measure The compounds of this invention suppresses the release of apoptosis, IL-1 β or directly suppresses the active ability of aspartic acid specificity cysteine protease.Every kind of active assay method all is known in the art.But, as will be for the technician recognized, prodrug compound of the present invention should be only therein prodrug partly will in the cleaved assay method activity be arranged, usually in vivo in the assay method.
The aspartic acid specificity cysteine protease activation measurement is as described in the WO 99/47545.
In other embodiments, the invention provides pharmaceutical composition, wherein comprise: a) The compounds of this invention or its pharmacy acceptable salt as herein defined; And b) pharmaceutically acceptable carrier, auxiliary agent or vehicle.
Should be understood that, in the present invention, comprise compound and pharmacy acceptable salt thereof.If use the pharmacy acceptable salt of The compounds of this invention in these compositions, these salt are preferably from inorganic or organic bronsted lowry acids and bases bronsted lowry deutero-.Such acid salt comprises as follows: acetate, adipate, alginate, aspartate, benzoate, benzene sulfonate, hydrosulfate, butyrates, Citrate trianion, camphorate, camsilate, cyclopentane propionate, digluconate, dodecyl sulfate, esilate, fumarate, glucoheptose salt, glycerophosphate, Hemisulphate, enanthate, hexanoate, hydrochloride, hydrobromate, hydriodate, the 2-isethionate, lactic acid salt, maleate, mesylate, the 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectate, persulphate, 3-phenylpropionic acid salt, picrate, Pivalate, propionic salt, succinate, tartrate, thiocyanate-, tosylate and undecane hydrochlorate.Subsalt comprise ammonium salt, an alkali metal salt (for example sodium and sylvite), alkaline earth salt (for example calcium and magnesium salts), organic bases salt (for example dicyclohexyl amine salt, N-methyl-D-glucamine salt) and with salt of amino acid (for example arginine, Methionin) etc.
And alkaline nitrogen-containing group can be quaternized with following reagent, for example elementary alkyl halide, for example muriate of methyl, ethyl, propyl group and butyl, bromide and iodide; Sulfuric acid dialkyl, for example vitriolic dimethyl, diethyl, dibutyl and diamyl ester; Long-chain halogenide, for example muriate of decyl, lauryl, myristyl and stearyl, bromide and iodide; Aralkyl halide, the bromide of benzyl and styroyl for example, or the like.Obtain water-or oil-solubility or dispersibility product thus.
The pharmaceutically acceptable carrier that can be used in these compositions includes but not limited to ion-exchanger, aluminum oxide, aluminum stearate, Yelkin TTS, serum protein (for example human serum albumin), buffer substance (for example phosphoric acid salt), glycine, Sorbic Acid, potassium sorbate, the partial glyceride mixture of saturated vegetable fatty acid, water, salt or ionogen (protamine sulfate for example, Sodium phosphate dibasic, potassium hydrogen phosphate, sodium-chlor, zinc salt, colloid silica, Magnesium Trisilicate), polyvinylpyrrolidone, based on cellulosic material, polyoxyethylene glycol, Xylo-Mucine, polyacrylic ester, wax, polyethylene-polyoxypropylene block polymer, polyoxyethylene glycol and lanolin.
According to preferred embodiment, the preparation present composition is for Mammals, preferred human administration.
Such pharmaceutical composition of the present invention can be by oral, parenteral, by sucking spraying, part, rectum, nose, cheek, vagina or via the administration of implantation Drug Storage.That term used herein " parenteral " comprises is subcutaneous, in the intravenously, intramuscular, intraarticular, synovial membrane, in the breastbone, in the sheath, in the liver, in the wound with intracranial injection or infusion techniques.Preferably, composition is oral or intravenous administration.
The sterile injectable form of the present composition can be water-based or oiliness suspensoid.These suspensoids can be prepared according to technology known in the art, the dispersion that utilize to be fit to or wetting agent and suspension agent.Aseptic injectable formulation can also be at nontoxic parenteral acceptable diluent or sterile injectable solution agent or the suspensoid in the solvent, for example solution in 1,3 butylene glycol.Acceptable carrier that can adopt and solvent have water, Ringer's solution and isoosmotic sodium chloride solution.In addition, aseptic expressed oil is also through being often used as solvent or suspension medium.For this reason, can adopt the expressed oil of any gentleness, comprise synthetic list-or two-glyceryl ester.Lipid acid, for example oleic acid and glyceride derivative thereof can be used for preparing injection, and they are natural pharmaceutically acceptable oil, for example sweet oil or Viscotrol C, especially their polyoxy ethylization form.These oily solutions or suspensoid can also contain long-chain alcohol thinner or dispersion agent, for example carboxymethyl cellulose or similar dispersion agent, and they generally are used to prepare pharmaceutically acceptable formulation, comprise emulsion and suspensoid.For the purpose of preparation, can also use other tensio-active agents commonly used, for example Tweens, spans and other emulsifying agents or bioavailability toughener, they generally are used in the preparation of pharmaceutically acceptable solid, liquid or other formulations.
Pharmaceutical composition of the present invention can include but not limited to capsule, tablet, aqueous suspension or solution with any oral acceptable forms oral administration.Orally using under the situation of tablet, carrier commonly used comprises lactose and W-Gum.Usually also add lubricant, for example Magnesium Stearate.With regard to regard to the oral capsule administration, useful thinner comprises lactose and exsiccant W-Gum.When oral use needs aqueous suspension, activeconstituents and emulsification and suspension agent coupling.If necessary, can also add some sweeting agent, correctives or tinting material.
Select as an alternative, pharmaceutical composition of the present invention can be with the suppository form rectal administration.They can prepare like this, and medicine is mixed with the nonirritant excipient that is fit to, and described vehicle at room temperature is a solid, but is liquid under rectal temperature, therefore will melt at internal rectum, discharges medicine.This class material comprises theobroma oil, beeswax and polyoxyethylene glycol.
Pharmaceutical composition of the present invention can also be by topical, especially when the treatment target comprises easily by approaching zone of local application or organ, comprises the disease of eye, skin or lower intestine.The topical formulations that is fit to is prepared according to every kind of these zone or organ easily.
The local application of lower intestine can carry out with rectal suppository (on seeing) or the enema that is fit to.Can also use the topical transdermal patch.
With regard to local application, pharmaceutical composition can be mixed with suitable ointment, wherein contain and suspend or be dissolved in active ingredient in one or more carriers.The carrier that is used for the The compounds of this invention topical includes but not limited to mineral oil, Albolene, white vaseline, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.Select as an alternative, pharmaceutical composition can be mixed with suitable lotion or creme, wherein contain and suspend or be dissolved in active ingredient in one or more pharmaceutically acceptable carriers.The carrier that is fit to includes but not limited to mineral oil, Arlacel-60, polysorbate 60, spermaceti ester type waxes, cetostearyl alcohol, 2-Standamul G, benzyl alcohol and water.
With regard to eye is used, pharmaceutical composition can be mixed with isoosmotic through the micronization suspensoid in the Sterile Saline of pH regulator, perhaps be preferably isoosmotic through the solution in the Sterile Saline of pH regulator, wherein contain or do not have sanitas, for example a benzalkonium chloride.Select as an alternative, with regard to eye is used, pharmaceutical composition can be mixed with ointment, for example Vaseline.In one embodiment, composition for example is as United States Patent (USP) 6,645,994 and/or United States Patent (USP) 6,630,473 preparation.
Pharmaceutical composition of the present invention can also be by nose aerosol or inhalation.This based composition is to prepare according to the technology that field of pharmaceutical preparations is known, can be formed in the solution in the salt solution, wherein adopt absorption enhancer, fluorocarbon and/or other the conventional solubilising or the dispersion agent of phenylcarbinol or other sanitass that is fit to, enhancing bioavailability.
Above-claimed cpd and composition are particularly useful for relating to the disease of IL-1 mediation, the disease of apoptosis mediation, inflammatory diseases, autoimmune disorders, destructive bone disorders, proliferative disorder, infectious diseases (infectation of bacteria for example, preferred ocular infection), degenerative disease, with the necrocytosis diseases associated, excessive diet alcohol is taken in disease, virus-mediated disease, retina obstacle, uveitis, inflammatory peritonitis, osteoarthritis, pancreatitis, asthma, adult respiratory distress syndrome, glomerulonephritis, rheumatoid arthritis, systemic lupus erythematous, scleroderma, chronic thyroiditis, the Ge Leifushi disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, the autoimmune neutrophilic leukocyte reduces, thrombopenia, chronic active hepatitis, myasthenia gravis, inflammatory bowel disease, Crohn disease, psoriasis, atopic dermatitis, cicatrization, graft-host disease, the organ-graft refection, organ cell's program death after burning, osteoporosis, leukemia and associated disorders, myelodysplastic syndrome, multiple myeloma-dependency bone disorders, acute myelogenous leukemia, chronic lymphocytic leukemia, metastatic melanoma, Kaposi, multiple myeloma, hemorrhagic shock, Sepsis, septic shock, burn, shigellosis, Alzheimer, Parkinson's disease, Huntington's disease, the Ken Nidishi disease, prion disease, cerebral ischemia, epilepsy, myocardial ischemia, acute and morbus cardiacus, myocardial infarction, congestive heart failure, atherosclerosis, the coronary bypass grafting thing, the ridge amyotrophy, amyotrophic lateral sclerosis, multiple sclerosis, HIV-dependency encephalitis, old and feeble, alopecia, by in the damage of wind-induced neurological, ulcerative colitis, traumatic brain injury, Spinal injury, hepatitis B, hepatitis C, hepatitis G, yellow jack, singapore hemorrhagic fever, Japanese encephalitis, various forms of hepatic diseases, the kidney disease, polycystic kidney disease, the gastroduodenal ulcer disease relevant with helicobacter pylori, HIV infects, tuberculosis, meningitis, the necrosis of toxic epidermis, pemphigus and from body inflammatory diseases (be sometimes referred to as from body inflammatory heating syndrome) and dependency syndrome, for example Muckle-Wells syndrome (MWS), familial cold urticaria (FCU), familial Mediterranean fever (FMF), chronic infancy neurological skin and joint syndrome (CINCAS), a.k.a. the ictal multisystem inflammatory diseases of newborn infant (NOMID), the cycle syndrome (TRAPS) relevant and super-IgD periodic fever syndrome (HIDS) with TNFR1.Compound and composition also can be used for treatment and coronary bypass grafting thing complications associated with arterial system.Compound and composition also can be used for reducing the generation of IGIF (being also referred to as IL-18) or IFN-γ.Compound and composition also can be used in the immunotherapy as cancer therapy.
Compound and composition also can be used in the method for preserving cell.These methods will can be used for preserving organ, those of particularly planning to transplant, perhaps blood products.
The compounds of this invention can be used as dual aspartic acid specificity cysteine protease-1 and aspartic acid specificity cysteine protease-8 inhibitor.Bound by theory not, the R of The compounds of this invention 2And R 3As if group relevant with this unexpected activity.The bridging A group of The compounds of this invention, for example
Figure S05811231120061019D000491
Or
Figure S05811231120061019D000492
Also as if relevant with this unexpected activity.Therefore, compound of the present invention and composition are particularly useful for treatment or prevention of inflammatory conditions.
In other embodiments, the present composition can further comprise another kind of therapeutical agent (one or more supplementary components just).This constituents includes but not limited to thrombolytics, for example tissue plasminogen activator and streptokinase.If use supplementary component, this supplementary component can be used as independent formulation or as the part of single formulation with The compounds of this invention or composition administration the time.
The content of compound in the present composition should be enough to cause the measurement according to any assay method known in the art, and disease seriousness or aspartic acid specificity cysteine protease activity and/or apoptosis have detectable reduction.
The dosage level that can be used for monotherapy is about 0.01 and about 50 or about 100mg/kg body weight between every day, preferably 0.5 and about 75mg/kg body weight between every day, most preferably about 1 and about 25 or the active compound component of about 50mg/kg body weight every day between.
Usually, compound of the present invention or composition to about 5 times, are perhaps selected administration every day about 1 with the administration of continuous infusion mode as an alternative.This class administration can be used as chronic or acute therapy.Can be combined to form the active principle of single formulation with solid support material will be different because of the host that treated and specific administering mode.Typical formulation will contain has an appointment 5% to about 95% active compound (w/w).Preferably, this class preparation contains and has an appointment 20% to about 80% active compound.
When the present composition comprises the combination of formula I compound and one or more other treatments or preventive, the dosage level of this compound and this other medicine all should be bio-occlusion pharmaceutical quantities in the monotherapy system about 10 to about 100%, more preferably between about 10 to about 80%.
In case patient's condition makes moderate progress, can give the maintenance dose of compound of the present invention, composition or combination, if necessary.Subsequently, the two function that can be used as symptom of the dosage of administration or frequency or this is reduced to the level of the condition that maintenance improved, and when symptom had alleviated to desired level, treatment should stop.But, in case disease symptoms has any recurrence, the patient may the intermittence on long-term basis treat.
To understand as the technician, may need to be below or above above-mentioned those dosage.Should be understood that, concrete dosage and treatment plan with regard to any particular patient will depend on multiple factor, comprise that the seriousness of activity, age, body weight, general health situation, sex, diet, administration time, discharge rate, drug regimen, specified disease of the particular compound that is adopted and process, patient are to the procatarxis of treatment disease and attending doctor's judgement.The amount of activeconstituents also will depend on specific compound and the other treatment agent in the composition, if any.
In preferred embodiment, the invention provides treatment and suffer from the patient of one of above-mentioned disease, the method for preferred mammal, comprise the step that described patient is given above-claimed cpd or pharmaceutically acceptable composition.In this embodiment, if the patient also is given another kind of therapeutical agent or aspartic acid specific cysteine proteinase inhibitors, it can be sent in single formulation or as independent formulation with The compounds of this invention so.When as independent formulation administration, the administration of other aspartic acid specific cysteine proteinase inhibitors or composition can prior to, simultaneously or be later than the pharmaceutically acceptable composition administration that comprises The compounds of this invention.
The compounds of this invention also can be incorporated in the composition that applies implantable medical apparatus, for example prosthese, artificial valve, blood vessel graft, Si Tanteshi die and conduit.Therefore, the present invention comprises the composition that applies implantable device on the other hand, comprises The compounds of this invention and the carrier that is suitable for applying described implantable device.On the other hand, the present invention includes the implantable device that scribbles composition, described composition comprises The compounds of this invention and is suitable for applying the carrier of described implantable device.
Another aspect of the present invention relates to and suppress the aspartic acid specificity cysteine protease activity in biological sample, and this method comprises to be made described biological sample contact The compounds of this invention or comprise described compound compositions.Term used herein " biological sample " comprises cell culture and extract thereof without limitation; Biopsy material from Mammals or the acquisition of its extract; With blood, saliva, urine, ight soil, seminal fluid, tear or other body fluid or its extract.
In biological sample, suppress the aspartic acid specificity cysteine protease activity and can be used for multiple purpose well known by persons skilled in the art.This classification example include but not limited to that blood transfusion, organ transplantation, biological specimen are stored and biology is measured.
The compounds of this invention can be used on the method for preserving cell, for example may need to be used for organ transplantation or preserving blood products.The existing report of the similar purposes of aspartic acid specific cysteine proteinase inhibitors [Schierleetal., NatureMedicine, 5,97 (1999)].This method involves the cell or tissue solution-treated that comprises aspartic acid specific cysteine proteinase inhibitors that will will preserve.The amount of required aspartic acid specific cysteine proteinase inhibitors will depend on the validity of this inhibitor with regard to given cell type and preserve cell and avoid the required time span of apoptosis.
Bound by theory not, applicant's cyclic acetal compound is considered to prodrug.That is to say that acetal part body implosion is separated and obtained corresponding acid-aldehyde cpd.As will be for what the technician recognized, compound is metabolism in vivo, for example in the site that is not the prodrug cracking site.Such meta-bolites all comprises within the scope of the invention arbitrarily.
In order to understand the present invention more fully, provide following preparation and tentative embodiment.These embodiment only for the purpose of setting forth, are not interpreted as limiting in any way scope of invention.
Example I-1
(S, S, S, R)-1-[(2S)-(3-methoxyl group-2-methyl-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000521
Method A
(S)-3-amino-4-hydroxy-butyric acid tertiary butyl ester
Figure S05811231120061019D000522
(S)-benzyloxycarbonyl amino-4-hydroxyl-butyric acid tertiary butyl ester is (as Michel et al, Helvetica Chimica Acta 1999,1960 described preparations) ethyl acetate (15ml) solution (0.94g) is through palladium hydroxide/carbon (20%w/w, 160mg) hydrogenation.(celite) removes by filter catalyzer by C salt.Concentrated filtrate obtains title compound in a vacuum, is colourless oil (486mg, 91%);
1H?NMR (400MHz，CDCl 3)?δ1.48?(9H，s)， 1.95?(3H，brs)， 2.28?(1H，dd)，2.46(1H，dd),3.29?(1H，brm)，3.42?(1H，m)，3.60?(1H，m).
Method B
(1S)-2-((S)-2-tertbutyloxycarbonyl-1-methylol-ethyl carbamyl)-tetramethyleneimine-1-carboxylic acid benzyl ester
Figure S05811231120061019D000531
To (the S)-3-amino-4-hydroxy that is stirring-butyric acid tertiary butyl ester (800mg, 4.57mmol) and Z-Pro-OH (1.14g, 4.57mmol) THF (30ml) solution add 2-hydroxy benzotriazole hydrate (741mg, 1.2eq.), DMAP (698mg, 1.25eq.), diisopropylethylamine (1.03ml, 1.3eq.) and 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride (EDC, 1.05g, 1.2eq.).The gained mixture was stirred 18 hours at ambient temperature, dilute with ethyl acetate then.With mixture water, saturated sodium bicarbonate aqueous solution and salt water washing,, filter then, under reduced pressure concentrate through dried over mgso.Resistates obtains the subhead compound through purification by flash chromatography (60% ethyl acetate/petroleum ether), is colorless solid (1.483g, 90%); MS ES (+) 407.3.
Method C
(1S)-2-((S)-2-tertbutyloxycarbonyl-1-formyl radical-ethyl carbamyl)-tetramethyleneimine-1-carboxylic acid benzyl ester
DCM (100ml) solution of (1S)-2-((S)-2-tertbutyloxycarbonyl-1-methylol-ethyl carbamyl)-tetramethyleneimine-1-carboxylic acid benzyl ester (10g) is cooled to 0 ℃ in nitrogen atmosphere.Add 2,2,6 then, (TEMPO 38mg), added trichloroisocyanuric acid (6g) in 30 minutes succeeded by going through to 6-tetramethyl piperidine oxygen base in batches.Mixture was stirred 2 hours at ambient temperature, filter by C salt then.With filtrate water, 1M hypo solution and salt water washing.Through dried over mgso, under reduced pressure concentrate, obtain the subhead compound, be light yellow oil (9.92g, 99%);
1H?NMR(400MHz，d-6DMSO)δ1.38?(9H，d)，1.79-1，86?(3H，m)，2.08-2.23 (1H，m)，2.36-2.51?(1H，2?x?dd)，2.61-2.86?(1H，2xdd)，?3.88-3.46 (2H，m)， 4.24-4.30?(2H，m)，5.05?(2H，quin)，7.28-7.37?(5H.m)，8.59-8.64?(1H，2?x?d)，9.21?(0.57H，s)，9.37?(0.43H，s).
Method D
(1S)-2-((S)-1-tertiary butyloxycarbonyl ylmethyl-2,2-diethoxy-ethyl carbamyl)-tetramethyleneimine-1-carboxylic acid benzyl ester
Methylene dichloride (70ml) solution to (1S)-2-((S)-2-tertbutyloxycarbonyl-1-formyl radical-ethyl carbamyl)-tetramethyleneimine-1-carboxylic acid benzyl ester (4.98g) adds triethyl orthoformate (6.2ml) and tosic acid-hydrate (47mg).The gained mixture is stirred at ambient temperature, do not have the aldehyde residue until analyzing according to TLC.Mixture is concentrated in a vacuum, be dissolved in methylene dichloride (35ml) again.Add saturated sodium bicarbonate aqueous solution (35ml) then, remove organic phase.Water and salt water washing, dry (sal epsom) filters, and under reduced pressure concentrates.Obtain the subhead compound, be light yellow oil (4.85g, 82%); 1HNMR (4 00MHz, d-6DMSO) δ 1.04-1.11 (6H, m), 1.35-1.37 (9H, m), and 1.73-1.89 (3H, m), 2.01-2.49 (3H, m), and 3.43-3.52 (6H, m), 4.05-4.29 (3H, m), and 4.96-5.06 (2H, m), 7.27-7.38 (5H, m), 7.80 (0.5H, d), 7.88 (0.5H, d).
Method E
(1S)-2-((2R, 3S)-2-oxyethyl group-5-oxo-tetrahydrochysene-furans-3-base carbamyl)-tetramethyleneimine-1-carboxylic acid benzyl ester 6.1
(1S)-2-((2S, 3S)-2-oxyethyl group-5-oxo-tetrahydrochysene-furans-3-base carbamyl)-tetramethyleneimine-1-carboxylic acid benzyl ester 6.2
Figure S05811231120061019D000543
Methylene dichloride (25ml) solution of (1S)-2-((S)-1-tertiary butyloxycarbonyl ylmethyl-2,2-diethoxy-ethyl carbamyl)-tetramethyleneimine-1-carboxylic acid benzyl ester (4.85g) is cooled to 0 ℃ in nitrogen atmosphere.Add trifluoroacetic acid (6ml) then, mixture was stirred 15 minutes down at 0 ℃, be warming up to envrionment temperature then, stir until reaction is completely according to TLC.Then mixture is diluted with methylene dichloride (90ml) and saturated sodium bicarbonate aqueous solution (130ml), stirred 15 minutes.Remove organic phase then, with the washing of 1: 1 saturated sodium bicarbonate aqueous solution/salt solution (100ml), merge water lotion, strip with DCM (100ml), merge organic layer, dry (sal epsom) filters, and under reduced pressure concentrates.Obtain the subhead compound, be epimer mixture about ketal center (C2).On silica gel, separate epimer, with 30% acetone/sherwood oil wash-out.Cis-isomeride 6.1 (white solid); 1H NMR
(400MHz，d-6?DMSO)δ1.08-1.17?(3H，m)，1.78-2.01?(3H，m)，
2.08-2.12?(1H，m)，2.37-2.57?(1H，2?x?dd)，2.61-2.79?(1H，2?x
dd)，3.35-3.51?(2H，m)，3.55-3.68?(1H，m)，3.71-3.82?(1H，d)，
4.20-4.32?(1H，m)，4.52-4.61?(1H，m)，4.98-5.11?(2H，m)，5.53-
5.58?(1H，m)，7.24-7.42?(5h,m)， 8.25-8.31?(1H，m)；MS?ES+
377.3?(100％)，ES-375.3?(10％)；
Trans-isomer(ide) 6.2 (colourless oil);
1H?NMR(400MHz，d-6?DMSO)δ1.08-1.19(3H，m)，1.78-1.89
(3H，m)，2.10-2.34?(1H，m)，2.92-3.07?(1H，2?x?dd)，3.36-3.51
(3H，m)，3.62-3.78 (2H，m)，4.12-4.21?(2H，m)，?4.97-5.12?(3H，
m)，7.28-7.40?(5H，m)，8.51-8.58?(1H，m)；MS?ES+377.4
(100％)，ES?-?375.3?(10％).
(1S)-2-((2R, 3S)-2-methoxyl group-5-oxo-tetrahydrochysene-furans-3-base carbamyl)-tetramethyleneimine-1-carboxylic acid benzyl ester 6.3
(1S)-2-((2S, 3S)-2-methoxyl group-5-oxo-tetrahydrochysene-furans-3-base carbamyl)-tetramethyleneimine-1-carboxylic acid benzyl ester 6.4
Figure S05811231120061019D000551
According to preparing to the described similar mode of method A-E, in step D, use trimethyl orthoformate, obtain the subhead compound, be the mixture of epimer 6.3 and 6.4.On silica gel, separate epimer, with 30% to 40%2-butanone/sherwood oil to 70% acetone/sherwood oil wash-out.Cis-isomeride 6.3 (oil that viscosity is colourless);
1H?NMR (400MHz，d-6?DMSO)δ1.77-1.89
(3H，m)，2.07-2.12?(1H，m)，?2.32-2.43 (1H，2?x?d)，2.55-2.61
(1H，2?x?d)，2.71-2.81?(1H，2?x?d)，3.39-3.62?(4H，m)，4.21-
4.30 (1H，m)， 4.57-4.64?(1H，m)，5.01-5.09?(2H，m)，5.42-5.47
(1H，m)，7.27-7.42?(5H，m)，8.24-8.31?(1H，m)；
Trans-isomer(ide) 6.4 (white solid);
1H?NMR?(400MHz，d-6?DMSO)δ1.79-1.90?(3H，m)，
2.09-2.21?(1H，m)，2.23-41?(1H，2?x?d)，2.91-3.05?(1H，2?xdd)，?3.35-3.71?(5H,?m)，4.09-4.21?(2H，m)，4.98-5.19?(3H，m)，7.28-7.41(5H，m)，8.51-8.58?(1H，m).
(1S)-2-((2R, 3S)-2-isopropoxy-5-oxo-tetrahydrochysene-furans-3-base carbamyl)-tetramethyleneimine-1-carboxylic acid benzyl ester 6.5
(1S)-2-((2S, 3S)-2-isopropoxy-5-oxo-tetrahydrochysene-furans-3-base carbamyl)-tetramethyleneimine-1-carboxylic acid benzyl ester 6.6
Figure S05811231120061019D000561
According to preparing to the described similar mode of method A-E, in step D, use orthoformic acid three isopropyl esters, obtain the subhead compound, be the mixture of epimer 6.5 and 6.6.On silica gel, separate epimer, with 30% to 40%2-butanone/sherwood oil wash-out.Cis-isomeride 6.5 (colourless colloid); 1H
NMR (400MHz，d-6?DMSO)δ1.07-1.16?(6H，m)，1.81-1.86?(2H，m)，2.37-2.71?(2H，m)，3.35-3.53?(2H，m)，3.86-3.90?(1H，m)，4.18-4.24?(1H，m)，4.46-4.55?(1H，m)，4.95-5.10?(2H，m)，5.63(1H，d)，7.27-7.38?(5H，m)，8.22-8.30?(1H，m)；?MS?ES+391.3(100％)；
Trans-isomer(ide) 6.6 (white solid); 1H NMR (400MHz, d-6 DMSO) δ 1.07-1.15 (6H, m), 1.78-1.82 (3H, m), and 2.07-2.41 (2H, m), 2.87-3.01 (1H, m), and 3.35-3.50 (2H, m), 3.74-3.96 (1H, m), and 4.07-4.18 (2H, m), 4.95-5.11 (2H, m), 5.22 (1H, 2 x s), 7.24-7.39 (5H, m), and 8.48-8.53 (1H, m); MS ES+391.4 (100%).
(1S)-2-((2R, 3S)-2-propoxy--5-oxo-tetrahydrochysene-furans-3-base carbamyl)-tetramethyleneimine-1-carboxylic acid benzyl ester 6.7
(1S)-2-((2S, 3S)-2-propoxy--5-oxo-tetrahydrochysene-furans-3-base carbamyl)-tetramethyleneimine-1-carboxylic acid benzyl ester 6.8
Figure S05811231120061019D000571
According to preparing to the described similar mode of method A-E, in step D, use tripropyl orthoformate, obtain the subhead compound, be the mixture of epimer 6.7 and 6.8.On silica gel, separate epimer, with 30% to 40%2-butanone/sherwood oil wash-out.Cis-isomeride 6.7 (colourless colloid); 1H NMR (400MHz, d-6 DMSO) δ 0.84-0.93 (3H, m), 1.55 (2H, m), 1.81-1.89 (3H, m), 2.08-2.22 (1H, m), 2.37-2.61 (1H, 2 x dd), 2.71-2.80 (1H, 2 x dd), 3.31-3.53 (2H, m), 3.60-3.69 (1H, m), 4.20-4.29 (1H, m), 4.52-4.61 (1H, m), 4.95-5.11 (2H, m), 5.50 (1H, m), 7.27-7.36 (5H, m), 8.27 (1H, m);
Trans-isomer(ide) 6.8 (colourless oil);
1H?NMR(400MHz，d-6?DMSO)δ0.82-0.90(3H，m)，1.46-1.57(2H，m)，1.77-1.89?(3H，m)，2.06-2.41?(1H，m)，2.90-3.05?(1H，2?x?dd),3.33-3.66?(5H，m)，4.11-4.20?(2H，m)，4.94-5.10?(3H，m)，7.28-7.37?(5H，m)，8.51(1H，m).
(1S)-2-((2R, 3S)-2-butoxy-5-oxo-tetrahydrochysene-furans-3-base carbamyl)-tetramethyleneimine-1-carboxylic acid benzyl ester 6.9
(1S)-2-((2S, 3S)-2-butoxy-5-oxo-tetrahydrochysene-furans-3-base carbamyl)-tetramethyleneimine-1-carboxylic acid benzyl ester 6.10
Figure S05811231120061019D000581
According to preparing to the described similar mode of method A-E, in step D, use tributyl orthoformate, obtain the subhead compound, be the mixture of epimer 6.9 and 6.10.On silica gel, separate epimer, with 30% to 40%2-butanone/sherwood oil wash-out.Cis-isomeride 6.9 (colourless colloid); 1HNMR
(400MHz，d-6?DMSO)δ0.86-0.92?(3H，m)，1.28-1.37?(2H，m)，1.4?5-1.54?(2H，m)，1.79-1.88?(3H，m)，2.07-2.21?(1H，m)，2.35-2.78?(2H，m)，3.31-3.54?(2H,?m)，3.63-3.70?(1H，m)，4.21-4.29(1H，m)，4.51-4.61?(1H，m)，4.95-5.09?(2H，m)，5.50?(1H，m)，7.27-7.37?(5H，m)，8.25?(1H，m)；
Trans-isomer(ide) 6.10 (colourless oil);
1H?NMR (400MHz，d-6?DMSO)δ0.85-0，93?(3H，m)，1.26-1.36(2H，m)，1.44-1.56?(2H，m)，1.77-1.90 (3H，m)，2.08-2.40 (1H，m)，2.89-3.05 (1H，2?x?dd)，3.34-3.70?(5H，m)，4.08-4.19?(2H，m)，4.95-5.10?(3H，m)，7.28-7.39?(5H，m)，8.53(1H，m).
Method F
(S)-and 1-[(1R, 3S, 4S)-3-((2R, 3S)-2-oxyethyl group-5-oxo-tetrahydrochysene-furans-3-base carbamyl)-2-tetramethyleneimine-2-carbonyl 1-2,2-dimethyl-propyl group }-the carboxylamine benzyl ester
Figure S05811231120061019D000582
To (1S)-2-((2R; 3S)-2-oxyethyl group-5-oxo-tetrahydrochysene-furans-3-base carbamyl)-ethyl acetate (160ml) and DMF (25ml) solution of tetramethyleneimine-1-carboxylic acid benzyl ester 6.1 (4.68g) adds triethylamine (2.5g); succeeded by palladium hydroxide/carbon (20%w/w, 1g).Mixture is stirred under nitrogen atmosphere, do not have raw material to exist until analyzing according to TLC.Remove by filter catalyzer by C salt.Add (S)-2-benzyloxycarbonyl amino-3 to filtrate, 3-two. and methyl-butyric acid (4.93g), hydroxy benzotriazole hydrate (2.01g) and 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride (EDC, 2.85g).The gained mixture stirred at ambient temperature spend the night.Add saturated sodium bicarbonate aqueous solution (180ml) then, remove organic phase.With saturated aqueous ammonium chloride (180ml), use salt solution (180ml) washing again, dry (sal epsom) filters, and under reduced pressure concentrates.Purifying crude product on silica gel is with 40-75% ethyl acetate/petroleum ether wash-out.Obtain the subhead compound, be white foam (4.02g, 66%);
1H?NMR(400MHz，CDCl 3)δ0.97(9H，s)，1.14(3H，t)，1.79-1.94?(3H，m)，2.02-2.10?(1H，m)，2.44?(1H，dd)，2.75?(1H，dd)，3.52-3.66?(2H,?m)，3.70-3.79?(2H，m)，4.22?(1H，d)，4.38-4.41?(1H，m)，4.48-4.58?(1H，m)，5.03?(2H，q)，5.56
(1H，d)，7.26?(1H，d)，7.29-7.40?(5H，m)，8.24?(1H，d)； MS?ES
+490.6?(100％)，ES-488.8?(10％).
Method G
(S, S, S, R)-1-[(2 S)-(3-methoxyl group-2-methyl-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
To (S)-1-[(1R; 3S; 4S)-3-((2R; 3S)-2-oxyethyl group-5-oxo-tetrahydrochysene-furans-3-base carbamyl)-2-tetramethyleneimine-2-carbonyl]-2; 2-dimethyl-propyl group }-ethyl acetate (20ml) solution of carboxylamine benzyl ester (344mg) add palladium hydroxide/carbon (20%w/w, 74mg).Mixture is stirred under nitrogen atmosphere, do not have raw material to exist until analyzing according to TLC.Remove by filter catalyzer by C salt, under reduced pressure concentrated filtrate obtains amine, is brown foam (260mg).This product of a part (153mg) is dissolved in THF, adding 3-methoxyl group-2-tolyl acid (146mg), Diisopropylamine (191 μ l), hydroxy benzotriazole hydrate (77mg) and 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride (EDC, 109mg).The gained mixture was stirred 24 hours at ambient temperature, dilute with saturated sodium bicarbonate aqueous solution then.Remove organic phase, with saturated aqueous ammonium chloride, use the salt water washing again, dry (sal epsom) filters, and under reduced pressure concentrates.The purifying crude product is used eluent ethyl acetate on silica gel.Obtain the subhead compound, be white solid (138mg, 62%); Analytical data is summarised in the table 3.
By basically with the described similar methods of example I-1, preparation formula I-2 to I-58 compound.
Example I-2
(S, S, S, R)-1-[(2S)-(2-methoxyl group-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000601
Example I-3
(S, S, S, R)-1-[3-methyl-(2 S)-(2-trifluoromethoxy-benzamido)-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-base of oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)]-acid amides
Example I-4
(S, S, S, R)-1-[(2S)-(3-hydroxy-2-methyl-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000603
Example I-5
(S, S, S, R)-1-[(2S)-(3-amino-2-methyl-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000611
Example I-6
(S, S, S, R)-1-[(2S)-(2,6-two chloro-benzamidos)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000612
Example I-7
(S, S, S, R)-N-{ (1S)-[(2S)-(and (2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-the Ji carbamyl)-tetramethyleneimine-1-carbonyl]-2-methyl-propyl group }-2-methyl-niacinamide
Figure S05811231120061019D000613
Example I-8
(S, S, S, R)-N-{ (1S)-[(2S)-(and (2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-the Ji carbamyl)-tetramethyleneimine-1-carbonyl]-2-methyl-propyl group }-4-methyl-niacinamide
Figure S05811231120061019D000614
Example I-9
(S, S, S, R)-1-{3-methyl-(2 S)-[(3-methyl-thiophene-2-carbonyl)-amino]-butyryl radicals }-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000621
Example I-10
(S, S, S, R)-2,3-two chloro-N-{ (1S)-[(2S)-(and (2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-the Ji carbamyl)-tetramethyleneimine-1-carbonyl]-2-methyl-propyl group }-Isonicotinamide
Example I-11
(S, S, S, R)-3,5-two chloro-N-{ (1S)-[(2S)-(and (2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-the Ji carbamyl)-tetramethyleneimine-1-carbonyl]-2-methyl-propyl group }-Isonicotinamide
Example I-12
(S, S, S, R)-1-[(2S)-and (3-methoxyl group-2-methyl-benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000631
Example I-13
(S, S, S, R)-1-[(2S)-(3-methoxyl group-2-methyl-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-methoxyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Example I-14
(S, S, S, R)-1-[(2S)-(3-methoxyl group-2-methyl-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-isopropoxy-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Example I-15
(S, S, S, R)-1-[(2S)-(3-methoxyl group-2-methyl-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2 S)-carboxylic acid [the 5-oxo-(2R)-propoxy--5-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000634
Example I-16
(S, S, S, R)-1-[(2S)-(2-chloro-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Example I-17
(S, S, S, R)-and 1-[3, the 3-dimethyl-(2S)-(2-methyl-benzamido)-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Example I-18
(S, S, S, R)-1-[3-methyl-2 (S)-(2-trifluoromethyl-benzamido)-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo one tetrahydrochysene one furans-3 (S) base]-acid amides
Figure S05811231120061019D000643
Example I-19
(S, S, S, R)-1-[2 (S)-(2-chloro-benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R) one methoxyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Example I-20
(S, S, S, R)-the 1-[3.3-dimethyl-(2S)-(2-trifluoromethyl-benzamido)-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-isopropoxy-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000651
Example I-21
(S, S, S, R)-1-[(2S)-and (2-chloro-benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000652
Example I-22
(S, S, S, R)-and 1-[3, the 3-dimethyl-(2S)-(2-trifluoromethyl-benzamido)-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Example I-23
(S, S, S, R)-1-[(2S)-and (2-chloro-benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [the 5-oxo-(2R)-propoxy--tetrahydrochysene-furans-(3S)-yl]-acid amides
Example I-24
(S, S, S, R)-1-[(2S)-and (2-chloro-benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-butoxy-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000661
Example I-25
(S, S, S, R)-1-[(2S)-and (2-chloro-3-trifluoromethoxy-benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000662
Example I-26
(S, S, S, R)-1-[(2S)-(2-chloro-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [the 5-oxo-(2R)-propoxy--tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000663
Example I-27
(S, S, S, S)-1-[(2S)-(2-chloro-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [the 5-oxo-(2S)-propoxy--tetrahydrochysene-furans-(3S)-yl]-acid amides
Example I-28
(S, S, S, S)-1-[(2S)-(2-chloro-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2S)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Example I-29
(S, S, S, R)-1-[(2S)-(2-chloro-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-butoxy-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000672
Example I-30
(S, S, S, S)-1-[(2S)-(2-chloro-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2S)-butoxy-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Example I-31
(S, S, S, R)-1-[(2S)-(2-chloro-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-isopropoxy-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000674
Example I-32
(S, S, S, S)-1-[(2S)-(2-chloro-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2S)-isopropoxy-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000681
Example I-33
(S, S, S, R)-1-[(2S)-and (2-chloro-3-encircles propoxy--benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000682
Example I-34
(S, S, S, R)-1-[(2S)-and (2-chloro-3-methyl-benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Example I-35
(S, S, S, R)-1-[(2S)-(2-chloro-3-methoxyl group-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2 S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000684
Example I-36
(S, S, S, R)-1-[(2S)-and (2-chloro-3-ethyl-benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Example I-37
(S, S, S, R)-1-[(2S)-(2-chloro-4-methoxyl group-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000692
Example I-38
(S, S, S, R)-1-[(2S)-and (2-chloro-3-cyclopropyl methyl-benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Example I-39
(S, S, S, R)-1-[(2S)-and (2-chloro-3-hydroxyl-benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000701
Example I-40
(S, S, S, R)-1-[(2S)-(2-chloro-4-acetylaminohydroxyphenylarsonic acid benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Example I-41
(S, S, S, R)-1-[(2S)-and (2-chloro-3-acetylaminohydroxyphenylarsonic acid benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Example I-42
(S, S, S, R)-1-[(2S)-and (2-methyl-3-acetylaminohydroxyphenylarsonic acid benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000704
Example I-43
(S, S, S, R)-1-[(2S)-and (2-chloro-4-acetylaminohydroxyphenylarsonic acid benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000711
Example I-44
(S, S, S, R)-1-[(2S)-and (2-fluoro-4-acetylaminohydroxyphenylarsonic acid benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000712
Example I-45
(S, S, S, R)-1-[(2S)-(2-fluoro-4-acetylaminohydroxyphenylarsonic acid benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000713
Example I-46
(S, S, S, R)-1-[(2S)-(2-chloro-4-isopropoxy-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000714
Example I-47
(S, S, S, R)-1-[(2S)-and (2-chloro-4-hydroxyl-benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Example I-48
(S, S, S, R)-1-[(2S)-and (2-chloro-4-methoxymethyl-benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Example I-49
(S, S, S, R)-1-[(2S)-and (2-chloro-4-isobutyryl amino-benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Example I-50
(S, S, S, R)-1-[(2S)-(2-chloro-4-acetylaminohydroxyphenylarsonic acid benzamido)-3-cyclohexyl]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000731
Example I-51
(S, S, S, R)-1-[(2S)-and (2-chloro-4-methoxycarbonyl amino-benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Example I-52
(S, S, S, R)-1-[(2S)-and (2-chloro-3-phenoxy group-benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Example I-53
(S, S, S, R)-1-[(2S)-and (2-chloro-4-thiazolyl amino-benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Example I-54
(S, S, S, R)-1-[(2S)-(3-amino-2-chloro-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Example I-55
(S, S, S, R)-1-[(2S)-(2-chloro-benzamido)-3-thiazole-4-base one propionyl]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-base of oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)]-acid amides
Figure S05811231120061019D000742
Example I-56
(S, S, S, R)-1-[(2S)-(3-methoxyl group-2-methyl-benzamido)-3-thiazole-4-base one propionyl]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-base of oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)]-acid amides
Example I-57
(S, S, S, R)-1-[(2S)-and (2-chloro-3-methoxyl group-benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Example I-58
(S, S, S, R)-1-[(2S)-and (2-chloro-benzamido)-3,3-dimethyl-butyryl radicals]-piperidines-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Example I-59
2-[(2S)-and (3-methoxyl group-2-methyl-benzamido)-3,3-dimethyl-butyryl radicals]-2-(1S, 4R)-aza-bicyclo [2.2.1] heptane-(3S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000753
Method H
(1R, 3S, 4S)-3-((S)-2-tertbutyloxycarbonyl-1-methylol-ethyl carbamyl)-2-aza-bicyclo [2.2.1] heptane-2-carboxylic acid benzyl ester
Figure S05811231120061019D000754
To (the S)-3-amino-4-hydroxy that is stirring-butyric acid tertiary butyl ester (486mg) and (1R, 3S, 4S)-2-aza-bicyclo [2.2.1] heptane-2,3-dicarboxylic acid 2-benzyl ester is (as Tararov etal, Tett.Asymm.2002,13, the described preparation of 25-28) THF (18ml) solution (767mg) add 2-hydroxy benzotriazole hydrate (452mg), DMAP (426mg), diisopropylethylamine (631 μ l) and 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride (EDC, 641mg).The gained mixture was stirred 18 hours at ambient temperature, dilute with ethyl acetate then.With mixture water, saturated sodium bicarbonate aqueous solution and salt water washing,, filter then, under reduced pressure concentrate through dried over mgso.Resistates obtains the subhead compound through purification by flash chromatography (60% ethyl acetate/petroleum ether), is colourless oil (1.1g, 91%); 1H NMR (400MHz, d-6 DMSO) δ 1.13-1.25 (1H, m), 1.30-1.48 (9H, m), and 1.49-1.88 (6H, m), 2.20-2.52 (2H, m), and 3.09-3.34 (2H, m), 3.64 (1H, d), and 4.00-4.16 (2H, brm), 4.80 (1H, m), and 4.90-5.15 (2H, m), 7.21-7.41 (5H, m), and 7.50-7.75 (1H, m); MS ES (+) 433.37.
Method I
(1R, 3S, 4S)-3-((S)-2-tertbutyloxycarbonyl-1-formyl radical-ethyl carbamyl)-2-aza-bicyclo [2.2.1] heptane-2-carboxylic acid benzyl ester
Figure S05811231120061019D000761
With (4S)-3 DCM (10ml) solution of ((S)-2-tertbutyloxycarbonyl-1-methylol-ethyl carbamyl)-2-aza-bicyclo [2.2.1] heptane-2-carboxylic acid benzyl ester (1.1g) is cooled to 0 ℃ in nitrogen atmosphere for 1R, 3S.Add 2,2,6 then, (TEMPO 4mg), added trichloroisocyanuric acid (621mg) in 30 minutes succeeded by going through to 6-tetramethyl piperidine oxygen base in batches.Mixture was stirred 1 hour at ambient temperature, filter by C salt then.With filtrate water, 1M hypo solution and salt water washing.Through dried over mgso, under reduced pressure concentrate, obtain the subhead compound, be colourless oil (698mg, 64%);
1H?NMR?(400MHz，d-6?DMSO)δ1.16-1.89?(16H，m)，2.30-2.80?(2H,?m)，3.68-3.81?(1H，m)，4.19?(1H，brm)，4.39(1H，m)，4.91-5.16?(2H，m)，7.21-7.43?(5H，m)，8.45?(0.4H，d)，8.60?(0.6，d)，9.19?(0.6H，s)，9.37?(0.4H，s).
Method J
(1R, 3S, 4S)-3-((S)-1-tertiary butyloxycarbonyl ylmethyl-2,2-diethoxy-ethyl carbamyl)-2-aza-bicyclo [2.2.1] heptane-2-carboxylic acid benzyl ester
To (1R; 3S, 4S)-methylene dichloride (10ml) solution of 3-((S)-2-tertbutyloxycarbonyl-1-formyl radical-ethyl carbamyl)-2-aza-bicyclo [2.2.1] heptane-2-carboxylic acid benzyl ester (698mg) adds triethyl orthoformate (720mg) and tosic acid monohydrate (6mg).The gained mixture is stirred at ambient temperature, do not have the aldehyde residue until analyzing according to TLC.Add saturated sodium bicarbonate aqueous solution then, remove organic phase.Water and salt water washing, dry (sal epsom) filters, and under reduced pressure concentrates.Obtain the subhead compound, be light yellow oil (635mg, 78%);
1H?NMR(400MHz，d-6?DMSO)δ0.96-1.15(6H，m)，1.26-1.84?(16H，m)，2.20-2.50?(2H，m)，3.40-3.81?(5H，m)，4.10-4.28?(2H，m)，4.37?(1H，m)，4.88-5.14?(2H，m)，7.20-7.40(5H，m)，7.65(0.5H，d)，7.80?(0.5H，d).
Method K
(1R, 3S, 4S)-3-((2R, 3S)-2-oxyethyl group-5-oxo-tetrahydrochysene-furans-3-base carbamyl)-2-aza-bicyclo [2.2.1] heptane-2-carboxylic acid benzyl ester
Will (1R, 3S, 4S)-methylene dichloride (3ml) solution of 3-((S)-1-tertiary butyloxycarbonyl ylmethyl-2,2-diethoxy-ethyl carbamyl)-2-aza-bicyclo [2.2.1] heptane-2-carboxylic acid benzyl ester (635mg) is cooled to 0 ℃ in nitrogen atmosphere.Add trifluoroacetic acid (0.7ml) then, mixture was stirred 15 minutes down at 0 ℃, be warming up to envrionment temperature then, stir until being completely according to the TLC analytical reaction.Then mixture is diluted with methylene dichloride (10ml) and saturated sodium bicarbonate aqueous solution (14ml).Remove organic phase, with the washing of 1: 1 saturated sodium bicarbonate aqueous solution/salt solution (8ml), dry (sal epsom) filters, and under reduced pressure concentrates.Obtain the subhead compound, be epimer mixture about the ketal center.On silica gel, separate epimer, with 30%2-butanone/sherwood oil wash-out.Cis-isomeride (oil) (115mg, 23%);
1H?NMR(400MHz，d-6?DMSO)δ0.80-1.91(10H，m)，2.35-2.79(2H，m)，3.56?(1H，m)，3.66-3.80?(2H，m)，4.18?(1H，m)，4.59(1H，m)，4.94-5.11?(2H，m)，5.53?(1H，d)，7.20-7.40 (5H，m)，8.18?(0.5H，d)，8.27?(0.5H，d)；MS?ES+403.31?(100％)，ES-401.37?(15％)；
Trans-isomer(ide) (oil) (103mg, 20%); 1H NMR (400MHz, d-6DMSO) δ 0.80-1.85 (10H, m), 2.25-2.60 (1H, m), 2.95 (1H, m), 3.42 (1H, m), 3.5-3.75 (2H, m), 4.88-5.15 (3H, m), 7.21-7.40 (5H, m), 8.50 (0.4H, d), 8.59 (0.6H, d).
Method L
(S)-and 1-[(1R, 3S, 4S)-3-((2R, 3S)-2-oxyethyl group-5-oxo-tetrahydrochysene-furans-3-base carbamyl)-2-aza-bicyclo [2.2.1] heptane-2-carbonyl]-2,2-dimethyl-propyl group }-the carboxylamine benzyl ester
Figure S05811231120061019D000781
To (1R; 3S; 4S)-3-((2R; 3S)-2-oxyethyl group-5-oxo-tetrahydrochysene-furans-3-base carbamyl)-ethyl acetate (160ml) and DMF (25ml) solution of 2-aza-bicyclo [2.2.1] heptane-2-carboxylic acid benzyl ester (5g) adds triethylamine (2.5g); succeeded by palladium hydroxide/carbon (20%w/w, 1g).Mixture is stirred under nitrogen atmosphere, do not have raw material to exist until analyzing according to TLC.Remove by filter catalyzer by C salt.Add (S)-2-benzyloxycarbonyl amino-3 to filtrate, and 3-dimethyl-butyric acid (4.93g), hydroxy benzotriazole hydrate (2.01g) and 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride (EDC, 2.85g).The gained mixture stirred at ambient temperature spend the night.Add saturated sodium bicarbonate aqueous solution (180ml) then, remove organic phase.With saturated aqueous ammonium chloride (180ml), use salt solution (180ml) washing again, dry (sal epsom) filters, and under reduced pressure concentrates.Purifying crude product on silica gel is with 40-75% ethyl acetate/petroleum ether wash-out.Obtain the subhead compound, be white foam (5.25g, 81%);
1HNMR?(400MHz，d-6?DMSO)δ0.85-1.03?(10H，m)，1.07-1.20?(3H，t)，1.30?(1H，m)，1.40?(1H，m)，1.50-1.80(3H，m)，1.93?(1H，m)，2.40-2.50?(1H，m)，2.78?(1H，m)，3.60(1H，m)，3.78?(1H，m)，3.89?(1H，s)，4.26?(1H，d)，4.52?(2H，m)，4.96-5.12(2H，m)，5.56?(1H，d)，7.10?(1H，d)，7.24-7.40(5H，m)，?8.27?(1H，d)；MS?ES+516.93?(100％)，?ES-515.05(100％).
Method M
(1R, 3S, 4S)-2-[(S)-and 2-(3-methoxyl group-2-toluyl amino)-3,3-dimethyl-butyryl radicals]-2-aza-bicyclo [2.2.1] heptane-3-carboxylic acid ((2R, 3S)-2-oxyethyl group-5-oxo-tetrahydrochysene-furans-3-yl)-acid amides
To (S)-1-[(1R; 3S; 4S)-3-((2R; 3S)-2-oxyethyl group-5-oxo-tetrahydrochysene-furans-3-base carbamyl)-2-aza-bicyclo [2.2.1] heptane-2-carbonyl]-2; 2-dimethyl-propyl group }-ethyl acetate (20ml) solution of carboxylamine benzyl ester (370mg) add palladium hydroxide/carbon (20%w/w, 74mg).Mixture is stirred under nitrogen atmosphere, do not have raw material to exist until analyzing according to TLC.Remove by filter catalyzer by C salt, under reduced pressure concentrated filtrate obtains amine, is brown foam (272mg).This product of a part (167mg) is dissolved in THF, adding 3-methoxyl group-2-tolyl acid (146mg), Diisopropylamine (191 μ l), hydroxy benzotriazole hydrate (77mg) and 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride (EDC, 109mg).The gained mixture was stirred 24 hours at ambient temperature, dilute with saturated sodium bicarbonate aqueous solution then.Remove organic phase, with saturated aqueous ammonium chloride, use the salt water washing again, dry (sal epsom) filters, and under reduced pressure concentrates.The purifying crude product is used eluent ethyl acetate on silica gel.Obtain the subhead compound, be white solid (121mg, 52%);
1H?NMR(400MHz，CDCl3)δ1.10?(9H，s)，1.28 (3H，t)，1.43-1.56 (1H，m)，1.79-1.86 (3H，m)，1.99?(1H，brd)，2.29?(3H，s)，2.30-2.37?(1H，m)，2.83 (1H，dd)，3.02(1H，brs)，3.66-3.74(1H，m)，3.87(3H，s)，3.88-3.94?(1H，m)，4.16 (1H，brs)，4.54 (1H，brs)，4.66-4.74?(1H，m)，4.97?(1H，d)，5.46 (1H，?d)，?6.44 (1H，brd)，6.93 (1H，d)，7.00?(1H，d)，7.22 (1H，t)，7.78 (1H，brd)；IR?(solid)?cm -12960，1791，1624，1505，1438，1261，1115，975?；MS?ES+530；ES-?528.
By basically with the described similar methods of example I-59, preparation formula I-60 to I-73 compound.
Example I-60
2-[(2S)-and (2-chloro-benzamido)-3,3-dimethyl-butyryl radicals]-2-(1S, 4R)-aza-bicyclo [2.2.1] heptane-(3S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Example I-61
2-[(2S)-and (4-acetylaminohydroxyphenylarsonic acid 2-chloro-benzamido)-3,3-dimethyl-butyryl radicals]-2-(1S, 4R)-aza-bicyclo [2.2.1] heptane-(3S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000802
Example I-62
2-[(2S)-and (2-chloro-4-propionamido-benzamido)-3,3-dimethyl-butyryl radicals]-2-(1S, 4R)-aza-bicyclo [2.2.1] heptane-(3S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000811
Example I-63
2-[(2S)-and (2-chloro-3-isobutyryl amino-benzamido)-3,3-dimethyl-butyryl radicals]-2-(1S, 4R)-aza-bicyclo [2.2.1] heptane-(3S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000812
Example I-64
2-[(2S)-and (2-fluoro-3-methoxyl group-benzamido)-3,3-dimethyl-butyryl radicals]-2-(1S, 4R)-aza-bicyclo [2.2.1] heptane-(3S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000813
Example I-65
2-[(2S)-(2-fluoro-3-methoxyl group-benzamido)-3-methyl-butyryl radicals]-2-(1S, 4R)-aza-bicyclo [2.2.1] heptane-(3S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000814
Example I-66
2-[(2S)-and (3-methoxyl group-2-methyl-benzamido)-3,3-dimethyl-butyryl radicals]-2-(1S, 4R)-aza-bicyclo [2.2.1] heptane-(3S)-carboxylic acid [(2S)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Example I-67
2-[(2s)-and (2-chloro-benzamido)-3,3-dimethyl-butyryl radicals]-2-(1S, 4R)-aza-bicyclo [2.2.1] heptane-(3S)-carboxylic acid [(2S)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000822
Example I-68
2-[(2S)-and (4-acetylaminohydroxyphenylarsonic acid 3-chloro-benzamido)-3,3-dimethyl-butyryl radicals]-2-(1S, 4R)-aza-bicyclo [2.2.1] heptane-(3S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Example I-69
2-[(2S)-and (3-chloro-4-propionamido-benzamido)-3,3-dimethyl-butyryl radicals]-2-(1S, 4R)-aza-bicyclo [2.2.1] heptane-(3S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Example I-70
2-[(2S)-and (isoquinolyl-1 carbonylamino)-3,3-dimethyl-butyryl radicals]-2-(1S, 4R)-aza-bicyclo [2.2.1] heptane-(3S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Example I-71
2-[(2S)-and (4-amino-3-chloro-benzamido)-3,3-dimethyl-butyryl radicals]-2-(1S, 4R)-aza-bicyclo [2.2.1] heptane-(3S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Example I-72
2-[(2S)-(4-amino-3-chloro-benzamido)-3-methyl-butyryl radicals]-2-(1S, 4R)-aza-bicyclo [2.2.1] heptane-(3S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Figure S05811231120061019D000833
Example I-73
2-[(2S)-and (isoquinolyl-1 carbonylamino)-3,3-dimethyl-butyryl radicals]-2-(1S, 4R)-aza-bicyclo [2.2.1] heptane-(3S)-carboxylic acid [(2S)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides
Table 3: the characterization data (according to compound number) of the formula I compound of selection
No. M+1(obs) 1H-NMR
I-1 490.1 (DMSO-d 6)0.94-0.95?(3H，m)，0.98-0.99(3H，m)，1.13-1.16?(3H，m)，1.80-2.0(4H，m)，2.10?(3H，s)，2.47-2.51?(2H，m)，2.73?(1H，m)，3.34-3.61?(2H，m)，3.73-3.77(2H，m)，3.79(3H，s)，3.90(1H，m)，4.39?(1H，m)，4.55(1H，m)，5.55?(1H，d)，6.83?(1H，d)，6.99?(1H，d)，7.19?(1H，m)，8.27?(1H，d)，8.34(1H，d)
I-2 476.0 (CDCl 3)?1.01-1.15?(6H，m)，1.26?(3H，t)，1.90-2.29?(5H，m)，2.55-2.59?(1H，m)，2.75-2.83?(1H，m)，3.65-3.98?(3H，m)，4.04?(3H，s)，4.44-4.49?(1H，m)，4.62-4.69?(1H，m)，4.75-4.80 (1H，m)，5.60(1H，d)，7.09?(1H，t)，7.19?(1H，d)，7.52?(1H，t)，7.97?(1H，d)
I-3 530.0 (CDCl 3)?1.02-1.10?(6H，m)，1.23-1.34(3H，m)，1.88-2.19(5H，m)，2.32-2.44(2H，m)，2.81-2.89?(1H，m)，3.66-3.72(2H，m)，3.83-3.98?(2H，m)，4.56-4.73(2H，m)，4.84-4.90?(1H，m)，5.46?(1H，d)，7.15?(1H，d)，7.35-7.60 (4H，m)，7.99?(1H，d)
I-4 476.1 (CDCl 3)?1.02?(3H，d)，1.09?(3H，d)，1.29(3H，t)，1.93-2.19 (4H，m)，2.29?(3H，s)，2.39?(2H，dd)，2.84?(1H，dd)，3.66-3.71?(2H，m)，3.88-3.95?(2H,?m)，4.63(1H，dd)，4.68-4.74?(1H，m)，4.85?(1H，dd)，5.32?(1H，s)，5.47?(1H，d)，6.44(1H，d)，6.87?(1H，d)，6.98-7.00 (1H，m)，7.07-7.12?(1H，m)，7.36?(1H，d)
No. M+1(obs) 1H-NMR
I-5 475.O (CDC1 3)?O.95-1.10 (6H，m)，1.3l?(3H，t)，1.93-2.2l?(4H，m)，2.25 (3H，s)，2.3?4-2.4l (2H，m)，2.80-2.88?(1H，m)，3.63-3.75 (4H，m)，3.87-3.93 (2H，m)，4.65-4.75?(2H，m)，4.82-4.88?(1H，m)，5.47(1H，d)，6.43 (1H，d)，6.74 (1H，d)，6.81(1H，d)，7.04 (1H，t)，7.40 (1H，d)
I-6 514.4 (CDC1 3) 1.03-1.05 (3H，m)，1.09-1.13(3H，m)，1.22-1.3O (3H，m)，1.95?(1H，m)，2.14-2.17 (2H，m)，2.44-2.5l (2H，m)，2.79?(1H,?m)，3.65-3.68?(2H，m)，3.86-3.9O?(2H，m),4.12?(1H，m)，4.6O- 4.6l (2H，m)，4.86 (1H，m)，5.47 (1H，m)，6.4 (1H，2?x?d)，7.29-7.37?(3H，m)，7.54 (1H，m)
I-7 461.1 (DMSO-d 6)?O.95-1.O1?(6H，m)，1.13-1.16(3H，m)，1.80-2.1O?(4H，m)，2.45-2.51(5H，m)，2.74?(1H，m)，3.33-3.59?(2H，m)，3.68?(1H，m)，3.95?(1H，m)， 4.38-4.44?(2H，m)，4.55?(1H，m)，5.55?(1H，m)，7.25?(1H，m)，7.62 (1H，m)，8.27(1H，m)，8.48 (1H，m)，8.63 (1H，m)
I-8 461.1 (CDC1 3)?1.02?(3H，d)，1.08?(3H，d)，1.28(3H，t)，1.95-2.2 (4H，m)，2.4-2.5?(2H，m)，2.55?(3H，s)，2.8-2.9?(1H，m)，3.7-3.8?(2H，m)，3.85-3.95?(2H，m)，4.7-4.85?(2H，m)，4，9-4.95 (1H，m)，5.55(1H，d)，6.6-6.65?(1H，m)，7.2-7.25(1H，m)，7.35-7.4 (1H，m)，8.6(1H，d)，8.7(1H，s)
I-9 465.6 (DMSO-d 6)?0.93-O.95?(3H，m)，?O.99-1.00(3H,m)，1.13-1.16?(3H，m)，1.80-2.10(4H，m)，2.40?(3H，s)，2.40-2.47?(2H，m)，2.73?(1H，m)，3.59-3.61?(2H，m)，3.73-3.75?(2H，m)，4.37-4.43 (2H，m)，4.55?(1H，m)，5.53?(1H，d)，6.97?(1H，m)，7.59?(1H，m)，7.81?(1H，d)，8.28(1H，d)
No. M+1(obs) 1H-NMR
I-10 515.0 (CDCl 3)?1.01?(3H，d)，1.25 (3H，d)，1.27(3H，t)，1.97-2.10 (2H，m)，2.14-2.26(1H，m)?2.38?(2H，dd)，2.84 (1H，dd)，3.67-3.71?(2H，m)，3.81-3.87?(1H，m)，3.90-3.98?(1H，m)，4.58-4.61?(1H，m)，4.65-4.73?(1H，m)，4.86-4.90?(1H，dd)，5.47 (1H，d)，6.78?(1H，d)，7.23?(1H，d)，7.42?(1H，d)，8.40?(1H，d)
I-11 515.0 (CDCl 3)?1.01?(3H，d)，1.14?(3H，d)，1.28(3H，t)，1.9?6-2.12?(2H，m)，2.17-2.23(2H，m)，2.38?(2H，dd)，2.83 (1H，dd)，3.6?6-3.71?(2H，m)，3.82-3.95?(2H，m)，4.59-4.62?(1H，m)，4.65-4.71?(1H,?m)，4.91?(1H，dd)，5.47?(1H，d)，6.54?(1H，br?dd)，7.21?(1H，br?dd)，8.57?(2H，s)
I-12 504.4 (DMSO-d 6)?0.9-1.08?(9H，s)，1.12?(3H，t)，1.75-2.00?(3H，m)，2.00-2.15?(4H，m)，2.34-2.50?(1H，m)，2.80?(1H，m)，3.48-3.91?(7H，m)，4.40?(1H，m)，4.46-4.70?(2H，m)，5.58?(1H，d)，7.81?(1H，d)，7.00?(1H，d)，7.19?(1H，dd),8.07(1H，d)，8.27?(1H，d)
I-13 476.0 (CDCl 3)?0.98-1.09 (6H，m)，1.90-2.05(4H，m)，2.35-2.56?(2H，m)，2.70-2.85(1H，m)，3.49+3.55(3H，2xs)，3.55-3.67(1H,?m)，3.86?(3H，s)，4.00-4.09 (1H，m)，4.58-4.90?(3H，m)，5.34-5.37?(1H，m)，6.25+6.40?(1H，2xd)，6.90-7.01?(2H，m)，7.18-7.25?(1H，m)，7.37+7.54 (1H，2xd)
I-14 504.0 (CDCl 3)?0.99-1.11?(6H，m)，1.18-1.30(6H，m)，1.86-2.15?(4H，m)，1.28+1.30(3H，2xS)，2.36-2.86(3H，m)，3.56-3.68(1H，m)，3.86(3H，s)，3.87-4.05?(2H，m)，4.50-4.84?(3H，m)，5.55+5.59?(1H，2xd)，6.86-7.01?(2H，m)，7.16-7.23?(1H，m)，7.37+7.54?(1H，2xd)
I-15 504.0 (CDCl 3)?0.85-1.11?(9H，m)，1.55-1.73(2H，m)，1.89-2.20 (4H，m)，2.28+2.29(3H，2xs)，2.35-2.55(2H，m)，2.71-2.87(1H，m)，3.48-3.76?(3H，m)，3.86?(3H，s)，3.98-4.06?(1H，m)，4.52-4.86?(3H，m)，5.44-5.49 (1H，m)，6.24+6.35?(1H，2xd)，6.88-6.99?(2H，m)，7.14-7.21?(1H，m)，7.41+7.55?(1H，2xd)
No. M+1(obs) 1H-NMR
I-16 480.5 (CDCl3)?1.0-1.15 (6H，m)， 1.3-1.4 (3H，m)，?1.9-2.2?(4H，m)，2.4-2.5?(2H，m)，2.8-2.9?(1H，m)，?3.7-3.8 (2H，m)，3.9-4.0 (2H，m)， 4.65-4.75 (2H，m)，4.88-4.92?(1H，m)，5.5-5.52?(1H，m)，6.85-6.9 (1H，m)， 7.4-7.55 (1H，m)，?7.7-7.75(1H，m)
I-17 474.6 (DMSO-d 6)?1.05 (9H，s)，1.15 (3H，t)，1.8-2.1 (4H，m)，2.3 (3H，s)，2.4-2.5(1H，m)，2.7-2.8 (1H，m)，3.6-3.9 (4H，m)，?4.4-4.45?(1H，m)，4.5-4.7?(2H，m)，5.55-5.6?(1H，m)，7.2-7.4?(4H，m)，8.1(1H，d)，8.25?(1H，d)
I-18 514.5 (DMSO-d 6)?0.9-1.0 (6H，m)， 1.15 (3H，t)，1.8-2.1 (4H，m)，2.4-2.5 (1H，m)，2.7-2.8 (1H，m)，3.6-3.85?(3H，m)，3.9-3.95(1H，m)，4.4-4.6 (3H，m)，5.5?5-5.6 (1H，m)，?7.4-7.45 (1H，m)， 7.6-7.8 (3H， m)，8.22 (1H，d)，8.75 (1H，d)
I-19 480.5 (CDCl 3) 1.13 (9H， s)， 1.90-2.20 (3H，m)，2.35-2.44 (2H，m)， 2.86 (1H， dd)， 3.56(3H，s)，?3.72-3.74?(1H，m)，3.90-3.991H，m)，4.62-4.65?(1H，m)，4.69-4.70(1H，m)，4.90 (1H，d)，5.36?(1H，d)，6.94 (1H，d)，7.28-7.46 (4H，m)，7.71(1H，dd)
I-20 542.5 (CDCl 3) 1.09 (9H，s)，1.27?(6H，m)，1.93-2.14 (3H，m)，2.34-2.42 (2H，m)，2.79-2.83 (1H，m)，3.71?(1H，?m)，3.90-3.94 (1H，m)，?4.01-4.04 (1H，?m)，?4.62-4.67?(2H，m)，4.88-4.91 (1H，m)，5.56(1H，m)，?6.46?(1H，?m)，7.40 (1H，m)，7.54-7.62?(3H，m)，7.74?(1H，m)
I-21 494.5 (CDCl 3)?1.12?(9H，s)，1.29 (3H，t)，1.90-2.20?(3H，m)，2.36-2.43 (2H，m)，2.85?(1H，dd)，3.67-3.72?(2H，m)，?3.90-3.96?(2H，m)，4.62-4.65?(2H，m)?4.91(1H，d)，5.46 (1H，d)，6.95?(1H，d)，7.34-7.46?(4H，m)，7.71?(1H，dd)
I-22 528.4 (CDCl 3) 1.10 (9H，s)，1.29?(3H，t)，1.90-2.20(3H，m)，2.35-2.42 (2H，m)，2.84 (1H，dd)，3.68-3.72?(2H，m)，3.90-3.95?(2H，m)， 4.62-4.80?(2H，m)，4.89(1H，d)，5.47?(1H，d)，6.45?(1H，d)，7.43?(1H，d)，7.54-7.61 (3H，m)，7.73(1H，dd)
No. M+1(obs) 1H-NMR
I-2?3 508.5 (CDCl 3)?0.95 (3H，t)，1.12 (9H，s)，1.60-1.70 (2H，m)，1.88-2.20?(3H，m)，2.35-2.45?(2H，m)，2.77-2.85?(1H，m)，3.53-3.61?(1H，m)，3.65-3.75?(1H，m)，3.76-3.84?(1H,?m)，3.88-3.96?(1H，m)，4.60-4.73?(2H，m)，4.91?(1H，d)，5.44(1H,d)，6.96 (1H，d)，7.30-7.50 (4H，m)，7.73?(1H,d)
I-24 522.5 (CDCl 3)0.86(3H，t)，1.18?(9H，s)，1.21-1.65?(4H，m),1.85-2.17(3H，m)，2.36-2.59(2H，m)，2.68-2.78?(1H，m)，3.44-3.54?(1H，m)，3.56-3.72?(2H，m)，3.98-4.10?(1H，m)，4.56-4.85(3H，m)，5.44?(1H，d)，6.95-7.02?(1H，m)，7.32-7.74?(5H，m)
I-25 578.3 (DMS0-d 6) 0.99-1.21?(12H，m)，1.70-2.00(3H，m)，2.01-2.17?(1H，m)，2.40-2.51(1H，m)，2.70-2.80?(1H，m)，3.50-3.88(4H，m)，4.40?(1H，m)，4.55?(1H，m)，4.65(1H，m)，5.58?(1H，d)，7.36?(1H，m)，7.50?(1H，m)，7.61?(1H，m)，8.21(1H，d)，8.70?(1H，d)
I-26 494.5 (CDCl 3)0.95(3H，t)，1.0?5-1.15(6H，m)，1.55-1.8(3H，m)，2.0-2.25(4H，m)，2.4-2.5(1H，m)，2.6-2.9(2H，m)，3.55-3.8(3H，m)，3.85-3.95(1H，m)，4.05-4.1(1H，m)，4.7-4.85(2H，m)，5.5-5.55(1H，m)，6.85-6.9(1H，m)，7.4-7.6(3H，m)，7.7-7.8(1H，m)
I-27 494.5 (CDCl 3)0.95(3H，t)，1.05-1.15(6H，m)，1.5-1.7(3H，m)，2.0-2.2(4H，m)，2.4-2.6(2H，m)，2.9-3.1(1H，m)，3.4-3.5(1H，m),3.55-3.7(2H，m)，4.0-4.1(1H，m)，4.35-4.5(2H，m)，4.6-4.75(1H，m)，4.8-4.9(0.5H，m)，5.35-5.38(1H，m)，6.85-6.95(1H，m)，7.4-7.55(3H，m)，7.6?4-7.8(1.5H，m)
I-28 480.3 (CDCl3)1.02-1.19(7H，m)，1.22-1.28(2H，m)，1.90-2.21(3H,m)，2.32-2.53(2H，m)，2.95(1H，2xdd)，3.44-3.50(1H，m)，3.5?9-7?8 (2H，m)， 3.83-3.92(1H，m)，4.02-4.09(1H，m)，4.294.41(1H，m),5.34(1H,2xs)，6.88(1H，2x?brdd)，7.31-7.42(4H，m)，7.57(1H，2xbrdd)，7.70(1H，2x?dd)
No. M+1(obs) 1H-NMR
I-29 508 (CDCl3)0.83-0.97(3H，m)，1.02-1.14(6H，m)，1.26-1.53(3H，m)，1.55-1.66(1H，m)，1.91-2.20(4H，m)，2.35-2.61(2H，m)，2.73-2.90(1H，m)，3.54-3.74(3H，m)，3.84-3.90(0.5H，m)，3.99-4.06(0.5H，m)，4.61-4.75(2H，m)，4.77-4.93(0.5H，m)，5.45-5.51(1H，m)，6.87(1H，brd)，7.34-7.45(4H，m)，7.55(0.5H，brd)，7.70-7.22(1H，m)
I-30 508 (400?MHz，CDCl3)0.87-0.97(3H，m)，0.99-1.16(6H，m)，1.27-1.40(2H，m)，1.48-1.59(1H，m)，1.91-2.19(4H，m)，2.30-2.52(2H，m)，2.90-3.07(1H，m)，3.39-3.45(0，5H，m)，3.54-3.71(2H，m)，3.78-3.82(0.5H，m)，3.86-3.92(0.5H，m)，4.04-4.09(0.5H，m)，4.31-4.35(1H，m)，4.39-4.43(1H，m)，4.56-4.59(0.5H，m)，4.66-4.68(1H，m)，4.80-4.86(0.5H，m)，5.32-5.41(1H，m)，6.87-6.91(1H，m)，7.31-7.45(4H，m)，7.55-7.76(2H，m)
I-31 494.4 (CDCl3)1.04-1.19(8H，m)，1.25-1.28(3H，m)，1.92-2.18(4H，m)，2.32-2.43(1H，m)，2.62-2.87(2H，m)，3.59-3.71(1H，m)，3.85-3.95(1H，m)，4.00-4.05(1H，m)，4.60-4.67?(3H，m)，5.60(1H，2xd)，6.88(1H，brdd)，7.36-7.50(4H，m)，7.52-7.56(1H，m)，7.76(1H，2xdd)
I-32 494.3 (CDCl3)0.87-1.24(10H，m)，1.88-2.07(3H,m)，2.13-2.21(1H，m)，2.32-2.54(2H，m)，2.94(1H，2Xdd)，3.57-3.68(1H，m)，3.83-3.87(1H，m)，4.02-4.09(1H，m)，4.27-4.30(1H，m)，4.41(1H，dd)，4.51-4.69(1H，m)，5.43(1H，2xs)，6.89(1h，2xbrdd)，7.30-7.45(4H，m)，7.52(1H，2xbrdd)，7.70(1H，2xdd)
No. M+1(obs) 1H-NMR
I-33 550.5 (DMSO)0.70(2H，m，CH2)，0.89(2H，m，CH2)，0.95-1.20(12H，m，CH3，tbutyl)，1.71-2.13(4H，m，CH2)，2.45(1H，m，asp?CH2)，2.75(1H，m,aspCH2)，3.35-3.89(4H，m，CH2， CH)，3.99(1H，m，CH)，4.37(1H，m，CH)，4.51(1H，m，CH)，4.65(1H，m，CH)，5.58(1H，d，CHO)，6.90(1H，m，ary1H)，7.35(1H，m，ary1H)，7.45(1H，m，arylH)，8.25(1H，d，NH)，8.35(1H，d，NH)
I-34 508.5 DMSO)0.99-1.21(12H，m，CH3,?tBu)，1.75-2.14(4H，m，CH2)，2.38(3H，s，CH3)，2.40-2.51(1H，m，asp?CH2)，2.70-2.82(1H，m，asp?CH2)，3.37-3.90(4H，m，CH2，CH)，4.39(1H，m，CH)，4.55(1H，m，CH)，4.67(1H，m，CH)，5.58(1H，d，CH)，7.15(1H，m，aryl?H)，7.28(1H，m，aryl?H)，7.38(1H，m，aryl?H)，8.25(1H，m,NH),8.38(1H，m，NH)
I-35 510 CDCl3?1.00(3H，d)，1.10(3H，d)，1.27(3H，t)，1.90-2.19(4H，m)，2.34-2.45(2H，m)，2.79-2.87(1H,m)，3.65-3.71(2H，m)，3.84-4.93?(2H，m)，3.92(3H，s)，4.56-4.70(2H，m)，4.82-4.88(1H，m)，4.45(1H，d)，6.69(1H，d)，6.99(1H，d)，7.16(1H，d)，7.27(1H，t)，7.37(1H，d)
I-36 522.5 (DMSO)0.95-1.25(15H，m，tBu，CH3)，1.78-2.13(4H，m，CH2)，2.43(1H，m，CH2)，2.65-2.80(3H，m，CH2)，3.50-3.88(4H，m，CH2,CH)，4.42(1H，m，CH)，4.58(1H，m，CH)，4.70(1H，d，CH)，5.58(1H，d，CH)，7.15(1H，m，aryl?H)，7.27(1H，m，aryl?H)，7.38(1H，m，arylH)，8.27(1H，d，NH)，8.39(1H，d，NH)
I-37 51O.5 CDCl31.05-1.12(6H,m)，1.25-1.3(3H，m)，1.9-2.2(2H，m)，2.4-2.5(2H，m)，2.8-2.9(1H，m)，3.65-3.75(2H，m)，3.85(3H，s)，3.9-4.0(1H，m)，4.65-4.75(2H，m)，4.85-4.9(1H，m)，6.9-6.93(1H，m)，6.98(1H，s)，7.05-7.1(1H，m)，7.4-7.45(1H，m)，7.75-7.8(1H，d)
No. M+1(obs) 1H-NMR
I-38 564 CDCl3 0.3?8-0.42?(2H，m)，?0.63-0.71(2H，m)，1.11(9H，s)，1.23-1.35(4H，m)，1.88-2.20?(3H，m)，2.34-2.45?(2H，m)，2.76-2.87(1H，m)，3.66-3.75(2H，m),3.87-3.96(4H，m)，4.62-4.73(2H，m)，4.89(1H，d)，5.47(1H，d)，6.80(1H，d)，7.00(1H，d)，7.19-7，29(2H，m)，7.48(1H，d)
I-39 510 (DMSO)?1.11 (9H，s)，1.28?(3H，t)，1.83-2.22(3H，m)，2.36-2.43?(2H，m)，2.82-2.87(1H，m)，3.66-3.76(2H，m)，3.86-3.97(2H，m)，4.62-4.71(2H，m)，4.88(1H，d),?5.45(1H，d)，6.31(1H，s)，6.73(1H，d)，7.05-7.20(3H，m)，7.38(1H，d)
I-40 537.4 (CDCl3)1.06?(6H，dd)，1.28-1.31(4H，m)，1.91-2.20?(4H，m)，2.23(3H，s)，2.39(1H，dd)，2.84(1H，dd)，3，65-3.72(2H，m)，3.86-3.94(2H，m)，4.61-4.73(2H，m)，4.87(1H，dd)，5.46(1H，dd)，7.00-7.04(1H，m)，7.22(1H，brds)，7.38-7.45(2H，m),7.73(1H，d)，7.80(1H，brds)
I-41 551.5 (DMSO)?0.95-1.20 (12H，m，tBu，CH3)，2.75-2.15?(7H，m，CH2，COCH3)，2.42(1H，m，CH2)，2.77(1H，m，CH2)，3.50-3.88(4H，m，CH2，CH)，4.37(1H，m，CH)，4.55(1H，m，CH)，4.67(1H，d，CH)，5.58(1H，d，CH)，7.09(1H，m，aryl?H)，7.32(1H，m，aryl?H)，7.71(1H，m，aryl?H)，8.26(1H，m，NH)，8.49(1H，m，NH)，9.58(1H，m，NH)
I-42 531.6 (DMSO)?0.95-1.20?(12H，m，tBu，CH3)，1.75-2.17?(10H，m，CH3，COCH3，CH2)，2.45(1H，m，CH2)，2.77(1H，m，CH2)，3.48-3.91(4H，m，CH2，CH)，4.31-4.70(3H，m，CH)，5.55(1H，d，CH)，7.04(1H，m，aryl?H)，7.18(1H，m，aryl?H)，7.41(1H，m，aryl?H)，8.20(1H，d，NH)，8.27(1H，d，NH)，9.39(1H，brs，NH)
No. M+1(obs) 1H-NMR
I-43 551.4 DMSO)1.04(9H，s),1.12-1.17(3H，m)，1.78-1.95(4H，m)，2.06(3H，s)，2.45(1H,dd)，2.72(1H，dd)，3.52-3.81(4H，m)，4.36-4.39(1H,m)，4.47-4.54(1H，m)，4.64(1H，d)，5.54(1H，dd)，7.33-7.35(1H，m)，7.43-7.46(1H，m)，7.81(1H，brds)，8.21-8.25(2H，m)，10.23(1H,brds)
I-44 535.4 (DMSO)1.02(9H，s)，1.14(3H,?t)，1.78-1.98(4H，m)，2.08(3H，s)，2.48(1H，dd)，2.79(1H，dd)，3.51-3.82(4H，m)，4.36-4.39(1H，m)，4.49-4.58(1H，m)，4.71(1H，d)，5.54(1H，d)，7.31-7.34(1H，m)，7.65-7.72(3H，m)，8.49(1H，d)，10.38(1H,s)
I-45 521.4 (DMSO)0.95(6H，dd)，1.12-1.16(4H，m)，1.72-1.97(4H，m)，2.07(3H，s)，2.48(1H，dd)，2.73(1H，dd)，3.51-3.62(2H，m)，3.71-3.83(2H，m)，4.35-4.38(1H，m)，4.48-4.59(2H，m)，5.53(1H，d)，7.29-7.31(1H，m)，7.59-7.67(2H，m)，8.01-8.05(1H，m)，8.28(1H，d)，10.35(1H，s)
I-46 538.5 (CDCl3?1.1-1.12(6H，m)，1.3(3H，m)，1.4(6H,d)，2.0-2.2(2H，m)，2.4-2.5(2H，m)，2.8-2.9(1H，m)，3.7-3.75(2H，m)，3.9-4.0(1H，m),4.6-4.75(3H，m)，4.85-4.95(1H，m)，6.85-6.9(1H，m)，6.95(1H,s)，7.05-7.1(1H，m)，7.4-7.45(1H，m)，7.8(1H，d)
I-47 510.5 (CDCl3)1.15(9H，m)，1.25(3H，t)，2.0-2.2(4H，m)，2.4-2.5(2H，m)，2.8-2.9(1H，m)，3.7-3.85(2H，m)，3.9-4.0(1H，m)，4.05-4.1(1H，m)，4.7-4.8(1H，m)，4.85(1H，d)，5.5(1H，m)，6.5(1H，d)，6.8(1H，s)，7.2(1H，d)，7.4(1H，d)，7.55(1H，d)
I-48 538.5 (CDCl3)1.12(9H，s)，1.29(3H，t)，1.90-2.20(3H，m)，2.36-2.43(2H，m)，2.85(1H，m)，3.42(3H，s)，3.68-3.74(2H，m)，3.91-3.95(2H，m)，4.48(2H，s)，4.62-4.75(2H，m)，4.90(1H，m)，5.47(1H，m)，7.00(1H，m)，7.31(1H，m)，7.43-7.54(2H，m)，7.72(1H，m)
No. M+1(obs) 1H-NMR
I-49 579.5 (CDCl3)1.12(9H，s)，1.28-1.31(9H，m)，1.90-2.20(3H，m)，2.36-2.43(2H，m)，2.54(1H，m)，2.85(1H，m)，3.68-3.72(2H，m)，3.91-3.95(2H，m)，4.62-4.69(2H，m)，4.88(1H，d)，5.47(1H，m)，7.14(1H，d)，7.27(1H，m)，7.41(1H，m)，7.50(1H，d)，7.78(1H，d)，7.87(1H，m)
I-50 577.3 (DMSO)1.12-1.16(7H，m)，1.58-1.81(5H，m)，1.83-1.92(5H，m)，2.04-2.08(4H，m)，2.50(1H，dd)，2.75(1H，dd)，3.57-3.66(2H，m)，3.72-3.78(1H，m)，3.82-3.91(1H，m)，4.33-4.36(1H，m)，4.46(1H,t)，4.52-4.61(1H，m)，5.54(1H，d)，7.32(1H，d)，7.43(1H，dd)，7.81(1H，d)，8.25(1H，d)，8.47(1H，d)，10.22(1H，s)
I-51 567.4 (DMSO)0.98-1.25(12H，m，tBu，CH3)，1.78-2.14(4H，m，CH2)，2.44(1H，m，CH2)，2.78(1H，m，CH2)，3.50-3.88(7H，m，CH3，CH2，CH)，4.38(1H，m，CH)，4.55(1H，m，CH),4.67(1H，d，CH)，5.58(1H，d，CH)，7.30-7.42(2H，m，arylH)，7.60(1H，brs，NH)，8.21(2H，m，aryl?H，NH)，9.99(1H，brs，NH).
I-52 586.4 (DMSO)?0.95-1.24 (12H，m，tBu，CH3)，1.70-2.13?(4H，m，CH2)，2.44?(1H，m，CH2)，2.75(1H，m，CH2)，3.45-3.90(4H，m，CH2，CH)，4.37(1H，m，CH)，4.55(1H，m，CH)，4.70(1H，d，CH)，5.57(1H，d，CH)，6.91(2H，d，aryl?H)，7.06-7.19(3H，m，aryl?H),7.30-7.45(3H， m， aryl?H)， 8.2?0 (1H， d， NH)， 8.55 (1H， d，NH)
I-53 578.5 (DMSO)0.9-1.0(6H，m)，1.18(3H，t)，1.8-2.15(4H，m)，2.4-2.5(1H，m)，2.7-2.8(1H，m)，3.6-3.85(4H，m)，4.4-4.6(3H，m)，5.55(1H，d)，7.05(1H，d)，7.3-7.35(2H，m)，7.98(1H，s),8.3(1H，d)，8.45(1H，d)，10.7(1H，s)
No. M+1(obs) 1H-NMR
I-54 495.0 (DMSO)0.94-0.98(6H，m)，1.13-1.18(3H，m)，1.80-2.10(5H，m)，2.50(1H，m)，2.73(1H，m)，3.58-3.61(2H，m)，3.74(1H，m)，3.9(1H，m)，4.38-4.41(2H，m)，4.60(1H，m)，5.46(2H，s)，5.54(1H，m)，6.48(1H，m)，6.80(1H，m)，7.04(1H，m)，8.27(1H，d)，8.40(1H，d)
I-55 535.0 (CDCl3)1.25(3H，t)，1.99-2.01(3H，s)，2.30-2.39(1H，m)，2.68(1H，dd)，2.79(1H，dd)，3.21-3.27(1H，m)，3.39(1H，dd)，3.47-3.51(2H，m)，3.65-3.75(1H，m)，3.88-3.94(1H，m)，4.64-4.68(1H，m)，4.70-4.78(1H，m)，5.56(1H，d)，7.31-7.35(5H，m)，7.63-7.65(1H，m)，8.00(1H，d)，8.76(1H，d)
I-56 545.0 (CDCl3)1.25(3H，t)，2.01-2.03(3H，m)，2.25(3H，s)，2.30-2.37(1H，m)，2.65(1H，dd)，2.80(1H，dd)，3.27-3.41(2H，m)，3.47(1H，dd)，3.65-3.79(2H，m)，3.85(3H,s)，3.86-3.90(1H，m)，4.64-4.67(1H，m)，4.71-4.80(1H，m)，5.18-5.22(1H，m)，5.54(1H,d)，6.83(1H，d)，6.90-6.97(2H，m)，7.19(1H，t)，7.24-7.28(1H，m)，7.90(1H，d)，8.77(1H，d)
I-57 524.0 (CDCl3)1.12(9H，s)，1.31(3H，t)，1.93-2.20(3H，m)，2.35-2.46(2H，m)，2.79-2.86(1H，m)，3.65-3.74(2H，m)，3.87-3.96(2H，m)，3.95(3H，s)，4.65-4.74(2H，m)，4.89(1H，d)，5.47(1H，d)，6.76(1H，d)，7.03(1H，d)，7.30(1H，t)，7.48(1H，d)
I-58 530.4 (CDCl3)1.10(9H，s)，1.28(3H，t)，1.43-1.56(1H，m)，1.79-1.86(3H，m)，1.99(1H，brd)，2.29(3H，s)，2.30-2.37(1H，m)，2.83(1H，dd)，3.02(1H，brs)，3.66-3.74(1H，m)，3.87(3H，s)，3.88-3.94(1H，m)，4.16(1H，brs)?,4.54(1H，brs)，4.66-4.74(1H，m)，4.97(1H，d)，5.46(1H，d)，6.44(1H，brd)，6.93(1H，d)，7.00(1H,d)，7.22(1H，t)，7.78(1H，brd)
No. M+1(obs) 1H-NMR
I-59 520.5 (CDCl3)1.13(9H，s)，1.29(3H，t)，1.76-1.90(3H，m)，2.00(1H，brd)，2.35(1H，dd)，2.83(1H，dd)，3.66-3.74(1H，m)，3，87-3.94(1H，m)，4.15(1H，s)，4.54(1H，brs)，4.62-4.78(1H，m)，4.99(1H，d)，5.46(1H，d)，6.92(1H，brd)，7.33-7.46(3H，m)，7.69(1H，brdd)，7.77(1H，brd)
I-60 577.5 (CDCl3)?1.12(9H，s)，1.26-1.31(3H，m)，1.43-1.45(1H，m)，1.83(3H，brs)，1.99(1H，brd),2.06(1H，m)，2.23(3H，s)，2.34(1H，brdd),2.83(1H，brdd)，3.01(1H，brs)，3.66-3.74(1H，m)，3.87-3.95(1H，m)，4.12-4.19(1H，m)，4.53(1H，brs)，4.65-4.76(1H，m)，4.98(1H，d)，5.45-5.47(1H，m)，7.08(1H，brd)，7.30(1H,m)，7.37(1H，brd)，7.73-7.75(1H，m)，7.80-7.82(2H，m)
I-61 591.5 (CDCl3) 1.14(9H，s)，1.22-1.30(6H，m)，1.54-1.57(1H，m)，1.77-1.85(3H，m)，1.97(1H，d)，2.30-2.45(3H，m)，2.75-2.84(1H，m)，3.00(1H，s)，3.63-3.72(1H，m)，3.84-3.93(1H，m)，4.10-4.16(1H，m)，4.51(1H，s)，4.64-4.71(1H，m)，4.96(1H，d)，5.45(1H，d)，7.05(1H，d)，7.26(1H，s)，7.36(1H，d)，7.73(1H，d)，7.80(1H，d)，7.82(1H，s)
I-62 605.6 (CDCl3)1.15(9H，s)，1.3(3H，t)，1.35(6H，d)，1.4-1.55(3H，m)，1.8-1.95?(3H， m)， 2.0-2.1 (1H，m)， 2.3-2.4(1H，m)，2.65-2.75(1H，m)，2.8-2.9(1H，m)，3.05(1H，s)，3.7-3.8(1H，m)，3.9-4.0(1H，m)，4.2(1H，s)，4.55(1H，s)，4.7-4.8(1H，m)，5.0(1H，d)，5.5(1H，d)，6.6(1H，d)，7.3-7.45(2H，m)，7.75(1H，d)，7.85(1H，s)，8.55(1H，d)
No. M+1(obs) 1H-NMR
I-63 534.4 (CDCl3)1.13(9H，s)，1.31(3H，t)，1.42-1.48(1H，m)，1.56(1H，brs)，1.77-1.83(3H，m)，1.99(1H，brd)，2.35(1H，dd)，2.83(1H，dd)，3.01(1H，brs)，3.67-3.76(1H，m)，3.88-3.99(4H，m)，4.14(1H，brs)，4.52(1H，brs)，4.65-4.73(1H，m)，5.00(1H，dd)，5.47(1H，d)，7.10-7.21(2H，m)，7.34-7.39(1H，m)，7.56-7.61(1H，m)，7.89(1H，d)
I-64 520.5 (CDCl3)?1.03(3H，d)，1.10(3H，d)，1.32(3H，t)，1.50(1H，m)，1.59(1H，m)，1.812-1.84(3H，m)，2.0(1H，m)，2.15(1H，m)，2.36(1H，m)，2.83(1H，m)，3.02(1H，brs)，3.69(1H，m)，3.90-3.95(4H，m)，4.13(1H，brs)，4.40(1H，brs)，4.67(1H，m)，4.97(1H，m)，5.47(1H，d)，7.12-7.21(2H，m)，7.28(1H，m),7.59(1H，m)，7.80(1H，m)
I-65 530.9 (DMSO)0.91-2.40(23H，m)，2.95-3.40(2H，m)，3.51-3.81(5H，m)，4.00-4，71(3H，m)，5.29(1H，m)，6.80(1H，d)，7.00(1H，d)，7.19(1H，t)，7.94(1H，d)，8.48(1H，d)
I-66 522.8 (DMSO)0.95-1.20?(12H，m)，1.24-1.40(2H，m)，1.41-2.40(6H，m)，3.05(1H，m)，3.50-3.80(3H,m)，4.15(1H，m)，4.60(1H，m)，4.70(1H，d)，5.30(1H，s)，7.28-7.50(4H，m)，8.35(1H，d)，8.48(1H，d)
I-67 577.5 (CDCl3)δ1.10(9H，s)，1.26-1.33(3H，m)，1.43-1.45(1H，m)，1.74-1.83(2H，m)，2.01(1H，brd)，2.06(1H，m)，2.30(3H，s)，2.37(1H，brdd)，2.85(1H，brdd)，2.99(1H，brs)，3.69-3.76(1H，m)，3.89-3.97(1H，m)，4.11-4.31(2H，m)，4.53(1H，brs)，4.65-4.76(1H，m)，4.95(1H，d)，5.45-5.47(1H，m)，6.75(1H，brd)，7.67-7.69(2H，m)，7.78(1H，brs)，7.92(1H，m)，8.55(1H，brd)
No. M+1(obs) 1H-NMR
I-68 577.5 (CDCl3)1.10(9H，s)，1.26-1.33(3H，m)，1.43-1.45(1H，m)，1.74-1.83(2H，m)，2.01(1H，brd)，2.06(1H，m)，2.30(3H，s)，2.37(1H，brdd)，2.85(1H，brdd)，2.99(1H，brs)，3.69-3.76(1H，m)，3.89-3.97(1H，m)，4.11-4.31(2H，m)，4.53(1H，brs)，4.6?5-4.76(1H，m)，4.95(1H，d)，5.45-5.47(1H，m)，6.75(1H，brd)，7.67-7.69(2H，m)，7.78(1H，brs)，7.92(1H，m)，8.55(1H，brd)
I-69 591.5 (CDC13)1.10(9H，s)，1.26-1.33(6H，m)，1.42-1.16(1H，m)，1.55-1.83(4H，m)，2.01(1H，brd)，2.36(1H，dd)，2.53(2H，q)，2.83?(1H，dd)，2.99(1H，brS)，3.69-3.76(1H，m)，3.89-3.96(1H,m)，4.11(1H，s)，4.53(1H，brs)，4.66-4.77(1H，m)，4.95(1H，d)，5.48(1H，d)，6.76(1H，d)，7.67-7.74(2H，m)，8.80(1H，s)，7.90(1H，d)，8.58(1H，d)
I-70 537.4 (CDCl3)1.12(9H，s)，1.23-1.30(3H，m)，1.36-1.41(1H，m)，1.73-1.84(3H，m)，1.98-2.03(1H，m)，2.33-2.41(1H，m)，2.75-2.83(1H，m)，2.96(1H，brs)，3.65-3.73(1H，m)，3.84-3.93(1H，m)，4.11(1H，brS)，4.56(1H，s)，4.63-4.71(1H，m)，4.96-4.99(1H，m)，5.43-5.46(1H，m)，7.64-7.72(2H，m)，7.79-7.87(3H，m)，8.48-8.52(1H，m)，8.90(1H，brd)，9.51(1H，d)
I-71 535.6 (CDCl3)1.09(9H，s)，1.32(3H，t)，1.41-1.71(5H，m)，1.76-1.87(3H，m)，2.00(1H，brd)，2.37(1H，dd)，2.83(1H,dd),2.98(1H，brs)，3.68-3.77(1H，m)，3.89-3.97(1H，m)，4.11(1H，s)，4.54(1H，brs)，4.67-4.74(1H，m)，4.95(1H，d)，5.48(1H，d)，6.64(1H，brd)，6.78(1H，d)，7.54(1H，dd)，7.71(1H，brd)，7.78(1H，d)
No. M+1(obs) 1H-NMR
I-72 521.5 (CDCl3)1.05(3H，d)，1.15(3H，d)，1.35(3H，t)，1.5-1.6(1H，m)，1.6-1.7(1H，m)，1.8-1.9(2H,s)，2.0-2.05(1H，m)，2.15-2.25(1H，m)，2.35-2.45(1H，m)，2.8-2.9(1H，m)，2.95(1H，s)，3.7-3.8(1H，m)，3.9-4.0(1H，m)，4.1(1H，s)，4.45(3H，s)，4.7-4.8(1H，m)，4.9-4.95(1H，m)，5.55(1H，d)，6.7(1H，d)，6.85(1H，d)，7.65(1H，d)，7.75(1H，d)，7.82(1H，s)
I-73 537.4 (CDCl3)1.14(9H，s)，1.25(3H，t)，1.40-1.46(1H，m)，1.77-1.89(3H，m)，1.98-2.02(1H，m)，2.34(1H，dd)，2.99-3.05(1H，m)，3.62-3.69(1H，m)，3.83-3.91(1H，m)，4.12(1H，s)，4.29-4.34(1H，m)，4.59(1H，s)，4.99(1H，d)，5.38(1H，s)，7.67-7.76(2H，m)，7.86(2H，dd)，8.13(1H，d)，8.56(1H，d)，8.96(1H，d)，9.56(1H，d)
Example II-1
(S, S, S)-(3S)-(1-[(2S)-(3-methoxyl group-2-methyl-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Method I
With (S; S; S; R)-1-[(2S)-(3-methoxyl group-2-methyl-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carboxylic acid [(2R)-oxyethyl group-5-oxo-tetrahydrochysene-furans-(3S)-yl]-acid amides (97.6mg, 0.20mmo l) is dissolved in the mixture of 2M HCl (2ml) and MeCN (2ml).Reaction mixture was at room temperature stirred 2.5 hours.The gained crude mixture is diluted with EtOAc, wash with water.Water layer EtOAc extracting twice.Merge organic extract liquid, use the salt water washing,, filter, concentrate in a vacuum through dried over mgso.Make resistates and DCM/ sherwood oil (Petrol) coevaporation, obtain title compound, be white solid (81.3mg, 88% yield).
By basically with the described similar methods of example II-1, preparation formula II-2 to II-61 compound.
Example II-2
(S, S, S)-(3S)-(1-[(2S)-(2-chloro-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Figure S05811231120061019D000991
Example II-3
(S, S, S)-(3S)-(the 1-[3-methyl-(2S)-(2-methyl-benzamido)-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Figure S05811231120061019D000992
Example II-4
(S, S, S)-(3S)-(1-[(2S)-(2-methoxyl group-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Example II-5
(S, S, S)-(3S)-(the 1-[3-methyl-(2S)-(2-trifluoromethoxy-benzamido)-butyryl radicals]-tetramethyleneimine-(2 S)-carbonyl }-amino)-4-oxo-butyric acid
Figure S05811231120061019D000994
Example II-6
(S, S, S)-(3S)-(1-[(2S)-(3-hydroxy-2-methyl-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Example II-7
(S, S, S)-(3S)-(1-[(2S)-(3-amino-2-methyl-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Example II-8
(S, S, S)-(3S)-(1-[(2S)-(2,3-two chloro-benzamidos)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Figure S05811231120061019D001003
Example II-9
(S, S, S)-(3S)-(1-[(2S)-(2-chloro-3-trifluoromethyl-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Example II-10
(S, S, S)-(3S)-(1-[(2S)-(3-chloro-2-methyl-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Figure S05811231120061019D001011
Example II-11
(S, S, S)-(3S)-(1-[(2S)-(2,4-two chloro-benzamidos)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Figure S05811231120061019D001012
Example II-12
(S, S, S)-(3S)-(1-[(2S)-(2,5-two chloro-benzamidos)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Figure S05811231120061019D001013
Example II-13
(S, S, S)-(3S)-(1-[(2S)-(2,6-two chloro-benzamidos)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Figure S05811231120061019D001014
Example II-14
(S, S, S)-(3S)-(1-[(2S)-(2,6-methyl-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Figure S05811231120061019D001021
Example II-15
(S, S, S)-(3S)-[(the 1-{3-methyl-(2S)-[(2-methyl-pyridine-3-carbonyl)-amino]-butyryl radicals }-tetramethyleneimine-(2S)-carbonyl)-amino]-4-oxo-butyric acid
Example II-16
(S, S, S)-(3S)-[(the 1-{3-methyl-(2S)-[(4-methyl-pyridine-3-carbonyl)-amino]-butyryl radicals }-tetramethyleneimine-(2S)-carbonyl)-amino]-4-oxo-butyric acid
Example II-17
(S, S, S)-(3S)-[(the 1-{3-methyl-(2S)-[(3-methyl-thiophene-2-carbonyl)-amino]-butyryl radicals }-tetramethyleneimine-(2S)-carbonyl)-amino]-4-oxo-butyric acid
Figure S05811231120061019D001024
Example II-18
(S, S, S)-(3S)-[(1-{ (2S)-[(2,3-two chloro-pyridine-4-carbonyl)-amino]-3-methyl-butyryl radicals }-tetramethyleneimine-(2S)-carbonyl)-amino]-4-oxo-butyric acid
Figure S05811231120061019D001031
Example II-19
(S, S, S)-(3S)-[(1-{ (2S)-[(3,5-two chloro-pyridine-4-carbonyl)-amino]-3-methyl-butyryl radicals }-tetramethyleneimine-(2S)-carbonyl)-amino]-4-oxo-butyric acid
Figure S05811231120061019D001032
Example II-20
(S, S, S)-(3S)-(1-[(2S)-(3-methoxyl group-2-methyl-benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Example II-21
(S, S, S)-the 4-oxo-(3S)-(1-[4,4,4-three fluoro-(2S)-(2-methyl-3-methoxyl group-benzamido)-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl)-amino)-butyric acid
Example II-22
(S, S, S)-(3S)-(1-[(2S)-5-(methoxyl group-2-methyl-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Example II-23
(S, S, S)-(3S)-(1-[(2S)-(3-methoxyl group-2-methyl-benzamido)-3-thiazole-4-base-propionyl]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Figure S05811231120061019D001042
Example II-24
(S, S, S)-(3S)-(1-[(2 S)-(2-chloro-benzamido)-4,4,4-three fluoro-butyryl radicalies]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Example II-25
(S, S, S)-(3S)-(1-[(2S)-(2-chloro-benzamido)-3-thiazole-4-base-propionyl]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Example II-26
(S, S, S)-(3S)-(1-[3, the 3-dimethyl-(2S)-(2-methyl-benzamido)-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Figure S05811231120061019D001051
Example II-27
(S, S, S)-(3S)-(the 1-[3-methyl-(2S)-(2-trifluoromethyl-benzamido)-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Example II-28
(S, S, S)-(3S)-(1-[(2S)-(2-chloro-benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Example II-29
(S, S, S)-(3S)-(1-[3, the 3-dimethyl-(2S)-(2-trifluoromethyl-benzamido)-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Figure S05811231120061019D001054
Example II-30
(S, S, S)-(3S)-(1-[(2S)-(2-chloro-3-methoxyl group-benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Example II-31
(S, S, S)-(3S)-(1-[(2S)-(2-fluoro-3-methoxyl group-benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Example II-32
(S, S, S)-(3S)-(1-[(2S)-(2-chloro-3-trifluoromethoxy-benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Example II-33
(S, S, S)-(3S)-(1-[(2S)-(2-chloro-3-encircles propoxy--benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Example II-34
(S, S, S)-(3S)-(1-[(2S)-(2-chloro-3-methyl-benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Figure S05811231120061019D001065
Example II-35
(S, S, S)-(3S)-(1-[(2S)-(2-chloro-3-methoxyl group-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Example II-36
(S, S, S)-(3S)-(1-[(2S)-(2-chloro-3-ethyl-benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2 S)-carbonyl }-amino)-4-oxo-butyric acid
Figure S05811231120061019D001072
Example II-37
(S, S, S)-(3S)-(1-[(2S)-(2-chloro-4-methoxyl group-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Example II-38
(S, S, S)-(3S)-(1-[(2S)-(2-chloro-3-cyclo propyl methoxy benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Figure S05811231120061019D001074
Example II-39
(S, S, S)-(3S)-(1-[(2S)-(2-chloro-3-hydroxyl-benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Figure S05811231120061019D001081
Example II-40
(S, S, S)-(3S)-(1-[(2S)-(2-chloro-4-acetylaminohydroxyphenylarsonic acid benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Figure S05811231120061019D001082
Example II-41
(S, S, S)-(3S)-(1-[(2S)-(2-chloro-3-acetylaminohydroxyphenylarsonic acid benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Example II-42
(S, S, S)-(3S)-(1-[(2S)-(2-methyl-3-acetylaminohydroxyphenylarsonic acid benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Example II-43
(S, S, S)-(3S)-(1-[(2S)-(2-chloro-4-acetylaminohydroxyphenylarsonic acid benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Figure S05811231120061019D001091
Example II-44
(S, S, S)-(3S)-(1-[(2S)-(2-fluoro-4-acetylaminohydroxyphenylarsonic acid benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Figure S05811231120061019D001092
Example II-45
(S, S, S)-(3S)-(1-[(2S)-(2-fluoro-4-acetylaminohydroxyphenylarsonic acid benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Figure S05811231120061019D001093
Example II-46
(S, S, S)-(3S)-((1-[(2S)-(2-chloro-4-isopropoxy-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Figure S05811231120061019D001094
Example II-47
(S, S, S)-(3S)-(1-[(S)-(2-chloro-4-hydroxyl-benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Figure S05811231120061019D001101
Example II-48
(S, S, S)-(3S)-(1-[(2S)-(2-chloro-4-methoxymethyl-benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Figure S05811231120061019D001102
Example II-49
(S, S, S)-(3S)-(1-[(2S)-(2-chloro-4-isobutyryl amino-benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Example II-50
(S, S, S)-(3S)-(1-[(2S)-(2-chloro-4-acetylaminohydroxyphenylarsonic acid benzamido)-3-cyclohexyl]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Figure S05811231120061019D001104
Example II-51
(S, S, S)-(3S)-(1-[(2S)-(2-chloro-4-methoxycarbonyl amino-benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Example II-52
(S, S, S)-(3S)-(1-[(2S)-(2-chloro-3-phenoxy group-benzamido)-3,3-dimethyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Figure S05811231120061019D001112
Example II-53
(S, S, S)-(3S)-(1-[(2S)-(2-chloro-6-amino-benzamido)-3-methyl-butyryl radicals]-tetramethyleneimine-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Example II-54
(S, S, S)-(3S)-(1-[(2S)-(2-chloro-benzamido)-3,3-dimethyl-butyryl radicals]-piperidines-(2S)-carbonyl }-amino)-4-oxo-butyric acid
Example II-55
(3S)-(2-[(2S)-(3-methoxyl group-2-methyl-benzamido)-3,3-dimethyl-butyryl radicals]-2-(1S, 4R)-aza-bicyclo [2.2.1] heptane-(3S)-carbonyl }-amino)-4-oxo-butyric acid
Example II-56
(3S)-(2-[(2S)-(2-chloro-benzamido)-3,3-dimethyl-butyryl radicals]-2-(1S, 4R)-aza-bicyclo [2.2.1] heptane-(3S)-carbonyl }-amino)-4-oxo-butyric acid
Example II-57
(3S)-(2-[(2S)-(4-acetylaminohydroxyphenylarsonic acid 2-chloro-benzamido)-3,3-dimethyl-butyryl radicals]-2-(1S, 4R)-aza-bicyclo [2.2.1] heptane-(3S)-carbonyl }-amino)-4-oxo-butyric acid
Figure S05811231120061019D001123
Example II-58
(3S)-(2-[(2S)-(2-chloro-4-propionamido-benzamido)-3,3-dimethyl-butyryl radicals]-2-(1S, 4R)-aza-bicyclo [2.2.1] heptane-(3S)-carbonyl }-amino)-4-oxo-butyric acid
Example II-59
(3S)-(2-[(2S)-(2-chloro-3-isobutyryl amino-benzamido)-3,3-dimethyl-butyryl radicals]-2-(1S, 4R)-aza-bicyclo [2.2.1] heptane-(3S)-carbonyl }-amino)-4-oxo-butyric acid
Figure S05811231120061019D001131
Example II-60
(3S)-(2-[(2S)-(2-fluoro-3-methoxyl group-benzamido)-3,3-dimethyl-butyryl radicals]-2-(1S, 4R)-aza-bicyclo [2.2.1] heptane-(3S)-carbonyl }-amino)-4-oxo-butyric acid
Figure S05811231120061019D001132
Example II-61
(3S)-(2-[(2S)-(2-fluoro-3-methoxyl group-benzamido)-3-methyl-butyryl radicals]-2-(1S, 4R)-aza-bicyclo [2.2.1] heptane-(3S)-carbonyl }-amino)-4-oxo-butyric acid
Example II-62
(3S)-(2-[(2S)-(4-acetylaminohydroxyphenylarsonic acid 3-chloro-benzamido)-3,3-dimethyl-butyryl radicals]-2-(1S, 4R)-aza-bicyclo [2.2.1] heptane-(3S)-carbonyl }-amino)-4-oxo-butyric acid
Figure S05811231120061019D001141
Example II-63
(3S)-(2-[(2S)-(3-chloro-4-propionamido-benzamido)-3,3-dimethyl-butyryl radicals]-2-(1S, 4R)-aza-bicyclo [2.2.1] heptane-(3S)-carbonyl }-amino)-4-oxo-butyric acid
Example II-64
(3S)-(2-[(2S)-(isoquinolyl-1 carbonylamino)-3,3-dimethyl-butyryl radicals]-2-(1S, 4R)-aza-bicyclo [2.2.1] heptane-(3S)-carbonyl }-amino)-4-oxo-butyric acid
Example II-65
(3S)-(2-[(2S)-(4-amino-3-chloro-benzamido)-3,3-dimethyl-butyryl radicals]-2-(1S, 4R)-aza-bicyclo [2.2.1] heptane-(3S)-carbonyl }-amino)-4-oxo-butyric acid
Figure S05811231120061019D001144
Example II-66
(3S)-(2-[(2S)-(4-amino-3-chloro-benzamido)-3-methyl-butyryl radicals]-2-(1S, 4R)-aza-bicyclo [2.2.1] heptane-(3S)-carbonyl }-amino)-4-oxo-butyric acid
Figure S05811231120061019D001151
The authentication data of Compound I I-1 to II-66 is summarised in the following table 4, comprise HPLC, LC/MS (observation) and 1H NMR data. 1H NMR data obtain under 400MHz, find consistent with structure.
Table 4: the characterization data (according to compound number) of the formula II compound of selection
No. M+1(obs) 1H-NMR
II-7 447.0 (CD 3OD)1.02-1.18(6H，m)，1.88-2.28(5H，m)，2.39(3H，s)，2.50-2.78(2H，m)，3.75-3.83(1H，m)，4.00-4.10(1H，m)，4.21-4.32(1H，m)，4.45-4.52(1H，m)，4.60-4.65(2H，m)，7.39-7.54(3H，m)
II-8 446.0 (DMSO-d 6)0.94-0.99(6H，m)，1.71-2.12(4H，m)，2.33(1H，brs)，2.67(1H，brs)，2.94-3.07(1H，m)，3.61-3.69(1H，m)，3.82-3.87(1H，m)，4.03-4.10(1H，m)，4.19-4.28(1H，m)，4.30-4.43(2H，m)，5.42-5.47(1H，m)，7.28-7.30(1H，m)，7.37-7.40(1H，m)，7.68-7.82(2H，m)，8.77(1H，d)
II-9 519.9 (DMSO-d 6)0.94-0.99(6H，m)，1.86-2.09(5H，m)，3.00(1H，m)，3.65(1H，m)，3.84(1H，m)，4.05(1H，m)，4.24(1H，m)，4.40(1H，m)，4.51(1H，m)，5.45(1H，m)，7.57-7.62(2H，m)，7.77(1H，d)，7.90(1H，m)，8.40?(1H，d)，8.87(1H，?d)
II-10 466.0 (DMSO-d 6)0.93-0.99(6H，2xd)，1.77-2.19(5H，m)，2.29(3H，s)，2.97(1H，brs)，3.62-3.65(1H，m)，3.85-3.88(1H，m)，4.00-4.32(2H，brm)，4.41-4.53(2H，m)，5.45(1h， brs)，7.18-7.27(2H，m)，7.45-7.50(1H，m)，7，85(1h，brd)，8.41(1H，br?d)，8.57(1H，d)
II-11 485.9 (DMSO-d 6)0.82-0.86(3H，m)，0.93-0.98(3H，m)，1.87-2.08(5H，m)，3.00(1H，m)，3.64(1H，m)，3.82(1H，m)，4.10(1H，m)，4.30(1H，m)，4.45(1H，m)，4.47(1H，m)，5.44(1H，d)，7.37(1H，m)，7.47(1H，m)，7.65(1H，m)，7.77(1H，m)，8.40(1H，m)，8.72(1H，m)
II-12 485.9 (DMSO-d 6) 0.94-0.99(6H，m)，1.91-2.09(5H，m)，3.00(1H，m)，3.64(1H，m)，3.83(1H，m)，4.03(1H，m)，4.20(1H，m)，4.40(1H，m)，4.47(1H，m)，5.45(1H，m)，7.37(1H，s)，7.50-7.52(2H，m)，7.78(1H，m)，8.44(1H，m)，8.79(1H，m)
No. M+1(obs) 1H-NMR
II-13 486.3 (DMSO-d 6)?0.82-0.86(3H，m)，0.92-0.99(3H，m)，1.80-1.87(2H，m)，1.9?-2.02(4H，m)，2.48(0.5H，m)，2.95(0.5H，m)，3.51(1H，m)，3.80-4.56(4H，m)，5.00?and?5.47(1H，2xm)，7.37-7.48(3H，m)，7.76-8.32(1H，m)，8.95-9.39(1H，3xdd)
II-14 446.0 (DMSO-d 6)?0.93-0.99(6H，m)，1.80-2.09(5H，m)，2.17(6H，d)，2.95(1H，br?s)，3.63-3.65(1H，m)，3.96-3.99(1H，m)，4.10(1H，br?s)，4.30(1H，br?s)，4.44(1H，t)，5.48(1H，br?s)，7.00(2H，d)，7.14(1H，t)，7.78(1H，br?s)，8.50(1H，br?s)，8.55(1H，d)
II-15 433.1 (DMSO-d 6)0.91-1.02(6H，m)，1.80-2.20(5H，m)，2.66-2.68(3H，s)，3.00(1H，m)，3.62-3.85(3H，m)，4.10(1H，m)，4.24(1H，m)，4.51(1H，m)，5.72(1H，m)，7.73-7.76(2H，m)，8.19(1H，m)，8.52(1H，m)，8.75(1H，d)，8.90(1H，m)
II-16 433.1 (DMSO-d 6)0.9-1.05(6H，m)，1.8-2.2(6H，m)，2.3-2.4?(1H，m)，2.7-2.75(1H，m)，2.9-3.0(1H，m)，3.65-3.75(1H，m)，3.8-3.9(1H，m)，4.1-4.15(1H，m)，4.3-4.4(1H，m)，4.45-4.65(1H,m)，7.8-7.9(1H，m)，8.7-8.8(2H，d)，8.9.8.95(1H，m)
II-17 438.0 (DMSO-d 6)0.83-0.99 (6H，m)， 1.80-2.20(5H，m)，2.40(3H，s)，3.00(1H，m)，3.61(1H，m)，3.81(1H，m),4.10(1H，m)，4.25(1H，m)，4.42-4.46(2H，m)，5，44(1H，brs),6.97(1H，m)，7.34(1H，m)，7.59(1H，m)，7.81(1H，m)，8.49?(1H，m)
II-18 487.0 (DMSO-d 6)0.92-1.00(6H，m)，1.75-2.08(5H，m)，2.30-2.34(1H，m)，2.99(1H，dd)，3.62-3.67(1H，m)，3.78-3.82(1H，m)，3.78-3.82(1H，m)，4.05-4.26(1H，m)，4.38-4.54(2H，m)，5.44-5.72(1H，m)，7.37-7.41(1H，m)，8.41-8.43(2H，m)，8.97-9.00(1H,d)
No. M+1(obs) 1H-NMR
II-19 487.0 (DMSO-d 6)0.94-1.00(6H，m)，1.77-2.15(5H，m)，3.02(1H，dd)，3.61-3.70?(1H，m)，3.80-3.90(1H，m)，4.03-4.08(1H，m)，4.52-4.56(1H，m)，4.95(2H，br?s)，5.45(1H，s)，8.42(1H，d)，8.67(2H，s)，9.17(1H，d)
II-20 476.4 (DMSO-d 6)0.91-1.11(9H，m)，1.70-2.14(7H，m)，2.31(1H，m)，3.01(1H，m)，3.50-3.97(5H，m)，4.00-4.62(3H，m)，5.50(1H，m)，6.77(1H，d)，7.00(1H，d)，7.18(1H，dd)，7.50-8.50(3H，m)
II-21 502.1 (DMSO-d 6)1.80-2.00(3H，m)，2.11(4H，overlapping?s?and?m)，2.60-2.80(2H，m)，3.64-3.69(1H，m)，3.80(3H，s)，4.10(1H，vbrs)，4.30(1H，vbrs)，5.00(1H，m)，6.86(1H，d)，7.03(1H，d)，7.22(1H，t)，8.45(1H，vbrs)，8.81(1H，d)
II-22 462.4 (DMSO-d 6)0.93-1.00(6H，m),1.70-2.15(5H，m)，2.22(3H，s)，2.33(1H，d)，2.99(1H，dd)，3.60-3.65(2H，m)，3.74(3H，s)，4.04-4.08(1H，m)，4.21-4.27(1H，m)，4.40-4.58(2H，m)，5.46(1H，brdd)，6.78-6.81?(1H，m)，6.85-6.91(1H，m)，7.09-7.14(1H，m)，8.37(2H，2xbrd?d)
II-23 517.0 (DMSO-d 6)1.77-2.19(5H，m)，2.95-3.28(3H，m)，3.60(1H，brd?d)，3.71-3.78(4H，m)，4.10-4.42(6H，m)，4.97(1H，brd?s)，5.45-72(1H，m)，6.74(1H，d)，6.97(1H，d)，7.10-7.22(1H，m)，7.44(1H，m)，8.37-8.68(2H，m),9.05(1H，brd?s)
II-24 492.0 (DMSO-d 6)1.75-1.98(3H，m)，2.08-2.13(1H，m)，2.64-2.77(2H，m)，2.99(0.5H，dd)，3.63-3.73(2H，m)，4.08(0.5H，brt)，4.20(0.5H，dd)，4.23-4.49(3multiplets，1H?total)，5.00-5.10(1H，m)，5.42(0.5H，s)，7.36-7.52(4H，m)，7.77(1H，m)，8.30?(0.5H，d)，9.09(1H，d)
No. M+1(obs) 1H-NMR
II-25 507.0 (DMSO-d 6)1.79-1.96(5H，m)，2.94-3.28(3H，m)，3.58(1H，brdd)，3.73(1H，brd?d)，4.04-4.59(2H，m)，4.98-5.02 .(1h，m)，5.54-5.74(2H，m)，7.26-7.46(5H,m)，8.43(1H，d)，8.82(1H，d)，9.39(1H，brd?s)
II-26 446.6 (DMSO-d 6)1.05(9H，S)，1.15(3H，t)，1.8-2.1(4H，m)，2.3(3H，s)，2.4-2.5(1H，m),2.9-3.0(1H，m)，3.7-3.75(1H，m)，3.8-3.85(1H,m)，4.1-4.15(0.5H，m)，4.25-4.3(1H，m)，4.4-4.5(0.5H，m)，4.7-4.75(1H，m)，5.55-5.6(1H，m)，7.2-7.4(4H，m)，7.7-7.75(1H，m)，8.1-8.15(1H，m)，8.35-8.4(1H，m)
II-27 486.5 (DMSO-d 6)0.95-1.05(6H，m)，1.8-2.1(4H，m)，2.4-2.5(1H，m)，3.0-3.1(1H，m)，3.7-3.75(1H，m),3.8-3.85(1H，m)，4.1-4.15(0.5H，m)，4.25-4.3(1H，m)，4.4-4.5(0.5H，m)，5.55-5.6(1H，m)，7.4-7.45(1H，m)，7.6-7.8(3H，m)，8.4-8.45(1H，m)，8.75-8.8(1H，m)
II-28 466.1 (CDCl 3)1.11-1.16(9H，m)，1.94-2.22(4H，m)，2.38-2.50(2H，m)，2.77-2.87(1H，m)，3.71-3.79(1H，m)，3.96-4.06(1H，m)，4.56-4.67(2H，m)，4.85-4.91(1H，m)，6.99-7.02(1H，m)，7.28-7.45(3H，m)，7.60-7.84(2H,m)
II-29 500.2 (CDCl 3)1.07(9H，s)，1.85-2.19(2H，m)，2.37-2.40(2H，m)，2.81-3.07(1H，m)，3.37(1H，brs)，4.01(1H，brs)，4.46-4.67(2H，m)，4.87(1H，d)，5.73(1H，brs)，6.68(1H，brs)，7.38-7.74(5H，m)
II-30 496.2 (CD 3OD)1.15(9H，s)，1.85-2.20(4H，m)，2.46-2.72(2H，m)，3.74-3.81(1H，m)，3.92(3H，s)，3.93-4.03(1H，m)，4.20-4.31(1H，m)，4.45-4.52(1H，m)，4.60-4.75(1H，m)，4.83(1H，s)，7.00(1H，d)，7.15(1H，d)，7.33(1H，t)
II-31 480.5 (DMSO-d 6)1.05(9H，s)，1.8-2.1(4H，m)，2.4-2.5(1H，m)，3.75-3.8(1H，m)，3.8-3.85(1H，m)，3.9(3H，s)，4.1-4.3(1H，m)，4.7(1H，d)，5.3-5.5(0.5H，brs)，7.1-7.3(3H，m)，7.7-7.8(1H，m)，8.0-8.1(1H，m)，8.35-8.45(1H，m)
No. M+1(obs) 1H-NMR
II-32 550.3 (DMSO-d 6)0.91-1.10(9H，m)，1.70-2.15(5H，m)，2.60-3.08(1H，m)，3.60-3.90(2H，m)，3.98-4.71(3H，m)，5.40-5.80(1H，m)，7.30-7.91(3H，m)，8.30-8.80(3H，m)
II-33 523.3 (DMSO)0.60-0.90(4H，m，cyclopropylCH2),0.92-1.10(9H，m，tBu)，1.71-2.21(5H，m，CH2)，2.65-3.10(1H，brm，CH2)，3.36-3.50(1H，m，CH)，3.60-4.75(6H，m，CH)，6.92(1H，d，aryl?H)，7.36(1H，m，aryl?H)，7.45(1H，m，aryl?H)，7.65-8.60?(3H，m，NH，OH)
II-34 480.3 (DMSO)0.99-1.10(9H，m，tBu)，1.70-2.12(5H，m，CH2)，2.35(3H，s，CH3)，2.60-3.08(1H，m，CH2)，3.58-3.87(2H，m，CH)，4.00-4.70(3H,?m，CH)，5.38-5.79(1H，m，CH),7.12(1H，d，aryl?H)，7.24(1H，m，aryl?H)，7.38(1H，m，arylH)，7.69-8.55(3H，m，NH，OH)
II-35 482 CD3OD?1.01-1.15?(6H，m)，1.95-2.22(5H，m)，2.48-2.69(2H，m)，3.73-3.80(1H，m)，4.92(3H，s)，3.99-4.19(1H，m)，4.20-4.30(1H，m)，4.58-4.67(2H，m)，7.00(1H，d)，7.14(1H，d)，7.31(1H，t)
II-36 494.4 (DMSO)?0.94-1.08(9H，s，tBu)，1.19(3H，t，CH3)，1.70-2.40(5H，m，CH2)，2.60-3.08(3H，m，CH2),3.69(1H，m，CH)，3.81(1H，m，CH)，4.04-4.71(3H，m，CH)，5.40-5.80(1H，m，CH)，7.14(1H，m，aryl?H)，7.31(1H，m,aryl?H)，7.39(1H，m，aryl?H)，7.70-8.50(3H，m，NH，OH)
II-37 482.5 (DMSO)?0.9-1.0(6H，m)，1.85-2.3(4H，m)，3.0-3.1(1H，m)，3.65-3.7(1H，m)，3.78(3H，s),?3.8-3.85(1H，m)，4.1-4.15(0.5H，m)，4.25-4.3(0.5H，m)，4.5-4.55(1H，m)，5.5-5.55(1H，m)，6.93(1H，d)，6.98(1H，s)，7.35(1H，d),7.75-7.8(1H，m)，8.45(1H，d)
No. M+1(obs) 1H-NMR
II-38 536 (CD3OD)0.34-0.40(2H，m)，0.60-0.67(2H，m)，1.16(9H，s)，1.25-1.32(1H，m)，1.93-2.22(4H，m)，2.50-2.66(2H，m)，3.74-3.84(1H，m)，3.91-4.03(3H，m)，4.22-4.32(1H，m)，4.45-4.54(1H，m)，4.61-4，69(1H，m)，4.82(1H，d)，6.99(1H,d)，7.12(1H，d)，7.32(1H，t)，8.40(1H，d)
II-39 482 (CD3OD) 1.12(9H，s),1.90-2.22(4H，m)，2.512.70(2H，m)，3.75-3.83(1H，m)，3.97-4.05(1H，m)，4.23-4.30(1H，m)，4.46-4.54(1H，m)，4.63-4.70(1H，m)，4.83(1H，d)，6.91(1H，d)，6.99(1H，d)，7.17(1H，t)，8.36(1H,d)
II-40 509.3 (DMSO)0.93-0.98(6H，m)1.71-2.09(10H，m)，2.35-2.45(2H，m)，3.61-3.64(1H，m)，4.02-4.04(1H，m)，4.06-4.35(2H，m)，4.43-4.46(1H，m)，7.33(1H，d)，7.43-7.46(1H，m)，7.80(1H，brds)，8.28-8.49(2H，m),10.25(1H，brds)
II-41 523.3 (DMSO)0.95-1.08(9H，s，tBu)，1.70-2.38(8H，m，COCH3，CH2)，2.58-3.08(1H，m，CH2)，3.65(1H，m，CH)，3.82(1H，m,CHO)，3.95-4.69(3H，m，CH)，5.40-5.60(1H，m,CH)，7.09(1H，m，aryl?H)，7.31(1H，m，aryl?H)，7.64-8.60(4H，m，aryl?H，NH)，9.55(1H，m，CH)
II-42 503.4 (DMSO)0.91-1.08(9H，s，tBu)，1.70-2.40(11H，m，CH3，COCH3，CH2)，2.60-3.08(1H，m，CH2)，3.66(1H，m，CH)，3.87(1H，m，CH)，4.00-4.65(3H，m，CH)，5.40-5.78(1H，m，CH)，7.04(1H，m，aryl?H)，7.18(1H，m，aryl?H)，7.38(1H，m，aryl?H)，7.65-7.88(1H，m，NH)，8.07-8.70(2H，m，NH)，9.34(1H，m，CH)
II-43 523.3 (DMSO)1.03(9H，s)，1.71-2.00(3H，m)，2.07(3H，s)，2.55-2.73(1H，m)，2.97(1H，dd)，3.60-3.67?(1H，m)，3.75-3.82(1H，m)，3.98-4.04?(1H，m)，4.19-4.24(1H，m)，4.37-4.45(1H，m)，4.63(1H，d)，5.45(1H，d)，7.33-7.35(1H，m)，7.43-7.45(1H，d)，7.76-7.83(2H，m)，8.25-8.28(1H，m)，8.41-8.58(1H，m)，10.27(1H，s)
No. M+1(obs) 1H-NMR
II-44 507.4 (DMSO)1.01(9H，2xs)，1.72-1.99(4H，m)，2.05-2.09(4H，m)，2.35-2.57(2H，m)，2.71-3.00(1H，brd?m)，3.60-3.65(1H，m)，3.71-3.80(1H,?m)，4.08-4.37(2H，brd?m)，4.70(1H，d)，7.32(1H，dd)，7.65-7.80(3H，m)，8.33-8.52(1H，brd?m)，10.37(1H，s)
II-45 493.4 (DMSO)0.94(6H，dd)，1.72-1.99?(10H，m)，2.36-2.52(2H，m)，3.57-3.68(1H，m)，3.76-3.88(1H，m)，4.20-4.43(2H，m)，4.51-4.55(1H，m)，7.30(1H，dd)，7.58-7.77(3H，m)，8.00-8.04?(1H，m)，10.34(1H，s)
II-46 510.5 (DMSO)0.95-1.0(6H，m)，1.25(6H，d)，1.85-2.2(4H，m)，3.0-3.1(1H，m)，3.9-4.0(3H?,m)，4.2-4.3(0.5H，m)，4.4-4.5(0.5H，m)，4.7-4.8(1H，m),6.9-6.95(1H，d)，6.99(1H，s)，7.3(1H，d)，8.3-8.4(1H，m)
II-47 482.5 (DMSO)1.05?(9H，m)，1.8-2.1(4H，m)，2.6-2.7(1H，m)，2.9-3.0?(2H，m)，3.6-3.7(2H，m),3.8-3.9(1H，m)，4.0-4.1(1H，m)，4.2-4.3(1H，m)，4.6-4.65(1H，m)，5.5-5.55(1H，m)，6.75-6.85(2H，m)，7.35(1H,d)，7.75(1H，d)，8.0-8.1(1H，m)，8.35(1H，m)，10.25(1H，s)
II-48 510.5 (DMSO)1.03(9H，s)，1.80-2.10(4H，m)，3.00(1H，brs)，3.30(3H,s)，3.66(1H，m)，3.81(1H，m)，4.06(1H，m)，4.25(1H，m)，4.44(2H，s)，4.65(1H，d)，5.461H，brs)，7.29-7.39(3H，m)，7.77(1H，br?s)，8.43(1H，m)
II-49 551.5 (DMSO)1.03(9H，s)，1.09(3H，m)，1.11(3H，m)，1.79-2.15?(4H，m)，2.32(1H，m)，2.98(1H,m)，3.51(1H，m)，3.79(1H，m)，4.10(1H，m)，4.23(1H，m)，4.40-4.65(2H，m)，5.45-5.73(1H，m)，7.35(1H，m)，7.4?(1H，m)，7.76-7.84(2H，m)，8.23-8.60(2H，m)?,10.11 (1H，s)
No. M+1(obs) 1H-NMR
II-50 493.3 (DMSO)0.92-1.19(4H，m)，1.49-1.90(9H，m)，1.91-1.99(2H，m)，2.06(4H，brd?s)，2.49-2.52(2H，m)，3.57-3.68(1H，m)，3.80-3.90(1H，m)，4.01-4.28(2H，m)，4.46(1H，t)，7.32(1H，d)，7.43(1H，dd)，7.81(2H，brd?s)，8.31-8.78(1H，m)，8.46(1H，d),10.22(1H，s)
II-51 539.3 (DMSO)0.90-1.07(9H，s，tBu)，1.70-2.40(4H，brm，CH2)，2.54-3.07(1H，m，CH2)，3.52-3.88(5H，m，CH3，CH)，4.00-4.65(3H，m，CH),5.40-5.80(1H，m，CH)，7.30-7.44(2H，m，aryl?H)，7.60(1H，m，aryl?H)，7.67(1H，br，NH)，8.10-8.70(2H，m，NH)，10.00(1H，m，CH)
II-52 558.3 (DMSO)0.91-1.11(9H，s，tBu)，1.70-2.41(4H，m，CH2)，2.56-3.09(1H，m，CH2)，3.60-3.90(2H,m，CH)，4.14-4.72(3H,m，CH)，5.38-5.80(1H，m，CH)，6.98(2H，m，aryl?H)，7.07-7.20(3H，m，aryl?H)，7.31-7.46(3H，m，aryl?H)，7.66-8.67(3H，m，NH， OH)
II-53 467 (DMSO)0.83-1.04(6H，m)，1.81-2.08(5H，m)，3.34-3.63(1H，m)，3.84-3.90(1H，m)，4.00-4.60(3H，m)，5.29-5.75(2H，m)，6.53-6.59(1H，m)，6.70-6.90(1H,m)，7.20-7.35(0.5H，m)，7.78(0.5H.brs)，8.43-8.60(2H，m)
II-55 502.6 (DMsO)0.96(1H，s).1.03(9H，s)，1.30-1.39(2H，m)，1.68-1.71(2H，m)，1.79-1.82(1H，m)，1.97(1H，brd)，2.11(3H，s)，3.79(3H，s)，3.84(1H，vbrs)，4.09(1H，vbrs)，4.56-4.58(1H，m)，4.67(1H，d)，6.81(1H，d)，7.00?(1H，d)，7.19(1H，t),7.79(0.5H，vbrs)，7.93(1H，brd)，8.42(0.5H，vbrs)
II-56 492.5 (CDC13)1.08-1.14(9H，m)，1.85-2.05(4H，m)，2.32-2.45(1H，m)，2.79-2.85(1H，m)，3.01-3.07(1H，m)，4.13-4.17(1H，m)，4.53-4.70(1H，m)，4.98(1H，t)，5.70and?5.81(1H?total，brsandbrd)，6.91-7.00(1H，m)，7.34-7.44(3H，m)，7.67-7.75(1H，m)
No. M+1(obs) 1H-NMR
II-57 549.5 (DMSO)1.03(9H，s)，1.31-1.38(2H，m)，1.62-1.74(3H，m)，1.98(1H，brt)，2.07(3H,s)，2.36(1H，vbrs)，2.83(1H，vbrs)，3.84(1H，brs)，4.17(1H，vbrs)，4.54-4.57(1H，m)，4.70(1H，d)，7.34(1H，d)，7.42-7.45(1H，m)，8.16(1H，t)，8.37(1H，brs)，10.23(1H，s)
II-58 563.5 (CD3OD)1.17(9H，s)，1.21(3H，t)，1.41-1.55(2H，m)，1.75-1.90(3H，m)，2.03-2.19(1H，m)，2.37-2，50(3H，m)，2.58-2.78(2H，m)，3.87-4.02(1H，m)，4.20-4.30(1H，m)，4.55-4.70(2H，m)，4.91(1H，obscured)，7.45(1H，d)，7.51(1H，d)，7.85(1H，s)，8.29(1H，d)
II-59 577.5 (DMSO)1.05(9H，s)，1.15(6H，d)，1.35-1.5(2H，m)，1.75-1.9(3H，m)，2.0-2.1(1H,m)，2.3-2.45(1H，m)，2.7-2.9(1H，m)，4.05-4.15(1H，m)，4.65(1H，s)，4.7-4.75(1H，m)，7.15(1H，d)，7.35(1H，t)，7.7(1H，d)，8.4-8.55(2H，m)，9.5(1H，s)
II-60 506.5 (DMSO)1.03(9H，s)，1.31-1.38(2H，m)，1.68(3H，m)，2.30-2.33(2H，m)，2.67(0.5H，brs)，2.99(0.5H，brs)，3.34(0.5H，brs)，3.76(3H，s)，4.04(0.5H，m)，4.58(1H，s)，4.72(1H，d)，7.09-7.12(1H，m)，7.16-7.20(1H，m)，7.26-7.30(1H，m)，7.78(0，5H，vbrs)，8.02(1H，brs)，8.42(0.5H，vbrs)
II-61 492.8 (DMSO)0.95(3H，d)，0.10(3H，d)，1.17(1H，m)，1.32(1H，m)，1.64-1.80(3H，m)，2.00(1H，m)，2.30(1H，brs)，2.67(0.5H，brs)，2.99(0.5H，br?s)，3.75(0.5H，br?s)，3.85(3H，s)，4.06(0.5H，m)，4.50-4.55(2H，m)，5.42(1H，br?s)，7.07(1H，m)，7.17(1H，m)，7.26(1H，m)，7.80(1H，br?s)，8.35(1H，m)
II-62 549.5 DMSO)δ1.04(9H，s)，1.29-1.34(2H，m)，1.59-1.67(3H，m)，1.91-1.97(1H，m)，2.13(3H，s)，2.96(1H，vbrs)，3.77(1H，vbrs)，4.10(1H，vbrs)，4.72(1H，s)，4.76(1H，d)，7.80-7.83(1H，m)，7.88-7.91(1H，m)，8.00-8.02(1H，m)，8.18-8.24(12H,m)，8.39(1H，vbrs)，9.62(1H，s)
No. M+1(obs) 1H-NMR
II-63 563.5 (DMSO)1.05(9H，s)，1.09(3H，t)，1.19-1.37(3H，m)，1.47-1.77(3H，m)，1.91-1.99(1H，m)，2.28(0.5H，brdd)，2.48(2H，q)，2.63-2.74(1H，m)，3.01(0.5H，dd)，3.63(0.5H,s)，3.78-4.37(2H，total，m)，4.42-4.59(1H.m)，4.75(1H，d)，5.42(0.5H，d)，7.76(0.5H，d)，7.80-7.83(1H，m)，7.87(1H，d)，8.01(1H，m)，8.08-8.15(1H，m)，8.36(0.5H，d)，9.53(1H，s)
II-64 509.5 (DMSO)1.07(9H，s)，1.34-1.37(2H，m)，1.64-1.72(3H，m)，1.95-2.04(1H，m)，2.31-2.35(1H，m)，2.65-2.70(1H，m)，3.01-3.03(1H，m)，3.99(0.5H，m)，4.26-4.28(0.5H，m)，4.68(1H，s)，4.82(1H，d)，5.45(0.5H，s)，7.73-7.86(3H，m)，8.05-8.08(2H，m)，8.49(0.5H，d)，8.57-8.59(1H，m)，8.69(0.5H，d)，9.15(1H，d)
II-65 507.5 (DMSO)1.02(9H，s)，1.28-1.34(2H，m)，1.57-1.64(3H，m)，1.90-1.96(1H，m)，3.72-3.80(1H，m)，4.50(1H，brs)，4.72-4.74(1H，m),?5.91(1H，s)，6.76(1H，d)，7.58-7.61(1H，m)，7.81-7.83(1H，m)
II-66 493.5 ?/
EXAMPLE III Biological method
Can utilize following method test The compounds of this invention.Table 5 is enumerated aspartic acid specificity cysteine protease-1 and the aspartic acid specificity cysteine protease-8 restraining effect data of Compound I I-1-II-25.In the form, the compound of Ki＜10 is decided to be category-A, and Ki is that the compound of 10-20 is decided to be category-B, and Ki is that the compound of 21-30 is decided to be the C class.
The external test method
Enzyme inhibition
Method (J.Biol.Chem., 272 pp.7223-7228 (1997)) by people such as Margolin obtains the Ki value of test compound for aspartic acid specificity cysteine protease-1 and aspartic acid specificity cysteine protease-8.Similarly can measure other aspartic acid specificity cysteine proteases (for example referring to WO 99/47545).Under 37 ℃, (Sigma Corp, StLouisMO) (Cleveland OH) and among the 0.1%CHAPS (Pierce, Rockford IL) measures for DTT, Research OrganiC INC for pH 7.5,1mM dithiothreitol (DTT) at 10mM Tris.With regard to aspartic acid specificity cysteine protease-3, add 8% glycerine solution to measuring damping fluid, to improve enzyme stability.Move on in the 96 hole flat boards measuring the 65 μ l aliquots containigs of damping fluid and the 5 μ l aliquots containigs suction of the suitable diluent of inhibitor in DMSO, handle with 10 μ l aspartic acid specificity cysteine proteases, be diluted in then and measure in the damping fluid (, being the 0.5-40nM active protein) according to the avtive spot titration.Each mensuration comprises the contrast that contains DMSO and do not have compound.Then with flat board 37 ℃ of following incubations 15 minutes, add suitable substrate (20 μ l, ultimate density 1-4 x KM finally measure volume 100 μ l) then, with initiation reaction.Under 37 ℃, according to the increase assaying reaction speed of absorbancy under the time-dependent manner 405nM (with regard to the pNA substrate) or fluorescence (Ex 390, and Em 460) (with regard to the AMC substrate).Gained speed is mapped to inhibitor concentration, data bring into Mo r r i s on competitive inhibitor combine closely equation (Morrison, J.F., Biochem.Biophys.Acta, 185 pp.269-286 (1969)).The substrate that is used for every mensuration is as follows:
Aspartic acid specificity cysteine protease-1 Suc-YVAD-pNA (Bachem, Kingof Prussia, PA) (the ultimate density 80 μ M in the mensuration);
Aspartic acid specificity cysteine protease-8 Ac-DEVD-pNA (Bachem, Kingof Prussia, PA) (the ultimate density 80 μ M in the mensuration).
Table 5: aspartic acid specificity cysteine protease-1 (Cl) and aspartic acid specificity cysteine protease-8 (C8) restraining effect data
Compound Ki?Cl(nM) Ki?C8(nM)
II-1 A A
II-2 A A
II-3 A A
II-4 A B
II-5 A B
II-6 A A
II-7 A B
II-8 A B
II-9 A B
II-10 A B
II-11 A C
II-12 A B
II-13 B B
II-14 B A
II-15 A C
II-16 A C
II-17 A A
II-18 A B
II-19 B A
II-20 A A
II-21 A C
II-22 A C
II-23 A C
II-24 A C
II-25 A C
II-26 A A
II-27 A A
II-28 A A
II-29 A A
II-30 A A
II-31 A A
II-32 A A
II-33 A A
II-34 A A
II-35 A A
II-36 A A
II-37 A B
II-38 A A
II-39 A A
II-40 A B
II-41 A A
II-42 A B
II-43 A A
II-44 A A
II-45 A A
II-46 A C
II-47 A A
II-48 A A
II-49 A A
II-50 A C
II-51 A A
II-52 A A
II-53 A C
II-55 A A
II-56 A A
II-57 A A
II-58 A A
II-59 A A
II-60 A A
II-61 A A
II-62 A B
II-63 A B
II-64 B B
II-65 A A
II-66 B A
The PBMC raji cell assay Raji
Utilize the monocytic mixed population of adhesion of human peripheral liquid monocyte (PBMC) or institute's enrichment to carry out the IL-1 beta determination
Use the various kinds of cell source can in cell culture, measure the elaboration of ICE to preceding-IL-1 β.The human PBMC who obtains from healthy donors provides lymphocyte subtype and monocytic mixed population, produces a series of interleukins and cytokine in response to the physiological stimulation thing of many types.Provide the normal cells of monocytic origin of institute's enrichment from the adhesion monocyte of PBMC, be used for the selectivity research that active cells produces cytokine.
Experimental technique:
The initial serial dilutions of preparation test compound in DMSO or ethanol, be diluted in respectively subsequently in the RPMI-10%FBS substratum and (contain 2mM L-glutaminate, 10mM HEPES, 50U and 50 μ g/ml penicillin/streptomycin), obtain 4 times of drug levels to final test concentration, contain 0.4%DMSO or 0.4% ethanol.The final DMSO concentration of all drug dilution liquid is 0.1%.The concentration titration generally is used for preliminary screening compound, and the apparent Ki of the test compound of measuring in ICE restraining effect assay method is parenthesized.
General test 5-6 kind diluted chemical compound liquid, the cellular component of assay method is duplicate, and the ELISA of every kind of cell culture supernatant liquid measures duplicate.
PBMC separates and IL-1 measures:
To be diluted to 80ml with substratum from one pint of isolating buffy coat of human blood (blood plasma that obtains the 40-45ml final volume adds cell), and cover every LeukoPREP with the 10ml cell suspension and separate test tube (Becton Dickinson).Behind the centrifugal 15min, suction blood plasma/culture medium layer is used Pasteur volumetric pipette collecting monocytic cell layer then under 1500-1800xg, is transferred to the conical centrifuge tube (Corning) of 15ml.Adding substratum to volume is 15ml, puts upside down gently and makes cytomixis, centrifugal 15min under 300xg.The PBMC precipitation is suspended in the small volume substratum again, and counting cells is adjusted to 6 * 10 6Cell/ml.
With regard to raji cell assay Raji, add 1.0ml cell suspension, 0.5ml test compound diluent and 0.5ml LPS solution (Sigma#L-3012 to every hole of the flat tissue culture plate in 24 holes (Corning); The 20ng/ml solution that in complete RPMI substratum, prepares; Final LPS concentration 5ng/ml).Add 0.5ml test compound and LPS and be enough to make the aperture contents mixed usually.Every experiment needs three kinds of control mixture, and promptly independent LPS, solvent carrier contrast and/or other substratum are to regulate the final cultures volume to 2.0ml.At 5%CO 2Existence under, with cell culture at 37 ℃ of following incubation 16-18hr.
When incubation period finished, harvested cell was transferred to the conical centrifuge tube of 15ml.Behind the centrifugal 10min, the results supernatant liquor is transferred to 1.5ml Eppendorf test tube under 200xg.Before using-and IL-1 β specific antisera, by western blot analysis or ELISA, before cell precipitation can be used for the kytoplasm extract-the biochemistry evaluation of IL-1 β and/or ripe IL-1 β composition.
The monocytic separation of adhesion:
Separate and prepare PBMC as mentioned above.Add substratum (1.0ml) to aperture earlier, succeeded by 0.5ml PBMC suspension.Behind the incubation one hour, vibration is dull and stereotyped gently, the non-AC of suction from every hole.Then aperture is washed three times gently with 1.0m l substratum, be suspended in again in the 1.0ml substratum at last.The inrichment of AC generally obtains 2.5-3.0 * 10 5The every hole of cell.Carry out the processing of adding, cell incubation conditions and the supernatant liquor of test compound, LPS as mentioned above.
ELISA：
QuantiKine medicine box (R﹠amp; D Systems) can be used for the measurement of ripe IL-1 β.Guidance according to manufacturer is measured.In PBMC and adhesion monocyte positive control, all observe the ripe IL-1 β level of about 1-3ng/ml.Measure carrying out ELISA, to select supernatant liquor thinning ratio best in the test group from 1: 5,1: 10 of the supernatant liquor of LPS-positive control and 1: 20 diluent.
The inhibition of compound is renderd a service can use IC 50Value representation, it is to detect the inhibitor concentration of comparing 50% ripe IL-1 β with positive control in supernatant liquor.
The technician recognizes that the numerical value that obtains may depend on multiple factor in raji cell assay Raji.These numerical value can be represented meticulous quantized result.
Tested the restraining effect of selected The compounds of this invention, IC to PBMC release IL-1 β 50Value is between 300nM and 4 μ M.
The whole blood assay method that IL-1 β produces utilizes following method can obtain the whole blood assay IC of The compounds of this invention 50Value:
Purpose:
Whole blood assay is to measure IL-1 β (or other cytokines) to produce and the active simple method of potential inhibitor.The complicacy of this mensuration system is the model of the vitro reactions of physiological condition in the human body, because it has complete lymph sample and inflammatory cell type, plasma proteins mass spectrum and red corpuscle.
Material:
The pyrogen-free syringe (～30cc)
The aseptic vacuum test tube of pyrogen-free contains freeze dried Na 2EDTA (4.5mg/10ml test tube)
People's whole blood sample (～30-50cc)
1.5ml Eppendorf test tube
Test compound stock solution (～25mM, DMSO or other solvents)
No intracellular toxin sodium chloride solution (0.9%) and HBSS lipopolysaccharides (Sigma; Cat.#L-3012) stock solution, the concentration 1mg/ml in HBSS
IL-1 β ELISA medicine box (R﹠amp; D Systems; Cat.#DLB50)
TNF α ELISA medicine box (R﹠amp; D Systems; Cat.#DTA50)
Water-bath or incubator
The whole blood assay experimental technique:
It is 30 ℃ that incubator or bath temperature are set.Distribute 0.25ml blood to 1.5ml eppendorf test tube equivalent.Attention: must after per two parts of aliquots containigs, reverse the whole blood sample test tube.If cell settlement and asymmetric suspension may cause the difference in the replicate test.Use positive displacement volumetric pipette also will minimize the difference that reappears between the aliquots containig.
In aseptic pyrogen-free saline at, prepare drug dilution liquid by serial dilution.Serial dilution generally is used for preliminary screening compound, and the apparent Ki of the test compound of measuring in ICE restraining effect assay method is parenthesized.With regard to the extreme hydrophobicity compound, the fresh plasma that obtains from same blood donors or containing preparation diluted chemical compound liquid among the 5%DMSO of PBS, to improve solubleness.
Add 25 μ l test compound diluent or vehicle Control, biased samples gently.Add the 5.0 μ l LPS solution (stock solution of 250ng/ml prepared fresh: LPS ultimate density 5.0ng/mi), mix once more then.The incubation test tube reaches 16-18hr in 30 ℃ of water-baths, mixes once in a while.Select as an alternative, test tube can be placed the whirler that is arranged on 4rpm reach identical incubation period.This mensuration should be in duplicate or is triplicate, uses following contrast: negative control---there is not LPS; Positive control---not for the examination inhibitor; The DMSO of vehicle Control---maximum concentration or the compound solvent that is used to test.Add other salt solution to all contrast test tubes, make the volume normalizing of contrast and experimental whole blood sample.
After the incubation period, in Eppendorf tube,, blood plasma is transferred to fresh Eppendorf tube with whole blood sample under～2000rpm centrifugal 10 minutes, centrifugal to being settled out remaining thrombocyte, if necessary under 1000xg.Before measuring cytokine levels with ELI SA, can be at-70 ℃ of following refrigerated storage plasma samples.
ELISA：
R﹠amp; D Systems (614 McKinley PlaceN.E.Minneapolis, MN 55413) QuantiKine medicine box can be used for the measurement of IL-1 β and TNF-α.Guidance according to manufacturer is measured.Can in the positive control of certain limit individuality, observe～the IL-1 β level of 1-5ng/ml.All 1: 200 plasma extender of sample is enough to make the ELISA experimental result to fall into the linearity range of ELISA typical curve usually.If in whole blood assay, observe difference, have necessary optimizing criterion thinning ratio (Nerad, J.L.et al., J.Leukocyte Biol., 52, pp.687-692 (1992)).
Measured the restraining effect of selected The compounds of this invention, IC to whole blood release IL-1 β 50Value is between 1 μ M and 40 μ M.
Assay method in the body
Test The compounds of this invention in the assay method in vivo, for example WO 99/47545 described those.
The every other document that WO 99/47545 and this paper quote all is incorporated herein by reference.
Although we have described some embodiments of the present invention, but obviously can change our basic embodiment, adopt the embodiment of The compounds of this invention and method so that other to be provided.What therefore, will be figured out is that scope of the present invention is subjected to claim but not limiting by the embodiment of the foregoing description representative.

Claims (63)

1. formula I compound:
Figure FSB00000167967900011
Wherein:
Y is
Figure FSB00000167967900012
Or
Figure FSB00000167967900013
R 1Be H, C 1-12Aliphatic group, C 3-10Cycloaliphatic groups, C 6-10Aryl, 5-10 unit heterocyclic radical, 5-10 unit heteroaryl, (C 3-10Cycloalkyl)-(C 1-12Aliphatic group)-, cycloalkenyl group-(C 1-12Aliphatic group)-, (C 6-10Aryl)-(C 1-12Aliphatic group)-, (5-10 unit heterocyclic radical)-(C 1-12Aliphatic group)-or (5-10 unit heteroaryl)-(C 1-12Aliphatic group)-, wherein arbitrarily hydrogen atom alternatively with independently by R 8Replace, the group with two hydrogen atoms of same atomic linkage is replaced by carbonyl alternatively and independently arbitrarily;
Ring A is:
Figure FSB00000167967900014
Wherein in each ring, arbitrarily hydrogen atom is alternatively with independently by R 4Replace, the group with two hydrogen atoms of same atomic linkage is replaced by carbonyl alternatively and independently arbitrarily;
A is when ring Or
Figure FSB00000167967900022
The time, then
R is R 3C (O)-, HC (O), R 3SO 2-, R 3OC (O), (R 3) 2NC (O), (R 3) (H) NC (O), R 3C (O) C (O)-, R 3-, (R 3) 2NC (O) C (O), (R 3) (H) NC (O) C (O) or R 3OC (O) C (O)-; And
R 3Be C 1-12Aliphatic group, C 3-10Cycloaliphatic groups, C 6-10Aryl, 5-10 unit heterocyclic radical, 5-10 unit heteroaryl, (C 3-10Cycloaliphatic groups)-(C 1-12Aliphatic group)-, (C 6-10Aryl)-(C 1-12Aliphatic group)-, (5-10 unit heterocyclic radical)-(C 1-12Aliphatic group) or (5-10 unit heteroaryl)-(C 1-12Aliphatic group)-; Perhaps two R with same atomic linkage 3Group constitutes 3-10 unit's aromatics or non-aromatic ring with this atom; Wherein arbitrarily ring alternatively with C 6-10Aryl, 5-10 unit heteroaryl, C 3-10Cycloalkyl or 5-10 unit heterocyclic radical condense; Wherein 3 aliphatic carbon atoms can be selected from O, N, NR at the most 9, S, SO and SO 2Group replace R wherein 3By at the most 6 independently be selected from R 8Substituting group replace;
A is when ring
Figure FSB00000167967900023
Or
R is R so 3C (O)-, shown in II:
Figure FSB00000167967900025
And R 3Be phenyl, thiophene or pyridine, wherein each the ring alternatively by at the most 5 independently be selected from R 8' group replace, and wherein on this phenyl, thiophene or the pyridine at least one and key x position adjacent by R 12Replace, wherein R 12Has the straight chain atom that is no more than 5;
R 4Be halogen ,-OR 9,-NO 2,-CN ,-CF 3,-OCF 3,-R 9, 1,2-methylene-dioxy, ethylenedioxy ,-N (R 9) 2,-SR 9,-SOR 9,-SO 2R 9,-SO 2N (R 9) 2,-SO 3R 9,-C (O) R 9,-C (O) C (O) R 9,-C (O) C (O) OR 9,-C (O) C (O) N (R 9) 2,-C (O) CH 2C (O) R 9,-C (S) R 9,-C (S) OR 9,-C (O) OR 9,-OC (O) R 9,-C (O) N (R 9) 2,-OC (O) N (R 9) 2,-C (S) N (R 9) 2,-(CH 2) 0-2NHC (O) R 9,-N (R 9) N (R 9) COR 9,-N (R 9) N (R 9) C (O) OR 9,-N (R 9) N (R 9) CON (R 9) 2,-N (R 9) SO 2R 9,-N (R 9) SO 2N (R 9) 2,-N (R 9) C (O) OR 9,-N (R 9) C (O) R 9,-N (R 9) C (S) R 9,-N (R 9) C (O) N (R 9) 2,-N (R 9) C (S) N (R 9) 2,-N (COR 9) COR 9,-N (OR 9) R 9,-C (=NH) N (R 9) 2,-C (O) N (OR 9) R 9,-C (=NOR 9) R 9,-OP (O) (OR 9) 2,-P (O) (R 9) 2,-P (O) (OR 9) 2Or-(H) (OR of P (O) 9);
R 2Be-C (R 5) (R 6) (R 7), C 6-10Aryl, 5-10 unit's heteroaryl or C 3-7Cycloalkyl;
R 5Be H or C 1-6The straight or branched alkyl;
R 6Be H or C 1-6The straight or branched alkyl;
R 7Be-CF 3,-C 3-7Cycloalkyl, C 6-10Aryl, 5-10 unit heteroaryl, heterocycle or C 1-6The straight or branched alkyl, wherein each carbon atom of this alkyl is alternatively with independently by R 10Replace;
Perhaps R 5And R 7Constitute 3-10 unit cycloaliphatic groups with the carbon atom that they connected;
R 8And R 8' be independently of one another halogen ,-OR 9,-NO 2,-CN ,-CF 3,-OCF 3,-R 91,2-methylene-dioxy, ethylenedioxy ,-N (R 9) 2,-SR 9,-SOR 9,-SO 2R 9,-SO 2N (R 9) 2,-SO 3R 9,-C (O) R 9,-C (O) C (O) R 9,-C (O) C (O) OR 9,-C (O) C (O) N (R 9) 2,-C (O) CH 2C (O) R 9,-C (S) R 9,-C (S) OR 9,-C (O) OR 9,-OC (O) R 9,-C (O) N (R 9) 2,-OC (O) N (R 9) 2,-C (S) N (R 9) 2,-(CH 2) 0-2NHC (O) R 9,-N (R 9) N (R 9) COR 9,-N (R 9) N (R 9) C (O) OR 9,-N (R 9) N (R 9) CON (R 9) 2,-N (R 9) SO 2R 9,-N (R 9) SO 2N (R 9) 2,-N (R 9) C (O) OR 9,-N (R 9) C (O) R 9,-N (R 9) C (S) R 9,-N (R 9) C (O) N (R 9) 2,-N (R 9) C (S) N (R 9) 2,-N (COR 9) COR 9,-N (OR 9) R 9,-C (=NH) N (R 9) 2,-C (O) N (OR 9) R 9,-C (=NOR 9) R 9,-OP (O) (OR 9) 2,-P (O) (R 9) 2,-P (O) (OR 9) 2With (H) (OR of-P (O) 9);
R 9Be hydrogen, C 1-12Aliphatic group, C 3-10Cycloaliphatic groups, C 6-10Aryl, 5-10 unit heterocyclic radical, 5-10 unit heteroaryl, (C 3-10Cycloaliphatic groups)-(C 1-12Aliphatic group)-, (C 6-10Aryl)-(C 1-12Aliphatic group)-, (5-10 unit heterocyclic radical)-(C 1-12Aliphatic group) or heteroaryl-(C 1-12Aliphatic group)-, wherein arbitrarily hydrogen atom alternatively with independently by R 8Replace, the group with two hydrogen atoms of same atomic linkage is replaced by carbonyl alternatively and independently arbitrarily;
R 10Be halogen ,-OR 11,-NO 2,-CN ,-CF 3,-OCF 3,-R 11Or-SR 11
R 11Be C 1-4-aliphatic group-; And
R 12Be halogen ,-OR 11,-NO 2,-CN ,-CF 3,-OCF 3,-R 11,-SR 9
2. according to the compound of claim 1, wherein R is R 3C (O)-; R 3Be C 6-10Aryl or 5-10 unit heteroaryl, wherein R 3Any hydrogen atom alternatively with independently by R 8' replace.
3. according to the compound of claim 1, it is a formula II compound:
Figure FSB00000167967900041
R wherein 3Be phenyl, thiophene or pyridine, wherein each the ring alternatively by at the most 5 independently be selected from R 8' group replace, and wherein on this phenyl, thiophene or the pyridine at least one and key x position adjacent by R 12Replace, wherein R 12Have and be no more than 5 straight chain atoms.
4. according to the compound of claim 1, wherein Y is
Figure FSB00000167967900042
5. according to the compound of claim 4, R wherein 1Be C 1-12Aliphatic group or C 3-10Cycloalkyl, wherein each group independently is selected from R by 1-3 alternatively 8Group replace.
6. according to the compound of claim 5, R wherein 1Be straight or branched C 1-4Alkyl, it independently is selected from R by 1-3 alternatively 8Group replace.
7. according to the compound of claim 6, R wherein 1Be unsubstituted straight or branched C 1-4Alkyl.
8. according to the compound of claim 7, R wherein 1Be ethyl, sec.-propyl, n-propyl or normal-butyl.
9. compound according to Claim 8, wherein R 1It is ethyl.
10. according to the compound of claim 4, R wherein 8Be halogen ,-OR 9,-CN ,-CF 3,-OCF 3Or-R 9
11. according to the compound of claim 10, wherein R 8It is benzyl.
12. according to the compound of claim 1, wherein Y is
13. the compound any according to claim 1-12 wherein encircles A and is:
Figure FSB00000167967900052
14., wherein encircle A and be according to the compound of claim 13:
Figure FSB00000167967900053
Alternatively by R 4Replace.
15. the compound any according to claim 1-12 wherein encircles A and is:
Figure FSB00000167967900061
Or
Figure FSB00000167967900062
Alternatively by R 4Replace.
16., wherein encircle A and be according to the compound of claim 15:
Figure FSB00000167967900063
Alternatively by R 4Replace.
17. according to the compound of claim 13, wherein R 4Be halogen ,-OR 9,-CF 3,-OCF 3,-R 9Or-SR 9
18. according to the compound of claim 15, wherein R 4Be halogen ,-OR 9,-CF 3,-OCF 3,-R 9Or-SR 9
19. according to the compound of claim 17, wherein R 4Be H.
20. according to the compound of claim 18, wherein R 4Be H.
21. the compound any, wherein R according to claim 1-12 2Be C 3-4Branched-chain alkyl.
22. according to the compound of claim 13, wherein R 2Be C 3-4Branched-chain alkyl.
23. according to the compound of claim 15, wherein R 2Be C 3-4Branched-chain alkyl.
24. according to the compound of claim 17, wherein R 2Be C 3-4Branched-chain alkyl.
25. the compound any, wherein R according to claim 1-12 5Be H or-CH 3, R 6Be-CH 3, and R 7Be-CH 3
26. according to the compound of claim 13, wherein R 5Be H or-CH 3, R 6Be-CH 3, and R 7Be-CH 3
27. according to the compound of claim 15, wherein R 5Be H or-CH 3, R 6Be-CH 3, and R 7Be-CH 3
28. according to the compound of claim 17, wherein R 5Be H or-CH 3, R 6Be-CH 3, and R 7Be-CH 3
29. according to the compound of claim 21, wherein R 5Be H or-CH 3, R 6Be-CH 3, and R 7Be-CH 3
30. the compound any, wherein R according to claim 1-12 12Have and be no more than 4 straight chain atoms.
31. according to the compound of claim 13, wherein R 12Have and be no more than 4 straight chain atoms.
32. according to the compound of claim 15, wherein R 12Have and be no more than 4 straight chain atoms.
33. according to the compound of claim 17, wherein R 12Have and be no more than 4 straight chain atoms.
34. according to the compound of claim 21, wherein R 12Have and be no more than 4 straight chain atoms.
35. according to the compound of claim 25, wherein R 12Have and be no more than 4 straight chain atoms.
36. according to the compound of claim 30, wherein R 12Have and be no more than 3 straight chain atoms.
37. according to the compound of claim 36, wherein R 12Be-OCF 3,-OCH 3,-CF 3,-CH 3,-CH 2CH 3,-Cl or-F.
38. according to the compound of claim 37, wherein R 12Be-CF 3,-CH 3,-Cl or-F.
39. according to the compound of claim 38, wherein R 12Be-CH 3,-Cl or-F.
40. the compound any, wherein each R according to claim 1-12 8' be independently halogen ,-OR 9,-NO 2,-CN ,-CF 3,-OCF 3,-R 9, 1,2-methylene-dioxy, ethylenedioxy ,-N (R 9) 2,-SR 9,-SOR 9,-SO 2R 9,-SO 2N (R 9) 2,-C (O) R 9,-C (O) C (O) N (R 9) 2,-C (O) N (R 9) 2,-OC (O) N (R 9) 2,-(CH 2) 0-2NHC (O) R 9,-N (R 9) SO 2R 9,-N (R 9) SO 2N (R 9) 2,-N (R 9) C (O) OR 9,-N (R 9) C (O) R 9Or-N (R 9) C (O) N (R 9) 2
41. according to the compound of claim 13, each R wherein 8' be independently halogen ,-OR 9,-NO 2,-CN ,-CF 3,-OCF 3,-R 9, 1,2-methylene-dioxy, ethylenedioxy ,-N (R 9) 2,-SR 9,-SOR 9,-SO 2R 9,-SO 2N (R 9) 2,-C (O) R 9,-C (O) C (O) N (R 9) 2,-C (O) N (R 9) 2,-OC (O) N (R 9) 2,-(CH 2) 0-2NHC (O) R 9,-N (R 9) SO 2R 9,-N (R 9) SO 2N (R 9) 2,-N (R 9) C (O) OR 9,-N (R 9) C (O) R 9Or-N (R 9) C (O) N (R 9) 2
42. according to the compound of claim 15, each R wherein 8' be independently halogen ,-OR 9,-NO 2,-CN ,-CF 3,-OCF 3,-R 9, 1,2-methylene-dioxy, ethylenedioxy ,-N (R 9) 2,-SR 9,-SOR 9,-SO 2R 9,-SO 2N (R 9) 2,-C (O) R 9,-C (O) C (O) N (R 9) 2,-C (O) N (R 9) 2,-OC (O) N (R 9) 2,-(CH 2) 0-2NHC (O) R 9,-N (R 9) SO 2R 9,-N (R 9) SO 2N (R 9) 2,-N (R 9) C (O) OR 9,-N (R 9) C (O) R 9Or-N (R 9) C (O) N (R 9) 2
43. according to the compound of claim 17, each R wherein 8' be independently halogen ,-OR 9,-NO 2,-CN ,-CF 3,-OCF 3,-R 9, 1,2-methylene-dioxy, ethylenedioxy ,-N (R 9) 2,-SR 9,-SOR 9,-SO 2R 9,-SO 2N (R 9) 2,-C (O) R 9,-C (O) C (O) N (R 9) 2,-C (O) N (R 9) 2,-OC (O) N (R 9) 2,-(CH 2) 0-2NHC (O) R 9,-N (R 9) SO 2R 9,-N (R 9) SO 2N (R 9) 2,-N (R 9) C (O) OR 9,-N (R 9) C (O) R 9Or-N (R 9) C (O) N (R 9) 2
44. according to the compound of claim 21, each R wherein 8' be independently halogen ,-OR 9,-NO 2,-CN ,-CF 3,-OCF 3,-R 9, 1,2-methylene-dioxy, ethylenedioxy ,-N (R 9) 2,-SR 9,-SOR 9,-SO 2R 9,-SO 2N (R 9) 2,-C (O) R 9,-C (O) C (O) N (R 9) 2,-C (O) N (R 9) 2,-OC (O) N (R 9) 2,-(CH 2) 0-2NHC (O) R 9,-N (R 9) SO 2R 9,-N (R 9) SO 2N (R 9) 2,-N (R 9) C (O) OR 9,-N (R 9) C (O) R 9Or-N (R 9) C (O) N (R 9) 2
45. according to the compound of claim 25, each R wherein 8' be independently halogen ,-OR 9,-NO 2,-CN ,-CF 3,-OCF 3,-R 9, 1,2-methylene-dioxy, ethylenedioxy ,-N (R 9) 2,-SR 9,-SOR 9,-SO 2R 9,-SO 2N (R 9) 2,-C (O) R 9,-C (O) C (O) N (R 9) 2,-C (O) N (R 9) 2,-OC (O) N (R 9) 2,-(CH 2) 0-2NHC (O) R 9,-N (R 9) SO 2R 9,-N (R 9) SO 2N (R 9) 2,-N (R 9) C (O) OR 9,-N (R 9) C (O) R 9Or-N (R 9) C (O) N (R 9) 2
46. according to the compound of claim 30, each R wherein 8' be independently halogen ,-OR 9,-NO 2,-CN, CF 3,-OCF 3,-R 9, 1,2-methylene-dioxy, ethylenedioxy ,-N (R 9) 2,-SR 9,-SOR 9,-SO 2R 9,-SO 2N (R 9) 2,-C (O) R 9,-C (O) C (O) N (R 9) 2,-C (O) N (R 9) 2,-OC (O) N (R 9) 2,-(CH 2) 0-2NHC (O) R 9,-N (R 9) SO 2R 9,-N (R 9) SO 2N (R 9) 2,-N (R 9) C (O) OR 9,-N (R 9) C (O) R 9Or-N (R 9) C (O) N (R 9) 2
47. according to the compound of claim 40, each R wherein 8' be independently-NH 2,-N (R 9) 2,-N (R 9) C (O) R 9,-OCF 3,-OR 9,-CF 3,-R 9,-SR 9Or halogeno-group.
48. be selected from following compound:
Figure FSB00000167967900141
Figure FSB00000167967900161
49. pharmaceutical composition comprises:
A) compound any according to claim 1-48; With
B) pharmaceutically acceptable carrier, auxiliary agent or vehicle.
50. be used for the treatment of purposes in the medicine of patient disease according to any one compound of claim 1-48 or according to the pharmaceutical composition of claim 49 in preparation, wherein said disease is the disease of I L-1 mediation, the disease of apoptosis mediation, inflammatory diseases, autoimmune disorders, destructive bone disorders, proliferative disorder, infectious diseases, degenerative disease, with the necrocytosis diseases associated, excessive diet alcohol is taken in disease, virus-mediated disease, retina obstacle, uveitis, inflammatory peritonitis, osteoarthritis, pancreatitis, asthma, adult respiratory distress syndrome, glomerulonephritis, rheumatoid arthritis, systemic lupus erythematous, scleroderma, chronic thyroiditis, the Ge Leifushi disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, the autoimmune neutrophilic leukocyte reduces, thrombopenia, chronic active hepatitis, myasthenia gravis, inflammatory bowel disease, Crohn disease, psoriasis, atopic dermatitis, cicatrization, graft versus host disease, the organ-graft refection, organ cell's program death after burning, osteoporosis, leukemia and associated disorders, myelodysplastic syndrome, multiple myeloma-dependency bone disorders, acute myelogenous leukemia, chronic lymphocytic leukemia, metastatic melanoma, Kaposi, multiple myeloma, hemorrhagic shock, Sepsis, septic shock, burn, shigellosis, Alzheimer, Parkinson's disease, Huntington's disease, the Ken Nidishi disease, prion disease, cerebral ischemia, epilepsy, myocardial ischemia, acute and morbus cardiacus, myocardial infarction, congestive heart failure, atherosclerosis, the coronary bypass grafting thing, the ridge amyotrophy, amyotrophic lateral sclerosis, multiple sclerosis, HIV-dependency encephalitis, old and feeble, alopecia, by in the damage of wind-induced neurological, ulcerative colitis, traumatic brain injury, Spinal injury, hepatitis B, hepatitis C, hepatitis G, yellow jack, singapore hemorrhagic fever, Japanese encephalitis, various forms of hepatic diseases, the kidney disease, polycystic kidney disease, the gastroduodenal ulcer disease relevant with helicobacter pylori, HIV infects, tuberculosis, meningitis, the necrosis of toxic epidermis, pemphigus, Muckle-Wells syndrome, the familial cold urticaria, familial Mediterranean fever, chronic infancy neurological skin and joint syndrome, the ictal multisystem inflammatory diseases of newborn infant, the cycle syndrome relevant or super-IgD periodic fever syndrome with TNFR1.
51. according to any one compound of claim 1-48 or be used for suppressing the purposes of medicine of the function of patient's aspartic acid specificity cysteine protease-mediation in preparation according to the pharmaceutical composition of claim 49.
52. according to any one compound of claim 1-48 or be used for reducing the purposes of the medicine that patient IGIF or IFN-γ produce in preparation according to the pharmaceutical composition of claim 49.
53. according to any one compound of claim 1-48 or the purposes that is used to preserve cell according to the pharmaceutical composition of claim 49.
54. according to the purposes of claim 53, wherein said cell is positioned at:
A) in the plan transplanted organ; Perhaps
B) in the blood sample goods.
55. according to any one compound of claim 1-48 or be used for utilizing the purposes of the medicine of immunotherapy treatment cancer in preparation according to the pharmaceutical composition of claim 49.
56. according to the purposes of claim 50, wherein said composition comprises the other treatment agent.
57. according to the purposes of claim 51, wherein said composition comprises the other treatment agent.
58. according to the purposes of claim 52, wherein said composition comprises the other treatment agent.
59. according to the purposes of claim 53, wherein said composition comprises the other treatment agent.
60. according to the purposes of claim 55, wherein said composition comprises the other treatment agent.
61. the method for preparation I compound:
Figure FSB00000167967900191
Wherein Y is:
Figure FSB00000167967900192
Its dependent variable be as claim 2-11 or 13-47 any one defined;
Comprise and make formula 1 compound:
Wherein each variable be as claim 2-11 or 13-47 any one defined,
With the reaction of formula RX compound, wherein X is OH or suitable derivatives or leavings group,
When X is OH, be reflected under the condition that is used for coupling amine and acid and carry out,
When X is suitable leavings group, be reflected under the condition that is used for coupling amine and suitable acid derivative and carry out,
Obtain formula I compound.
62. the method for preparation I compound:
Wherein Y is:
Its dependent variable be as claim 1-11 or 13-47 any one defined,
Comprise and make formula 7-A compound:
Wherein each variable is as claim 1,5-9 any one defined,
With formula RNHCH (R 2) reaction of C (O) X compound, wherein X is OH or suitable derivatives or leavings group,
When X is OH, be reflected under the condition that is used for coupling amine and acid and carry out,
When X is suitable derivatives or leavings group, be reflected under the condition that is used for coupling amine and suitable acid derivative and carry out,
Obtain formula I compound.
63. the method for preparation formula IV compound:
Figure FSB00000167967900211
Wherein each variable be as claim 1-3 or 12-47 any one defined,
Comprise and make formula I compound:
Figure FSB00000167967900212
Wherein Y is:
Figure FSB00000167967900213
R wherein 1Be as claim 1 or 5-9 any one defined,
Under hydrolysising condition, react, obtain formula II compound.
CN2005800112311A 2004-02-27 2005-02-28 Caspase inhibitors and uses thereof Expired - Fee Related CN1942466B (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US54861004P 2004-02-27 2004-02-27
US60/548,610 2004-02-27
US62974304P 2004-11-19 2004-11-19
US62966104P 2004-11-19 2004-11-19
US60/629,743 2004-11-19
US60/629,661 2004-11-19
PCT/US2005/006540 WO2005085236A2 (en) 2004-02-27 2005-02-28 Caspase inhibitors and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2010106215884A Division CN102161656B (en) 2004-02-27 2005-02-28 Aspartic acid-specific caspase inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
CN1942466A CN1942466A (en) 2007-04-04
CN1942466B true CN1942466B (en) 2011-02-23

Family

ID=37959787

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800112311A Expired - Fee Related CN1942466B (en) 2004-02-27 2005-02-28 Caspase inhibitors and uses thereof

Country Status (2)

Country Link
CN (1) CN1942466B (en)
CA (1) CA2820541A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101979403A (en) * 2010-09-13 2011-02-23 沈陵陵 Novel broad caspase inhibitor and preparation method and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
UA74133C2 (en) * 1998-03-19 2005-11-15 Вертекс Фармасьютикалс Інкорпорейтед caspase inhibitors
PE20011350A1 (en) * 2000-05-19 2002-01-15 Vertex Pharma PROPHARMAC OF AN INHIBITOR OF INTERLEUKIN-1ß CONVERTER ENZYME (ICE)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Donald S.Karanewsky et al,.CONFORMATIONALLY CONSTRAINED INHIBITORS OF CASPASE-1 (INERRLEUKIN-1B CONVERTING ENZYME) AND OF THE HUMAN CED-3 HOMOLOGUE CASPASE-3 (CPP32,APOPAIN).Bioorganic &amp *
Donald S.Karanewsky et al.,.CONFORMATIONALLY CONSTRAINED INHIBITORS OF CASPASE-1 (INERRLEUKIN-1B CONVERTING ENZYME) AND OF THE HUMAN CED-3 HOMOLOGUE CASPASE-3 (CPP32,APOPAIN).Bioorganic & Medicinal Chemisitry Letters.1998,82757-2762.
Medicinal Chemisitry Letters.1998,82757-2762. *

Also Published As

Publication number Publication date
CN1942466A (en) 2007-04-04
CA2820541A1 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
CN102161656B (en) Aspartic acid-specific caspase inhibitors and uses thereof
CN104185477B (en) Cytotoxic peptides and antibody drug conjugates thereof
TWI736566B (en) Tlr7/8 antagonists and uses thereof
TWI243828B (en) Inhibitors of caspases
AU2019265703A1 (en) Anti-MSR1 antibodies and methods of use thereof
CN110291097A (en) Steroidal compounds and its protein-conjugate
EP2686336B1 (en) N-carboxyalkyl-auristatins and use thereof
DE60123232T2 (en) TAMANDARINE AND DIDEMNINE ANALOGUE AND METHODS FOR THEIR PREPARATION AND USE
CN113905767A (en) Traceless linkers and protein conjugates thereof
CA3096424A1 (en) Pladienolide derivatives as spliceosome targeting agents for treating cancer
DE60203006T2 (en) PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS
JP2000501111A (en) Aspartyl protease inhibitor
CA3166404A1 (en) A bifunctional molecule comprising an active compound,a linker and a degradation moiety, and its use to treat disorders associated with baf complex function
CN104884455B (en) Hepatitis c virus inhibitors
CN1942466B (en) Caspase inhibitors and uses thereof
AU2011226946B2 (en) Caspase Inhibitors and Uses Thereof
RU2815064C2 (en) Pladienolide derivatives as drugs with targeted influence on spliceosome for treatment of cancer
CN1325473C (en) Novel azasugar derivative and drug containing the same as the active ingredient
CA3228146A1 (en) Protease inhibitors for the treatment of coronavirus infections
KR20230061505A (en) Sulfamoyl urea derivatives containing an alkyl-oxacycloalkyl moiety and uses thereof
MXPA06009771A (en) Caspase inhibitors and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1099757

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1099757

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110223

Termination date: 20150228

EXPY Termination of patent right or utility model